Benzamides of pyrazolyl-amino-pyrimidinyl derivatives and compositions and methods thereof

By designing selectively potent JAK inhibitor compounds suitable for oral and topical administration, the problems of existing JAK inhibitor resistance and side effects are solved, and effective inhibition and immune retention of JAK2 and other JAK kinases are achieved.

CN118903142APending Publication Date: 2024-11-08LYNK PHARMACEUTICALS CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202411028131.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-12-14
Filing Date
2019-12-16
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing JAK inhibitors are difficult to avoid drug resistance and systemic side effects in the treatment of cancer and inflammatory diseases, and are difficult to achieve long-term effectiveness.

Method used

Design a new class of JAK inhibitor compounds that are selectively potent and suitable for oral and topical administration, especially GI limitations and topical skin use, reduce side effects by limiting systemic exposure, retain immune function, and at the action The site showed high exposure.

Benefits of technology

Effective inhibition of JAK2 and other JAK kinases was achieved, reducing drug resistance risks and systemic side effects, retaining immune function, and having excellent pharmacokinetic characteristics and drug properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004969153100000031
    Figure BDA0004969153100000031
  • Figure BDA0004969153100000041
    Figure BDA0004969153100000041
  • Figure BDA0004969153100000051
    Figure BDA0004969153100000051
Patent Text Reader

Abstract

The present invention provides a new class of selectively potent JAK inhibitors that are orally and / or locally available, which are safe and effective therapeutic agents against a variety of different diseases and disorders. The invention also provides pharmaceutical compositions of these compounds and methods of making and using the same.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese invention patent application with application number 201980076141.2, application date December 16, 2019, and invention name “Benzamides of pyrazolyl-amino-pyrimidinyl derivatives and their compositions and methods”.

[0002] Priority claims and related patent applications

[0003] This application claims the benefit of priority of PCT International Application No. PCT / CN2018 / 121165, filed on December 14, 2018, the entire contents of which are incorporated herein by reference for all purposes. Technical Field

[0004] The present invention generally relates to novel compounds and methods for their therapeutic use. More specifically, the present invention relates to a new class of therapeutic agents that are safe and effective JAK inhibitors. The present invention also relates to pharmaceutical compositions of these compounds, methods for their preparation, and their use for a variety of diseases and disorders. Background Art

[0005] Janus kinases (JAKs) are a class of intracellular, non-receptor tyrosine kinases that transduce cytokine-mediated signals through the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. The human JAK enzyme family consists of four members: JAK1, JAK2, JAK3, and TYK2. This family is defined by the presence of two adjacent kinase domains, JH1 and JH2. JH1 performs the phosphorylation involved in pathway activation, while JH2 regulates the function of JH1. (Thomas et al., 2015 British Journal of Cancer 113, 365–371).

[0006] These cytoplasmic tyrosine kinases bind to membrane cytokine receptors, such as the common γ-chain receptor and the glycoprotein 130 (gp130) transmembrane protein. (Murray et al., 2007 Immunol. 178(5):2623-2629). Approximately 40 cytokine receptors signal through a combination of these four JAKs and their seven downstream substrates, the STAT family members. (Ghoreschi et al., 2009 Immunol Rev. 228(1):273-287).

[0007] The JAK-STAT signaling pathway, which activates genes through transcription via communication between chemical signals from outside the cell and the cell nucleus, plays an important role in many fundamental biological processes, such as apoptosis and inflammation. Dysfunctional JAK-STAT pathways can cause a wide range of diseases, such as cancer and disorders affecting the immune system.

[0008] There is growing interest in JAK inhibitors as drugs that inhibit the activity of one or more members of the JAK family, thereby interfering with the JAK-STAT signaling pathway. Certain JAK inhibitors have been shown to have therapeutic benefits in treating cancer or inflammatory diseases such as rheumatoid arthritis (Kontzias et al., 2012 Current Opinion in Pharmacology 12(4):464–70; Pesu et al., 2008 Immunological Reviews 223:132–42; Norman 2014 Expert Opinion on Investigational Drugs 23(8):1067–77; Forster et al., 2017 Bioorganic & Medicinal Chemistry Letters 27(18):4229–4237).

[0009] The development of JAK inhibitors for the treatment of cancer that are less susceptible to drug resistance remains challenging but is essential to improving the long-term effectiveness of such drugs. Across a wide range of therapeutic areas, there is an urgent need for JAK inhibitors that have improved efficacy and minimal side effects compared to existing therapeutics and are less likely to develop or overcome drug resistance. Summary of the Invention

[0010] The present invention provides novel, selective, and potent compounds that are orally and / or topically available and / or suitable for localized and / or topical administration to the gastrointestinal (GI) tract. These therapeutic agents are safe and effective JAK inhibitors and may exhibit fewer and / or less severe side effects than currently available drugs. The present invention provides pharmaceutical compositions of these compounds and methods for their preparation and use.

[0011] Disclosed herein are a series of novel JAK inhibitors that are specifically designed to be potentially suitable for (I) oral administration or (II) GI and / or topical use on the skin. For compounds designed for oral administration, they are potent for JAK2 and have selectivity over other JAK kinases and good overall drug properties. For compounds potentially suitable for GI-restricted or topical use on the skin, they are designed to exhibit strong pan-JAK activity, including JAK1 and / or TYK2. Specifically, these compounds are designed to exhibit minimal oral absorption to limit systemic exposure, but to exhibit high exposure at the site of action, particularly in the gastrointestinal tract.

[0012] This new class of inhibitors exhibits a remarkable potency profile, with JAK2 IC in the low nanomolar range at Km ATP concentrations. 50Some of these compounds also showed remarkable potency against JAK1 and / or TYK2.

[0013] In one aspect, the present invention generally relates to a compound having structural formula (I):

[0014]

[0015] in

[0016] X is N or CR x , where R x is R', halogen, CN or OR';

[0017] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0018] R 1 It is Cl;

[0019] R 2 is a C1-C ... 16 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen, OR', NRR', CN, CONRR', NRCOR', and C1-C6 alkyl, which in turn are optionally substituted with F, OR', or NRR';

[0020] R 3 is R', halogen or CN;

[0021] R 4’ is H or C1-C6 alkyl;

[0022] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen, OR', NRR', CN, CONRR', NRCOR', and C1-C6 alkyl, which in turn are optionally substituted with F, OR', or NRR'; and

[0023] Each of R and R' is independently hydrogen or C1-C 12 unsubstituted or substituted alkyl,

[0024] or a pharmaceutically acceptable form or isotopic derivative thereof.

[0025] In another aspect, the present invention generally relates to a compound having structural formula (I):

[0026]

[0027] in

[0028] X is N or CR x , where R x is R', halogen, CN or OR';

[0029] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0030] R 1 It is CH3;

[0031] R 2 is a C1-C ... 16 an aliphatic group, wherein the aliphatic group is substituted with one or more of CN, CONRR', or NRCOR', which in turn are optionally substituted with F, OR', or NRR';

[0032] R 3 is R', halogen or CN;

[0033] R 4’ is H or C1-C6 alkyl;

[0034] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen, OR', NRR', CN, CONRR', NRCOR', and C1-C6 alkyl, which in turn are optionally substituted with F, OR', or NRR'; and

[0035] Each of R and R' is independently hydrogen or C1-C 12 unsubstituted or substituted alkyl,

[0036] or a pharmaceutically acceptable form or isotopic derivative thereof.

[0037] In another aspect, the present invention generally relates to a compound having structural formula (I):

[0038]

[0039] in

[0040] X is N or CR x , where R x is R', halogen, CN or OR';

[0041] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0042] R 1 It is CH3;

[0043] R 2 is a C3-C ... 16 an aliphatic group, wherein the aliphatic group is substituted with 0-4 C1-C6 alkyl groups;

[0044] R 3 is R', halogen or CN;

[0045] R 4’ is H or C1-C6 alkyl;

[0046] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen, OR', NRR', CN, CONRR', NRCOR', and C1-C6 alkyl, which in turn are optionally substituted with F, OR', or NRR'; and

[0047] Each of R and R' is independently hydrogen or C1-C 12 unsubstituted or substituted alkyl,

[0048] or a pharmaceutically acceptable form or isotopic derivative thereof.

[0049] In another aspect, the present invention generally relates to a pharmaceutical composition comprising a compound disclosed herein and a pharmaceutically acceptable excipient, carrier, or diluent effective for treating or ameliorating one or more diseases or disorders in mammals, including humans.

[0050] In another aspect, the present invention generally relates to a pharmaceutical composition comprising an amount of a compound of formula (I) effective to treat or alleviate one or more diseases or disorders in mammals, including humans:

[0051]

[0052] in

[0053] X is N or CR x , where R x is R', halogen, CN or OR';

[0054] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0055] R 1 It is Cl;

[0056] R 2 is a C1-C ... 16 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen, OR', NRR', CN, CONRR', NRCOR', and C1-C6 alkyl, which in turn are optionally substituted with F, OR', or NRR';

[0057] R 3 is R', halogen or CN;

[0058] R 4’ is H or C1-C6 alkyl;

[0059] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen, OR', NRR', CN, CONRR', NRCOR', and C1-C6 alkyl, which in turn are optionally substituted with F, OR', or NRR'; and

[0060] Each of R and R' is independently hydrogen or C1-C 12 unsubstituted or substituted alkyl,

[0061] or a pharmaceutically acceptable form or isotopic derivative thereof, and a pharmaceutically acceptable excipient, carrier or diluent.

[0062] In another aspect, the present invention generally relates to a pharmaceutical composition comprising an amount of a compound of formula (I) effective to treat or alleviate one or more diseases or disorders in mammals, including humans:

[0063]

[0064] in

[0065] X is N or CR x , where R x is R', halogen, CN or OR';

[0066] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0067] R 1 It is CH3;

[0068] R 2 is a C1-C ... 16 an aliphatic group, wherein the aliphatic group is substituted with one or more of CN, CONRR', or NRCOR', which in turn are optionally substituted with F, OR', or NRR';

[0069] R 3 is R', halogen or CN;

[0070] R 4’ is H or C1-C6 alkyl;

[0071] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen, OR', NRR', CN, CONRR', NRCOR', and C1-C6 alkyl, which in turn are optionally substituted with F, OR', or NRR'; and

[0072] Each of R and R' is independently hydrogen or C1-C 12 unsubstituted or substituted alkyl,

[0073] or a pharmaceutically acceptable form or isotopic derivative thereof, and a pharmaceutically acceptable excipient, carrier or diluent.

[0074] In another aspect, the present invention generally relates to a pharmaceutical composition comprising an amount of a compound of formula (I) effective to treat or alleviate one or more diseases or disorders in mammals, including humans:

[0075]

[0076] in

[0077] X is N or CR x , where R x is R', halogen, CN or OR';

[0078] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0079] R 1 It is CH3;

[0080] R 2 is a C3-C ... 16 an aliphatic group, wherein the aliphatic group is substituted with 0 to 4 C1-C6 alkyl groups;

[0081] R 3 is R', halogen or CN;

[0082] R 4’ is H or C1-C6 alkyl;

[0083] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen, OR', NRR', CN, CONRR', NRCOR', and C1-C6 alkyl, which in turn are optionally substituted with F, OR', or NRR'; and

[0084] Each of R and R' is independently hydrogen or C1-C 12 unsubstituted or substituted alkyl,

[0085] or a pharmaceutically acceptable form or isotopic derivative thereof, and a pharmaceutically acceptable excipient, carrier or diluent.

[0086] In another aspect, the present invention generally relates to a unit dosage form comprising a pharmaceutical composition disclosed herein.

[0087] In another aspect, the present invention generally relates to a method for treating or alleviating a disease or disorder, comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula (I) that is effective for treating, preventing, or alleviating one or more inflammatory diseases, immune-mediated diseases, cancer, or related diseases or disorders in mammals, including humans:

[0088]

[0089] in

[0090] X is N or CR x , where R x is R', halogen, CN or OR';

[0091] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0092] R 1 It is Cl;

[0093] R 2 is a C1-C ... 16 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen, OR', NRR', CN, CONRR', NRCOR', and C1-C6 alkyl, which in turn are optionally substituted with F, OR', or NRR';

[0094] R 3 is R', halogen or CN;

[0095] R 4’ is H or C1-C6 alkyl;

[0096] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen, OR', NRR', CN, CONRR', NRCOR', and C1-C6 alkyl, which in turn are optionally substituted with F, OR', or NRR'; and

[0097] Each of R and R' is independently hydrogen or C1-C 12 unsubstituted or substituted alkyl,

[0098] or a pharmaceutically acceptable form or isotopic derivative thereof, and a pharmaceutically acceptable excipient, carrier or diluent.

[0099] In another aspect, the present invention generally relates to a method for treating or alleviating a disease or disorder, comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula (I) that is effective for treating, preventing, or alleviating one or more inflammatory diseases, immune-mediated diseases, cancer, or related diseases or disorders in mammals, including humans:

[0100]

[0101] in

[0102] X is N or CR x , where R x is R', halogen, CN or OR';

[0103] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0104] R 1 It is CH3;

[0105] R 2 is a C1-C ... 16 an aliphatic group, wherein the aliphatic group is substituted with one or more of CN, CONRR', or NRCOR', which in turn are optionally substituted with F, OR', or NRR';

[0106] R 3 is R', halogen or CN;

[0107] R 4’ is H or C1-C6 alkyl;

[0108] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen, OR', NRR', CN, CONRR', NRCOR', and C1-C6 alkyl, which in turn are optionally substituted with F, OR', or NRR'; and

[0109] Each of R and R' is independently hydrogen or C1-C 12 unsubstituted or substituted alkyl,

[0110] or a pharmaceutically acceptable form or isotopic derivative thereof, and a pharmaceutically acceptable excipient, carrier or diluent.

[0111] In another aspect, the present invention generally relates to a method for treating or alleviating a disease or disorder, comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula (I) that is effective for treating, preventing, or alleviating one or more inflammatory diseases, immune-mediated diseases, cancer, or related diseases or disorders in mammals, including humans:

[0112]

[0113] in

[0114] X is N or CR x , where R x is R', halogen, CN or OR';

[0115] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0116] R 1 It is CH3;

[0117] R 2 is a C3-C ... 16 an aliphatic group, wherein the aliphatic group is substituted with 0-4 C1-C6 alkyl groups;

[0118] R 3 is R', halogen or CN;

[0119] R 4’ is H or C1-C6 alkyl;

[0120] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen, OR', NRR', CN, CONRR', NRCOR', and C1-C6 alkyl, which in turn are optionally substituted with F, OR', or NRR'; and

[0121] Each of R and R' is independently hydrogen or C1-C 12 unsubstituted or substituted alkyl,

[0122] or a pharmaceutically acceptable form or isotopic derivative thereof, and a pharmaceutically acceptable excipient, carrier or diluent.

[0123] In another aspect, the present invention generally relates to the use of a compound disclosed herein and a pharmaceutically acceptable excipient, carrier, or diluent for the preparation of a medicament for treating a disease or disorder.

[0124] definition

[0125] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The general principles of organic chemistry, as well as specific functional components and reactivity, are described in Organic Chemistry (Thomas Sorrell, University Science Books, Sausalito: 2006).

[0126] Certain compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds that fall within the scope of the present invention, including cis- and trans-isomers, atropisomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are intended to be included in the present invention.

[0127] According to the present invention, isomeric mixtures containing any of a variety of isomeric ratios can be used. For example, where only two isomers are combined, the present invention encompasses mixtures containing isomeric ratios of 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0. One of ordinary skill in the art will readily recognize that similar ratios are contemplated for more complex isomeric mixtures.

[0128] If, for example, a specific enantiomer of a compound of the invention is desired, it can be prepared by asymmetric synthesis or by derivatization with a chiral auxiliary, in the latter case separation of the resulting diastereomeric mixture and cleavage of the auxiliary group to provide the pure desired enantiomer. Alternatively, where the molecule contains a basic functional group such as an amino group or an acidic functional group such as a carboxyl group, diastereomeric salts are formed with a suitable optically active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic methods well known in the art, followed by recovery of the pure enantiomer.

[0129] Solvates and polymorphs of the compounds of the invention are also contemplated herein. Solvates of the compounds of the invention include, for example, hydrates.

[0130] Definitions of specific functional groups and chemical terms are described in more detail below. When a range of values ​​is listed, it is intended to encompass every value and subrange within the range. For example, "C 1-6 "Alkyl" is intended to cover C1, C2, C3, C4, C5, C6, C 1-6 、C 1-5 、C 1-4 、C 1-3 、C 1-2 、C 2-6 、C 2-5 、C 2-4 、C 2-3 、C 3-6 、C 3-5 、C 3-4 、C 4-6 、C 4-5 and C 5-6 alkyl.

[0131] Where substituents are specified using their conventional chemical formula written from left to right, they equally encompass chemically identical substituents resulting from writing the structure from right to left, e.g., -C(=O)-O- is equivalent to -OC(=O)-.

[0132] The structures of the compounds of the present invention are constrained by the principles of chemical bonding known to those skilled in the art. Thus, where a group may be substituted with one or more of a variety of substituents, these substitutions are selected to adhere to the principles of chemical bonding and to provide compounds that are not inherently unstable and / or known by those of ordinary skill in the art to be potentially unstable under environmental conditions (e.g., aqueous, neutral, and several known physiological conditions).

[0133] As used herein, the term "alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, having no unsaturation and having from 1 to 10 carbon atoms (e.g., C 1-10 Whenever it appears herein, a numerical range such as "1 to 10" refers to each integer in the given range; for example, "1 to 10 carbon atoms" means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms, although this definition also covers instances where the term "alkyl" is not specified. In certain embodiments, "alkyl" may be C 1-6Alkyl. In certain embodiments, the alkyl group has 1 to 10, 1 to 8, 1 to 6, or 1 to 3 carbon atoms. Representative saturated straight-chain alkyl groups include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, and -n-hexyl; while saturated branched-chain alkyl groups include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, 2-methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, and the like. The alkyl group is attached to the parent molecule by a single bond. Unless stated otherwise in the specification, an alkyl group is optionally substituted with one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azido, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halogen, haloalkoxy, haloalkyl, ester, ether, sulfhydryl, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamido, sulfone, sulfonate, urea, -Si(R) a )3, -OR a , -SR a ,-OC(O)-R a ,-N(R a )2,-C(O)R a ,-C(O)OR a ,-OC(O)N(R a )2,-C(O)N(R a )2,-N(R a )C(O)OR a ,-N(R a )C(O)R a ,-N(R a )C(O)N(R a )2,-N(R a )C(NR a )N(R a )2,-N(R a )S(O) t N(R a )2(wherein t is 1 or 2), -P(=O)(R a )(R a ) or -OP(=O)(OR a )2, where each R ais independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, and each of these components may be optionally substituted as defined herein. In non-limiting embodiments, the substituted alkyl may be selected from fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 3-fluoropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, benzyl and phenethyl.

[0134] As used herein, the term "alkoxy" refers to an -O-alkyl group comprising from 1 to 10 carbon atoms (C 1-10 ) in straight chain, branched, saturated cyclic configurations and combinations thereof. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, cyclopropyloxy, cyclohexyloxy, and the like. "Short chain alkoxy" refers to an alkoxy group containing 1 to 6 carbon atoms. In certain embodiments, C 1-3 Alkoxy is an alkoxy group encompassing both straight and branched chain alkyl groups of 1 to 3 carbon atoms. Unless otherwise stated in this specification, an alkoxy group may be optionally substituted with one or more substituents, the substituents independently including: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amide, amidino, imino, azido, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halogen, haloalkoxy, haloalkyl, ester, ether, sulfhydryl, sulfenyl, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamido, sulfone, sulfonate, urea, -Si(R a )3, -OR a , -SR a ,-OC(O)-R a ,-N(R a )2,-C(O)R a ,-C(O)OR a ,-OC(O)N(R a )2,-C(O)N(R a )2,-N(R a )C(O)OR a ,-N(R a )C(O)R a ,-N(R a )C(O)N(R a )2,-N(R a )C(NR a )N(R a )2,-N(R a )S(O) t N(Ra )2(wherein t is 1 or 2), -P(=O)(R a )(R a ) or -OP(=O)(OR a )2, where each R a is independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, and each of these components may be optionally substituted as defined herein.

[0135] As used herein, the term "aromatic" or "aryl" refers to a group having 6 to 14 ring atoms (e.g., C 6-14 Aromatic compounds or C 6-14 aryl), which has at least one carbon ring with a conjugated π electron system (e.g., phenyl, fluorenyl, and naphthyl). In certain embodiments, the aryl is C 6-10 Aryl. For example, a divalent group formed by a substituted benzene derivative and having a free valence at a ring atom is named a substituted phenylene group. In other embodiments, a divalent group derived from a monovalent polycyclic hydrocarbon group whose name ends with "-" by removing a hydrogen atom from a carbon atom with a free valence is named by adding "sub" to the name of the corresponding monovalent group, for example, a naphthyl group with two attachment points is called a naphthylene group. Whenever it appears in this article, a numerical range such as "6 to 14 aryl" refers to each integer in a given range; for example, "6 to 14 ring atoms" means that the aryl group can be composed of 6 ring atoms, 7 ring atoms, etc. up to and including 14 ring atoms. The term includes monocyclic or fused-ring polycyclic (i.e., rings having adjacent paired ring atoms) groups. Polycyclic aryl groups include bicyclic, tricyclic, tetracyclic, etc. In a polycyclic group, only one ring needs to be aromatic, so for example, a group such as indanyl is covered by the definition of aryl. Non-limiting examples of aryl groups include phenyl, benzonaphthyl, naphthyl, tetrahydronaphthyl, phenanthrenyl, anthracenyl, fluorenyl, indolyl, indanyl, and the like. Unless stated otherwise in the specification, an aryl moiety may be optionally substituted with one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azido, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halogen, haloalkoxy, haloalkyl, ester, ether, sulfhydryl, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamido, sulfone, sulfonate, urea, -Si(R) a )3, -OR a , -SR a,-OC(O)-R a ,-N(R a )2,-C(O)R a ,-C(O)OR a ,-OC(O)N(R a )2,-C(O)N(R a )2,-N(R a )C(O)OR a ,-N(R a )C(O)R a ,-N(R a )C(O)N(R a )2,-N(R a )C(NR a )N(R a )2,-N(R a )S(O) t N(R a )2(wherein t is 1 or 2), -P(=O)(R a )(R a ) or -OP(=O)(OR a )2, where each R a is independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, and each of these components may be optionally substituted as defined herein.

[0136] As used herein, the terms "cycloalkyl" and "carbocyclyl" each refer to a monocyclic or polycyclic group containing only carbon and hydrogen and which may be saturated or partially unsaturated. Partially unsaturated cycloalkyl groups may be referred to as "cycloalkenyl" if the carbocyclic ring contains at least one double bond, or as "cycloalkynyl" if the carbocyclic ring contains at least one triple bond. Cycloalkyl groups include groups having 3 to 13 ring atoms (i.e., C 3-13 Cycloalkyl). Whenever it appears in this article, a numerical range such as "3 to 10" refers to each integer in the given range; for example, "3 to 13 carbon atoms" means that the cycloalkyl can be composed of 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, etc. up to and including 13 carbon atoms. The term "cycloalkyl" also includes bridged and spiro-fused ring structures that do not contain heteroatoms. The term also includes monocyclic or fused-ring polycyclic (i.e., rings that share adjacent paired ring atoms) groups. Polycyclic aromatic groups include bicyclic, tricyclic, tetracyclic, etc. In certain embodiments, "cycloalkyl" can be C 3-8 In certain embodiments, a cycloalkyl group may be C 3-5 Cycloalkyl groups. Illustrative examples of cycloalkyl groups include, but are not limited to, the following components: C 3-6Carbocyclic groups include, but are not limited to, cyclopropyl (C3), cyclobutyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), etc. ar7 Examples of carbocyclic groups include norbornyl (C7). 3-8 Examples of the carbocyclic group include the above-mentioned C 3-7 Carbocyclic groups and cycloheptyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, etc. 3-13 Examples of the carbocyclic group include the above-mentioned C 3-8 Unless otherwise stated in the specification, cycloalkyl groups may be optionally substituted with one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azido, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halogen, haloalkoxy, haloalkyl, ester, ether, sulfhydryl, sulfhydryl, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamido, sulfone, sulfonate, urea, -Si(R) a )3, -OR a , -SR a ,-OC(O)-R a ,-N(R a )2,-C(O)R a ,-C(O)OR a ,-OC(O)N(R a )2,-C(O)N(R a )2,-N(R a )C(O)OR a ,-N(R a )C(O)R a ,-N(R a )C(O)N(R a )2,-N(R a )C(NR a )N(R a )2,-N(R a )S(O) t N(R a )2(wherein t is 1 or 2), -P(=O)(R a )(R a ) or -OP(=O)(OR a )2, where each Ra In some embodiments, the cycloalkenyl radical is a cycloalkyl radical having 3 to 13 ring atoms, for example, 5 to 8 ring atoms. In some embodiments, the cycloalkynyl radical is a cycloalkyl radical having 5 to 13 ring atoms. In some embodiments, the cycloalkenyl radical is a cycloalkyl radical having 3 to 13 ring atoms, for example, 5 to 8 ring atoms. In some embodiments, the cycloalkynyl radical is a cycloalkyl radical having 5 to 13 ring atoms.

[0137] When used in this article, term " halogen " refers to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I).When used in this article, term " halide " or " halo " mean fluorine, chlorine, bromine or iodine.Term " haloalkyl ", " haloalkenyl ", " haloalkynyl " and " haloalkoxy " include alkyl, alkenyl, alkynyl and alkoxy structure that are replaced by one or more halogen groups or by its combination.For example, term " fluoroalkyl " and " fluoroalkoxy " include respectively halogenated alkyl and halogenated alkoxy wherein halogen is fluorine, such as but not limited to trifluoromethyl, difluoromethyl, 2,2,2- trifluoroethyl, 1- fluoromethyl -2- fluoroethyl etc..Each described alkyl, alkenyl, alkynyl and alkoxy are as defined herein, and can optionally be further substituted as defined herein.

[0138] As used herein, the term "heteroatom" refers to oxygen (O), nitrogen (N), sulfur (S), and phosphorus (P).

[0139] As used herein, the term "heteroalkyl" refers to an alkyl group having one or more backbone chain atoms selected from atoms other than carbon, such as oxygen, nitrogen, sulfur, phosphorus, or combinations thereof. Numerical ranges may be provided, such as C 1-4Assorted alkyl refers to the overall chain length, which in this example is 4 atoms long. For example, a -CH2OCH2CH3 group is referred to as a "C4" assorted alkyl group, which includes the heteroatom center in the atomic chain length description. Connection to the parent molecular structure can be through heteroatoms or carbons in the assorted alkyl chain. For example, an N-containing assorted alkyl component refers to a group in which at least one backbone atom is a nitrogen atom. One or more heteroatoms in the assorted alkyl group can be optionally oxidized. One or more nitrogen atoms, if present, can also be optionally quaternized. For example, assorted alkyl groups also include backbone chains substituted with one or more nitrogen oxide (-O-) substituents. Exemplary heteroalkyl groups include, but are not limited to, ethers such as methoxyethyl (-CH2CH2OCH3), ethoxymethyl (-CH2OCH2CH3), (methoxymethoxy)ethyl (-CH2CH2OCH2OCH3), (methoxymethoxy)methyl (-CH2OCH2OCH3), and (methoxyethoxy)methyl (-CH2OCH2CH2OCH3), and the like, amines such as (-CH2CH2NHCH3, -CH2CH2N(CH3)2, -CH2NHCH2CH3, -CH2N(CH2CH3)(CH3)), and the like.

[0140] As used herein, the term "heteroaryl" or alternatively "heteroaromatic" refers to a radical of a 5-18 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic, tetracyclic, etc.) aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic arrangement) having ring carbon atoms and 1-6 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorus, and sulfur ("5-18 membered heteroaryl"). A heteroaryl polycyclic ring system may include one or more heteroatoms in one or both rings. Whenever it appears herein, a numerical range such as "5 to 18" refers to each integer in the given range; for example, "5 to 18 ring atoms" means that the heteroaryl group may be composed of 5 ring atoms, 6 ring atoms, etc., up to and including 18 ring atoms. In some cases, a heteroaryl group may have 5 to 14 ring atoms. In certain embodiments, the heteroaryl group has a divalent radical, for example, derived from a monovalent heteroaryl group whose name ends in "-yl" by removing one hydrogen atom from the atom with the free valence, which is named by adding "sub" to the name of the corresponding monovalent radical, for example, a pyridyl group having two points of attachment is a pyridylene group.

[0141] For example, an N-containing "heteroaromatic" or "heteroaryl" moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom. One or more heteroatoms in the heteroaryl group may optionally be oxidized. One or more nitrogen atoms, if present, may also be optionally quaternized. Heteroaryl also includes ring systems substituted with one or more nitrogen oxide (-O-) substituents, such as pyridyl N-oxide. The heteroaryl group is attached to the parent molecular structure through any atom of the ring.

[0142] "Heteroaryl" also includes ring systems in which a heteroaryl ring as defined above is fused to one or more aryl groups, wherein the point of attachment to the parent molecular structure is on the aryl or heteroaryl ring, or a heteroaryl ring as defined above is fused to one or more cycloalkyl or heterocyclyl groups, wherein the point of attachment to the parent molecular structure is on the heteroaryl ring. For polycyclic heteroaryls in which one ring does not contain heteroatoms (e.g., indolyl, quinolinyl, carbazolyl, etc.), the point of attachment to the parent molecular structure can be on either ring, i.e., on the ring with the heteroatom (e.g., 2-indolyl) or the ring without the heteroatom (e.g., 5-indolyl). In certain embodiments, the heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorus, and sulfur ("5-10 membered heteroaryl"). In certain embodiments, the heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorus, and sulfur (“5-8 membered heteroaryl”). In certain embodiments, the heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorus, and sulfur (“5-6 membered heteroaryl”). In certain embodiments, the 5-6 membered heteroaryl group has 1-3 ring heteroatoms selected from nitrogen, oxygen, phosphorus, and sulfur. In certain embodiments, the 5-6 membered heteroaryl group has 1-2 ring heteroatoms selected from nitrogen, oxygen, phosphorus, and sulfur. In certain embodiments, the 5-6 membered heteroaryl group has 1 ring heteroatom selected from nitrogen, oxygen, phosphorus, and sulfur.

[0143] Examples of heteroaryl groups include, but are not limited to, azacycloheptatrienyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepenyl, benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxanyl, benzoxazolyl, benzopyranyl, benzopyrone, benzofuranyl, benzopyrone, benzofurazanyl, benzothiazolyl, benzothiophenyl (benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo [4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furazanyl, furanonyl, furano[3,2-c]pyridinyl, 5,6,7,8,9,10-hexahydrocyclooctano[d]pyrimidinyl, 5,6,7,8,9,10-hexahydrocyclooctano[d]pyridazinyl, 5,6,7,8,9,10-hexahydrocyclo octa[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolyl, isoquinolinyl, indolizinyl, isoxazolyl, 5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyridinonyl, oxadiazolyl, 2-oxaziridine, oxazolyl, oxirane, 5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl , pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, thiopyranyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-c]pyridinyl, and thiophenyl (i.e., thienyl).Unless stated otherwise in the specification, a heteroaryl moiety may be optionally substituted with one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azido, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, sulfhydryl, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamido, sulfone, sulfonate, urea, -Si(R). a )3, -OR a , -SR a ,-OC(O)-R a ,-N(R a )2,-C(O)R a ,-C(O)OR a ,-OC(O)N(R a )2,-C(O)N(R a )2,-N(R a )C(O)OR a ,-N(R a )C(O)R a ,-N(R a )C(O)N(R a )2,-N(R a )C(NR a )N(R a )2,-N(R a )S(O) t N(R a )2(wherein t is 1 or 2), -P(=O)(R a )(R a ) or -OP(=O)(OR a )2, where each R a is independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, and each of these components may be optionally substituted as defined above.

[0144] As used herein, the term "administering" refers to oral administration to a subject, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intracranial, intranasal or subcutaneous administration, or implantation of a sustained-release device such as a microperistaltic pump. The route of administration suitable for a particular patient depends on the nature and severity of the disease or condition to be treated or the nature of the therapy used and the nature of the active compound.

[0145] Administration can be by any suitable route, including parenteral and transmucosal (e.g., buccal, sublingual, palate, gums, nose, vagina, rectum, or transdermal). Parenteral administration includes, for example, intravenous, intramuscular, intraarteriolar, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other delivery methods include, but are not limited to, the use of liposome formulations, intravenous infusion, transdermal patches, etc.

[0146] "Co-administered" means that a composition described herein is administered at the same time as, immediately before, or immediately after the administration of one or more additional therapies.

[0147] The compounds of the present invention can be administered alone or co-administered to a patient. Co-administration is meant to include administration of the compounds individually or in combination (more than one compound or agent) simultaneously or sequentially. Thus, the formulations can also be combined with other active substances (e.g., to reduce metabolic degradation) if desired.

[0148] The compositions of the present invention can be delivered transdermally, topically, in the form of applicators, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, coatings, powders, and aerosols. Oral formulations include tablets, pills, powders, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, and the like suitable for ingestion by a patient. Solid form formulations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. Liquid form formulations include solutions, suspensions, and emulsions, gels, such as water or water / propylene glycol solutions.

[0149] The compositions of the present invention may further include components that provide sustained release and / or comfort. These components include high molecular weight anionic mucus-mimicking polymers, gelling polysaccharides, and finely divided drug carrier materials. These components are discussed in more detail in U.S. Patent Nos. 4,911,920, 5,403,841, 5,212,162, and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes. The compositions of the present invention may also be delivered as microspheres for slow release in vivo. For example, the microspheres can be administered by intradermal injection of drug-containing microspheres that are slowly released subcutaneously (see Rao, 1995 J. Biomater Sci. Polym. Ed. 7:623-645), as a biodegradable and injectable gel formulation (see, e.g., Gao 1995 Pharm. Res. 12:857-863), or as microspheres for oral administration (see, e.g., Eyles 1997 J. Pharm. Pharmacol. 49:669-674).

[0150] As used herein, the terms "disease," "condition," and "disorder" are used interchangeably herein and refer to a state of being or health in a patient or subject that is treatable using the compounds, pharmaceutical compositions, or methods provided herein.

[0151] As used herein, the term "effective amount" of an active agent refers to an amount sufficient to elicit a desired biological response. As will be appreciated by those of ordinary skill in the art, the effective amount of a compound of the invention may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the disease to be treated, the mode of administration, and the patient.

[0152] When used in this article, for biological target (such as JAK) inhibitor interaction, the term "inhibition" refers to a negative effect (such as reduction) on the activity or function of the protein relative to the activity or function of the protein in the absence of the inhibitor. In an embodiment, inhibition means a negative effect (such as reduction) on the concentration or level of the protein relative to the concentration or level of the protein in the absence of the inhibitor. In an embodiment, inhibition refers to the alleviation of a disease or a symptom of a disease. In an embodiment, inhibition refers to a reduction in the activity of a specific protein target. Inhibition includes at least in part a partial or complete stimulation blocking, reduction, prevention or activation of a signal transduction or enzymatic activity or amount of a protein. In an embodiment, inhibition refers to a reduction in the activity of a target protein caused by a direct interaction (such as an inhibitor binds to a target protein). In an embodiment, inhibition refers to a reduction in the activity of a target protein caused by an indirect interaction (such as an inhibitor binds to a protein that activates the target protein, thereby preventing the target protein from activating).

[0153] As used herein, the terms "isolated" or "purified" refer to material that is substantially or essentially free from components that normally accompany it in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques, such as polyacrylamide gel electrophoresis or high performance liquid chromatography.

[0154] As used herein, "pharmaceutically acceptable forms" of the disclosed compounds include, but are not limited to, pharmaceutically acceptable salts, esters, hydrates, solvates, isomers, prodrugs, and isotopically labeled derivatives thereof. In one embodiment, "pharmaceutically acceptable forms" include, but are not limited to, pharmaceutically acceptable salts, esters, prodrugs, and isotopically labeled derivatives thereof. In certain embodiments, "pharmaceutically acceptable forms" include, but are not limited to, pharmaceutically acceptable isomers and stereoisomers, prodrugs, and isotopically labeled derivatives thereof.

[0155] In certain embodiments, the pharmaceutically acceptable form is a pharmaceutically acceptable salt. When used herein, the term "pharmaceutically acceptable salt" refers to salts that are suitable for use in contact with the tissues of a subject without excessive toxicity, irritation, allergic response, etc., within the scope of sound medical judgment, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66: 1-19. Pharmaceutically acceptable salts of the compounds provided herein include salts derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods used in the art, such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, p-toluenesulfonate, undecanoate, valerate, and the like. In certain embodiments, organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, lactic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.

[0156] The salts can be prepared in situ during the isolation and purification of the disclosed compounds, or separately, for example, by reacting the free base or free acid of the parent compound with a suitable base or acid, respectively. Pharmaceutically acceptable salts derived from suitable bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4alkyl) 4 salts. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, iron, zinc, copper, manganese, aluminum and the like. Other pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium and amine cations formed using counterions such as halogen ions, hydroxides, carboxylates, sulfates, phosphates, nitrates, short-chain alkyl sulfonates and aryl sulfonates when appropriate. Organic bases from which salts can be derived include, for example, primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins and the like, such as isopropylamine, trimethylamine, triethylamine, tripropylamine and ethanolamine. In certain embodiments, the pharmaceutically acceptable base addition salt can be selected from ammonium salts, potassium salts, sodium salts, calcium salts and magnesium salts.

[0157] In certain embodiments, the pharmaceutically acceptable form is a "solvate" (e.g., a hydrate). When used herein, the term "solvate" refers to a compound that also includes a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. The solvate can be a solvate of a disclosed compound or a pharmaceutically acceptable salt thereof. When the solvent is water, the solvate is a "hydrate." Pharmaceutically acceptable solvates and hydrates are complexes that can, for example, include 1 to about 100, or 1 to about 10, or 1 to about 2, about 3, or about 4 solvent or water molecules. It should be understood that when used herein, the term "compound" encompasses the compound and solvates of the compound and mixtures thereof.

[0158] In some embodiments, the pharmaceutically acceptable form is a prodrug. When used in this article, the term "prodrug" refers to a compound that is converted in vivo to produce a pharmaceutically acceptable form of the disclosed compound or the compound. Prodrugs can be inactive when administered to an object, but are converted into active compounds in vivo by, for example, hydrolysis (e.g., hydrolysis in the blood). In some cases, prodrugs have improved physical and / or delivery properties compared to the parent compound. Prodrugs can improve the bioavailability of compounds when administered to an object (e.g., by allowing enhanced absorption into the blood after oral administration) relative to the parent compound, or enhance delivery to the biological compartment of interest (e.g., brain or lymphatic system). Exemplary prodrugs include derivatives of the disclosed compounds that have enhanced water solubility or active transport by intestinal membranes relative to the parent compound.

[0159] The prodrug compounds generally provide advantages of solubility, tissue compatibility, or delayed release in mammalian organisms (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam). A discussion of prodrugs is provided in Higuchi, T. et al., Pro-drugs as Novel Delivery Systems, ACS Symposium Series, No. 14, and Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference in their entirety.

[0160] Prodrug forms generally provide the advantages of solubility, tissue compatibility or delayed release in mammalian organisms. (See Bundgard, " Design of Prodrugs " (Design of Prodrugs), pp. 7-9, 21-24, Elsevier, Amsterdam 1985 and Silverman, " Organic Chemistry of Drug Design and Drug Action " (The Organic Chemistry of Drug Design and Drug Action), pp. 352-401, Academic Press, San Diego, Calif., 1992). Prodrugs well known in the art include well-known acid derivatives, such as esters prepared by the reaction of parent acid and suitable alcohol, amides prepared by the reaction of parent acid compound and amine, basic group reactions to form acylated base derivatives etc. Other prodrug derivatives can be combined with other features disclosed herein to enhance bioavailability. Therefore, those skilled in the art will recognize that some of the disclosed compounds with free amino groups, amide groups, hydroxyl groups or carboxyl groups can be converted into prodrugs. Prodrugs include compounds having a carbonate, carbamate, amide, or alkyl ester moiety covalently bonded to any of the above-described substituents disclosed herein.

[0161] Exemplary advantages of a prodrug include, but are not limited to, its physical properties such as enhanced water solubility compared to the parent compound for parenteral administration at physiological pH, or it may enhance absorption from the digestive tract, or it may improve drug stability for long-term storage.

[0162] As used herein, the term "pharmaceutically acceptable" excipient, carrier, or diluent refers to a pharmaceutically acceptable material, composition, or medium such as a liquid or solid filler, diluent, vehicle, solvent, or encapsulating material, which participates in carrying or transporting the subject agent from one organ or body part to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials that can serve as pharmaceutically acceptable carriers include: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffered saline; and other nontoxic, compatible substances used in pharmaceutical formulations. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate, magnesium stearate and polyethylene oxide-polypropylene oxide copolymers, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

[0163] As used herein, the term "subject" refers to any animal (e.g., mammal) that is the recipient of a particular treatment, including but not limited to humans, non-human primates, rodents, and the like. It is contemplated that subjects to whom administration may be given include, but are not limited to, humans (e.g., males or females of any age group, such as pediatric subjects (e.g., infants, children, adolescents) and adult subjects (e.g., young adults, middle-aged adults, or elderly adults)) and / or other non-human animals such as non-human mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and / or dogs), rodents (e.g., rats and / or mice)), and the like. In certain embodiments, the non-human animal is a mammal. The non-human animal can be male or female at any stage of development. Non-human animals can be transgenic animals. Generally, the terms "subject" and "patient" are used interchangeably herein to refer to human subjects.

[0164] As used herein, the term "treating" a disease or disorder refers to a method of alleviating, delaying or ameliorating such a condition before or after the onset of the condition. Treatment can be directed to one or more effects or symptoms of the disease and / or the underlying pathology. Treatment can be any alleviation and can be, but is not limited to, the complete elimination of the disease or disease symptoms. Thus, treatment refers to any sign of success in the treatment or improvement of an injury, disease, pathology or condition, including any objective or subjective parameter such as elimination, alleviation, attenuation of symptoms or making the injury, pathology or condition more tolerable to the patient, slowing the rate of deterioration or decline, reducing the debilitation caused by the endpoint of degeneration, and improving the patient's physical or mental health. Treatment or improvement of symptoms can be based on objective or subjective parameters, such as the results of a physical examination, neuropsychiatric examination and / or psychiatric assessment. When measured by any standard technique, the degree of such alleviation or improvement can be at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95% or 100% compared to an equivalent untreated control.

[0165] The treatment method comprises administering to the subject a therapeutically effective amount of a compound described herein. The administration step may be a single administration or may include a series of administrations. The length of treatment time depends on various factors, such as the severity of the condition, the age of the patient, the concentration of the compound, the activity of the composition used in the treatment, or a combination thereof. It should also be recognized that the effective dose of the agent used for treatment may increase or decrease over the course of a particular treatment regimen. Changes in dosage may play a role and become apparent through standard diagnostic assays known in the art. In some cases, long-term administration may be required. For example, the composition may be administered to the subject in an amount and duration sufficient to treat the patient. Detailed Description of the Invention

[0167] The present invention is based on the unexpected discovery of new selective and potent compounds that are orally and / or topically available and / or suitable for gastrointestinal (GI) tract limited administration. Disclosed herein is a series of new JAK inhibitors that have been designed to be potentially suitable for (I) oral administration or (II) GI and / or topical use on the skin. For compounds designed for oral administration, they are potent for JAK2 and have selectivity over other JAK kinases and good overall drug properties. For compounds potentially suitable for GI restricted or topical use on the skin, they are designed to show strong pan-JAK activity, including JAK1 and / or TYK2. Specifically, these compounds are designed to show minimal oral absorption to limit systemic exposure, but to show high exposure at the site of action, particularly in the gastrointestinal tract.

[0168] Inhibition of Janus kinases will inevitably suppress immune function and may increase the risk of both bacterial and viral infections. By limiting JAK inhibition to the GI tract for GI-limited compounds or topically for compounds designed for topical application on the skin, systemic exposure of the compound can be greatly reduced or eliminated, thereby preserving immune function. In oncology indications where JAK2 is a driver of cancer and JAK2 inhibition is an appropriate treatment approach, JAK2-selective inhibitors preserve immune function independent of JAK2 signaling.

[0169] The selected compounds of the present invention are suitable for oral administration to combat cancer. These compounds are designed to show good efficacy against JAK2 and have good oral absorption and good in vivo stability. In addition, the compounds may be selective for other JAK kinases (such as JAK1).

[0170] Selected compounds of the present invention are suitable for treating GI diseases and have limited systemic exposure after oral administration. These compounds have good potency against JAK kinases (such as JAK1, TYK2 and JAK2) and show higher exposure at the site of action through limited absorption.

[0171] Selected compounds of the present invention are suitable for topical skin administration. These compounds show good potency against JAK kinases (e.g., JAK1, TYK2, and JAK2), have limited systemic exposure, and have higher exposure at the site of action in the dermis / epidermis and, therefore, in the skin.

[0172] The present invention also provides pharmaceutical compositions of these compounds and methods of preparing and using the same. The JAK inhibitors disclosed herein exhibit excellent efficacy profiles while enjoying favorable pharmacokinetic profiles and pharmaceutical properties suitable for target indications.

[0173] In one aspect, the present invention generally relates to a compound having structural formula (I) or a pharmaceutically acceptable form or isotopic derivative thereof:

[0174]

[0175] in

[0176] X is N or CR x , where R x is R', halogen (e.g., Cl, F), CN or OR';

[0177] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0178] R 1is hydrogen, halogen (e.g., Cl, F), CN, C1-C6 (e.g., C1-C3) unsubstituted or substituted alkyl, or OR';

[0179] R 2 is a C1-C ... 16 (e.g. C1-C6, C7-C 16 ) aliphatic groups (e.g., linear or cyclic), wherein the aliphatic groups are optionally substituted with one or more of halogen (e.g., Cl, F), OR', NRR', CN, CONRR', NRCOR', and C1-C6 (e.g., C1-C3) alkyl, which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR';

[0180] R 3 is R', halogen (e.g., Cl, F) or CN;

[0181] R 4 and R 4’ Each of the C1-C ... 12 (e.g. C1-C6, C7-C 12 ) aliphatic group, and R 4 and R 4’ can together form a 3- to 7-membered (eg 3- or 4-membered) ring having 0 to 3 heteroatoms selected from O, N and S, and wherein R 4 and R 4’ Each of is optionally substituted by CN, CF3 or OR'; provided that if R 4 and R 4’ If one of is hydrogen, then the other is not hydrogen; and

[0182] Each of R and R' is independently hydrogen or C1-C 12 (e.g. C1-C6, C7-C 12 ) unsubstituted or substituted alkyl (eg, CH2F, CHF2 or CF3).

[0183] In certain embodiments,

[0184] X is CR x , where R x is R', halogen (e.g., Cl, F), CN or OR';

[0185] Z1 is CR' and Z2 is N;

[0186] R 1is halogen (e.g., Cl, F), CN, C1-C6 (e.g., C1-C3), unsubstituted or substituted alkyl, or OR';

[0187] R 2 is a C1-C ... 16 (e.g. C1-C6, C7-C 16 ) aliphatic groups (e.g., linear or cyclic), wherein the aliphatic groups are optionally substituted with one or more of halogen (e.g., Cl, F), OR', NRR', CN, CONRR', NRCOR', and C1-C6 (e.g., C1-C3) alkyl, wherein one or more of the groups are further optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR';

[0188] R 3 is R', halogen (e.g., Cl, F) or CN;

[0189] R 4 and R 4’ Each of the C1-C ... 12 (e.g. C1-C6, C7-C 12 ) aliphatic group, and R 4 and R 4’ can together form a 3- to 7-membered (eg 3- or 4-membered) ring having 0 to 3 heteroatoms selected from O, N and S, and wherein R 4 and R 4’ Each of is optionally substituted by CN, CF3 or OR'; provided that if R 4 and R 4’ If one of is hydrogen, then the other is not hydrogen; and

[0190] Each of R and R' is independently hydrogen or C1-C 12 (e.g. C1-C6, C7-C 12 ) unsubstituted or substituted alkyl (eg, CH2F, CHF2 or CF3).

[0191] In another aspect, the present invention generally relates to a compound having structural formula (I) or a pharmaceutically acceptable form or isotopic derivative thereof:

[0192]

[0193] in

[0194] X is N or CR x , where R x is R', halogen (e.g., Cl, F), CN or OR';

[0195] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0196] R 1 It is Cl;

[0197] R 2 is a C1-C ... 16 (e.g. C1-C6, C7-C 16 ) aliphatic groups (e.g., linear or cyclic), wherein the aliphatic groups are optionally substituted with one or more of halogen (e.g., Cl, F), OR', NRR', CN, CONRR', NRCOR', and C1-C6 (e.g., C1-C3) alkyl, which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR';

[0198] R 3 is R', halogen (e.g., Cl, F) or CN;

[0199] R 4’ is H or C1-C6 (e.g. C1-C3) alkyl;

[0200] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 (e.g. C1-C3) alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen (e.g., Cl, F), OR', NRR', CN, CONRR', NRCOR', and C1-C6 (e.g., C1-C3) alkyl, which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR'; and

[0201] Each of R and R' is independently hydrogen or C1-C 12 (e.g. C1-C6, C7-C 12 ) unsubstituted or substituted alkyl (eg, CH2F, CHF2 or CF3).

[0202] In certain embodiments, X is CR x .

[0203] In certain embodiments, X is N.

[0204] In certain embodiments, R x It’s H.

[0205] In certain embodiments, R 4’ is H, X is CR x , Z1 is CH and Z2 is N, the compound has the structural formula (II):

[0206]

[0207] In certain embodiments, R x It is hydrogen, halogen (e.g., Cl, F), C1-C6 (e.g., C1-C3), unsubstituted or substituted alkyl or alkoxy.

[0208] In certain embodiments, R 3 It’s H.

[0209] In certain embodiments, R 3 It is F, CH3 or Cl.

[0210] In certain embodiments, X is CR x , R 4’ is H, Z1 is CH and Z2 is N, the compound has the structural formula (III):

[0211]

[0212] In certain embodiments, R x It's H, R ” It is CH3, R 3 is H and R 5 It is CN.

[0213] In certain embodiments, R 2 is a C1-C6 (e.g. C1-C3) aliphatic (e.g. linear or cyclic) group in which 0 to 2 carbon atoms are replaced by one or more heteroatoms selected from N, O and S and optionally substituted by CN or CF3 groups.

[0214] In certain embodiments, R 2 is a C7-C ... 16 Aliphatic groups (eg, straight-chain or cyclic).

[0215] In certain embodiments, R 2 comprising C3-C ... 16 Cycloalkyl.

[0216] In certain embodiments, R 2Contains C3-C6 cycloalkyl.

[0217] In certain embodiments, R 2 It is cyclopropyl.

[0218] In certain embodiments, the compound has the structural formula (II):

[0219]

[0220] in

[0221] R 2 is C1-C6 (e.g., C1-C3) alkyl;

[0222] R 3 It is R';

[0223] R 5 Contains CN;

[0224] R x is R', halogen (e.g., Cl, F), CN or OR';

[0225] R' is hydrogen or C1-C 12 (e.g. C1-C6, C7-C 12 ) unsubstituted or substituted alkyl (e.g., CH2F, CHF2 or CF3); and

[0226] R" is H, C1-C6 (e.g. C1-C3) alkyl,

[0227] or a pharmaceutically acceptable form or isotopic derivative thereof.

[0228] In certain embodiments, R" is in the S-configuration, and the compound has structural formula (III):

[0229]

[0230] In certain embodiments, R" is methyl.

[0231] In certain embodiments, R x It's H, R 3 is H and R 5 It is CN.

[0232] In certain embodiments, R 2 Contains C3-C6 cycloalkyl.

[0233] In certain embodiments, R 2 It is cyclopropyl.

[0234] In another aspect, the present invention generally relates to a compound having structural formula (I) or a pharmaceutically acceptable form or isotopic derivative thereof:

[0235]

[0236] in

[0237] X is N or CR x , where R x is R', halogen (e.g., Cl, F), CN or OR';

[0238] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0239] R 1 It is CH3;

[0240] R 2 is a C1-C ... 16 (e.g. C1-C6, C7-C 16 ) aliphatic groups (e.g., linear or cyclic), wherein the aliphatic groups are substituted with one or more of CN, CONRR', or NRCOR', which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR';

[0241] R 3 is R', halogen (e.g., Cl, F) or CN;

[0242] R 4’ is H or C1-C6 (e.g. C1-C3) alkyl;

[0243] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 (e.g. C1-C3) alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen (e.g., Cl, F), OR', NRR', CN, CONRR', NRCOR', and C1-C6 (e.g., C1-C3) alkyl, which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR'; and

[0244] Each of R and R' is independently hydrogen or C1-C 12 (e.g. C1-C6, C7-C 12 ) unsubstituted or substituted alkyl (eg, CH2F, CHF2 or CF3).

[0245] In certain embodiments, X is N.

[0246] In certain embodiments, X is CR x .

[0247] In certain embodiments, R x It’s H.

[0248] In certain embodiments, R 2 It is a C1-C6 (eg C1-C3) aliphatic group substituted by a CN group.

[0249] In certain embodiments, R 2 It is a C1-C3 alkyl group substituted by a CN group.

[0250] In certain embodiments, R 2 It is CH2CN.

[0251] In certain embodiments, R 4’ It’s H.

[0252] In certain embodiments, R 4 Yes-CH2R 5 , where R 5 Contains CN or CF3.

[0253] In certain embodiments, R 5 It is CN.

[0254] In certain embodiments, R 3 It’s H.

[0255] In certain embodiments, Z1 is CH and Z2 is N.

[0256] In certain embodiments, R 2 is CH2CN, R 3 It's H, R 4’ is H, X is CR x , where R x is H, Z1 is CH and Z2 is N.

[0257] In certain embodiments, R 4 It is -CH2CN.

[0258] In another aspect, the present invention generally relates to a compound having structural formula (I) or

[0259] Pharmaceutically acceptable forms or isotopic derivatives:

[0260]

[0261] in

[0262] X is N or CR x , where R x is R', halogen (e.g., Cl, F), CN or OR';

[0263] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2

[0264] is N and the other is CR';

[0265] R 1 It is CH3;

[0266] R 2 is a C3-C ... 16 aliphatic groups (e.g., linear or cyclic), wherein the aliphatic groups are separated by 0-4 C1-C6 (e.g.,

[0267] Such as C1-C3) alkyl substitution;

[0268] R 3 is R', halogen (e.g., Cl, F) or CN;

[0269] R 4’ is H or C1-C6 (e.g. C1-C3) alkyl;

[0270] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 (e.g., C1-C3) alkyl, and

[0271] R 5 is CN, CF3, OR' or wherein 0 to 4 carbon atoms are replaced by one or more selected from N, O

[0272] and S heteroatom substituted C1-C 11 An aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen (e.g., Cl, F), OR', NRR', CN, CONRR', NRCOR', and C1-C6 (e.g., C1-C3) alkyl, which in turn is optionally substituted with F

[0273] (eg, CH2F, CHF2 or CF3), OR' or NRR'; and each of R and R' is independently hydrogen or C1-C 12 (e.g. C1-C6, C7-C 12 ) unsubstituted or substituted alkyl (eg, CH2F, CHF2 or CF3).

[0274] In certain embodiments, R 4’ is H, X is CR x, Z1 is CH and Z2 is N, and the compound has structural formula (II):

[0275]

[0276] In certain embodiments, X is CR x , where R x is hydrogen, halogen (such as Cl, F),

[0277] C1-C6 (e.g., C1-C3) unsubstituted or substituted alkyl or alkoxy.

[0278] In certain embodiments, R x It’s H.

[0279] In certain embodiments, X is N.

[0280] In certain embodiments, R 3 It’s H.

[0281] In certain embodiments, R 3 It is F, CH3 or Cl.

[0282] In certain embodiments, Z1 is CH and Z2 is N.

[0283] In certain embodiments, R ” is H and R 5 It is CN.

[0284] In certain embodiments, X is CR x , R 3 It's H, R 4’ is H, Z1 is CH and Z2 is N, and the compound has structural formula (III):

[0285]

[0286] In certain embodiments, R" is CH3 and R 5 It is CN.

[0287] In certain embodiments, R 2 is a C5-C7 aliphatic group (eg, linear or cyclic) optionally containing one or more heteroatoms selected from N, O, and S, wherein the aliphatic group is substituted with two or more C1-C6 (eg, C1-C3) alkyl groups.

[0288] In certain embodiments, R 2 is a 6-membered cyclic aliphatic group containing O, wherein the aliphatic group is substituted with two or more C1-C3 alkyl groups.

[0289] In certain embodiments, R2 is a 6-membered cyclic aliphatic group containing O, wherein the aliphatic group is substituted with two or more methyl groups.

[0290] In certain embodiments, R 2 is a 6-membered cyclic aliphatic group containing O, wherein the aliphatic group is substituted by four methyl groups.

[0291] In certain embodiments, R 2 yes:

[0292]

[0293] in

[0294] Z3 is N, CH or O, wherein when Z3 is O, R 6 does not exist;

[0295] Each of m and n is independently 0, 1, 2, 3 or 4; provided that both m and n are not 0 at the same time, and

[0296] R 6 is C1-C6 (e.g., C1-C3) alkyl, CN, halogen (e.g., Cl, F), or C(O)R 7 , where R 7 is C1-C6 (e.g., C1-C3) alkyl; provided that when Z3 is N, R6 is not CN or halogen.

[0297] In certain embodiments, the compound has structural formula (IV):

[0298]

[0299] where R x It's H, R 3 =H, R" is H or C1-C6 (e.g. C1-C3) alkyl, R 6 is C1-C6 (e.g. C1-C3) alkyl or C(O)R 7 , where R 7 is C1-C6 (e.g. C1-C3) alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group (e.g., linear or cyclic), wherein the aliphatic group is optionally substituted with one or more of halogen (e.g., Cl, F), OR', NRR', CN, CONRR', NRCOR', and C1-C6 (e.g., C1-C3) alkyl, which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR'.

[0300] In certain embodiments, R 2 It is R 8 -CN, where R 8 Yes (CH2) m , where m is 1, 2, 3, 4, 5, or 6.

[0301] In certain embodiments, m is 1.

[0302] In which R 4 and R 4’ In certain embodiments of (I) that together form a 3- to 7-membered (eg, 3- or 4-membered) ring, the compound has the structural formula (V):

[0303]

[0304] where k is 0, 1, 2, or 3.

[0305] In certain embodiments of (V), k is 0 or 1.

[0306] In certain embodiments of (V), R 1 It’s H.

[0307] In certain embodiments of (V), R 1 It is F, CH3 or Cl.

[0308] Amide of compound (I) (ie -C(=O)NR 4 R 4’ A list of non-limiting examples of ) components is provided in Table 1.

[0309] Table 1

[0310]

[0311] R of compound (I) 2 A list of non-limiting examples is provided in Table 2.

[0312] Table 2

[0313]

[0314] Non-limiting examples of compounds according to the present invention include:

[0315] (S)-4-(5-chloro-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide

[0316] 4-(5-chloro-2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(cyanomethyl)benzamide

[0317] (S)-4-(5-chloro-2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide

[0318] (S)-4-(5-chloro-2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide-2,3,5,6-d4

[0319] (S)-4-(5-chloro-2-((1-isopropyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide

[0320] (S)-4-(5-chloro-2-((1-ethyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide 4-methylbenzenesulfonate

[0321] (S)-4-(5-chloro-2-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide

[0322] (S)-4-(5-chloro-2-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanopropyl)benzamide

[0323] (S)-4-(5-chloro-2-((1-(piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide

[0324] 4-(5-chloro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(cyanomethyl)benzamide

[0325] (S)-4-(5-chloro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide

[0326] 4-(5-chloro-2-((1-(cyanomethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(cyanomethyl)benzamide

[0327] (S)-4-(5-chloro-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanopropyl)benzamide

[0328] (S)-4-(5-chloro-2-((1-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide

[0329] (S)-4-(5-chloro-2-((1-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanopropyl)benzamide

[0330] 4-(5-chloro-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(cyanomethyl)benzamide

[0331] (S)-4-(5-chloro-2-((1-(cyanomethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide

[0332] (S)-4-(5-chloro-2-((1-(piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanopropyl)benzamide

[0333] (S)-4-(2-((1H-pyrazol-4-yl)amino)-5-chloropyrimidin-4-yl)-N-(1-cyanoethyl)benzamide.

[0334] Non-limiting examples of compounds according to the present invention include:

[0335] (S)-N-(1-cyanobutyl)-4-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide

[0336] (S)-N-(1-cyanoethyl)-4-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide

[0337] N-(Cyanomethyl)-4-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide

[0338] N-(Cyanomethyl)-4-(2-((1-(Cyanomethyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide

[0339] (S)-N-(1-cyanoethyl)-4-(2-((1-(cyanomethyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide

[0340] (S)-4-(2-((1-(Cyanomethyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)-N-(1-cyanopropyl)benzamide

[0341] (S)-N-(1-cyanoethyl)-4-(5-methyl-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0342] (S)-N-(Cyano(cyclopropyl)methyl)-4-(5-methyl-2-((1-(piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0343] (S)-N-(1-cyanopropyl)-4-(5-methyl-2-((1-(piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0344] (S)-N-(1-cyanopropyl)-4-(5-methyl-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0345] N-(Cyanomethyl)-4-(5-methyl-2-((1-(piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0346] N-((S)-1-cyanoethyl)-4-(2-((1-(trans-2,6-dimethylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide

[0347] N-((S)-1-cyanoethyl)-4-(2-((1-((2S,4s,6R)-2,6-dimethylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide

[0348] N-((S)-1-cyanoethyl)-4-(2-((1-((2S,4r,6R)-2,6-dimethylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide

[0349] (S)-N-(Cyano(cyclopropyl)methyl)-4-(2-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide

[0350] (S)-N-(1-cyanoethyl)-4-(2-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide

[0351] (S)-N-(1-cyanobutyl)-4-(2-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide

[0352] (S)-N-(1-cyanopropyl)-4-(2-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide

[0353] N-(Cyanomethyl)-4-(5-methyl-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0354] N-(Cyanomethyl)-4-(5-methyl-2-((1-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0355] (S)-N-(1-cyanoethyl)-4-(5-methyl-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0356] (S)-N-(1-cyanoethyl)-4-(5-methyl-2-((1-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0357] N-(Cyanomethyl)-2-fluoro-4-(5-methyl-2-((1-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0358] (S)-N-(1-cyanopropyl)-4-(5-methyl-2-((1-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0359] (S)-N-(1-cyanopropyl)-4-(5-methyl-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0360] N-((1-Cyanocyclopropyl)methyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0361] N-(2-Cyano-2-methylpropyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0362] (S)-N-(1-cyanoethyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0363] N-(Cyanomethyl)-4-(5-methyl-2-((1-(1-pivaloylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0364] N-(Cyanomethyl)-4-(5-methyl-2-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0365] N-(Cyanomethyl)-4-(5-methyl-2-((1-(1-(1-methylcyclopropanecarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0366] (S)-N-(1-cyanoethyl)-4-(2-((1-(1-(2-hydroxyacetyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide

[0367] 4-(2-((1-(trans-4-cyanocyclohexyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)-N-((S)-1-cyanoethyl)benzamide

[0368] N-((S)-1-Cyanoethyl)-4-(5-methyl-2-((1-((S*)-1,1,1-trifluoropropan-2-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0369] N-((S)-1-Cyanoethyl)-4-(5-methyl-2-((1-((R*)-1,1,1-trifluoropropan-2-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0370] (S)-N-(1-cyanoethyl)-4-(5-methyl-2-((1-(piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0371] (S)-4-(2-((1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)-N-(1-cyanoethyl)benzamide

[0372] N-((S)-1-Cyanopropyl)-4-(5-methyl-2-((1-((R*)-1,1,1-trifluoropropan-2-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide

[0373] N-((S)-1-Cyanopropyl)-4-(5-methyl-2-((1-((S*)-1,1,1-trifluoropropan-2-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide.

[0374] In another aspect, the present invention generally relates to a pharmaceutical composition comprising a compound disclosed herein effective for treating or ameliorating one or more diseases or disorders in mammals, including humans, and a pharmaceutically acceptable excipient, carrier, or diluent.

[0375] In another aspect, the present invention generally relates to a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable form or isotopic derivative thereof, and a pharmaceutically acceptable excipient, carrier or diluent in an amount effective to treat or alleviate one or more diseases or disorders in mammals, including humans:

[0376]

[0377] in

[0378] X is N or CR x , where R x is R', halogen (e.g., Cl, F), CN or OR';

[0379] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0380] R 1 It is Cl;

[0381] R 2 is a C1-C ... 16 (e.g. C1-C6, C7-C 16 ) aliphatic groups (e.g., linear or cyclic), wherein the aliphatic groups are optionally substituted with one or more of halogen (e.g., Cl, F), OR', NRR', CN, CONRR', NRCOR', and C1-C6 (e.g., C1-C3) alkyl, which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR';

[0382] R 3 is R', halogen (e.g., Cl, F) or CN;

[0383] R4’ is H or C1-C6 (e.g. C1-C3) alkyl;

[0384] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 (e.g. C1-C3) alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen (e.g., Cl, F), OR', NRR', CN, CONRR', NRCOR', and C1-C6 (e.g., C1-C3) alkyl, which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR'; and

[0385] Each of R and R' is independently hydrogen or C1-C 12 (e.g. C1-C6, C7-C 12 ) unsubstituted or substituted alkyl (eg, CH2F, CHF2 or CF3).

[0386] In another aspect, the present invention generally relates to a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable form or isotopic derivative thereof, and a pharmaceutically acceptable excipient, carrier or diluent in an amount effective to treat or alleviate one or more diseases or disorders in mammals, including humans:

[0387]

[0388] in

[0389] X is N or CR x , where R x is R', halogen (e.g., Cl, F), CN or OR';

[0390] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0391] R 1 It is CH3;

[0392] R 2 is a C1-C ... 16 (e.g. C1-C6, C7-C 16) aliphatic groups (e.g., linear or cyclic), wherein the aliphatic groups are substituted with one or more of CN, CONRR', or NRCOR', which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR';

[0393] R 3 is R', halogen (e.g., Cl, F) or CN;

[0394] R 4’ is H or C1-C6 (e.g. C1-C3) alkyl;

[0395] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 (e.g. C1-C3) alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen (e.g., Cl, F), OR', NRR', CN, CONRR', NRCOR', and C1-C6 (e.g., C1-C3) alkyl, which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR'; and

[0396] Each of R and R' is independently hydrogen or C1-C 12 (e.g. C1-C6, C7-C 12 ) unsubstituted or substituted alkyl (eg, CH2F, CHF2 or CF3).

[0397] In another aspect, the present invention generally relates to a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable form or isotopic derivative thereof, and a pharmaceutically acceptable excipient, carrier or diluent in an amount effective to treat or alleviate one or more diseases or disorders in mammals, including humans:

[0398]

[0399] in

[0400] X is N or CR x , where R x is R', halogen (e.g., Cl, F), CN or OR';

[0401] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0402] R 1 It is CH3;

[0403] R 2 is a C3-C ... 16 an aliphatic group (e.g., linear or cyclic), wherein the aliphatic group is substituted with 0 to 4 C1-C6 (e.g., C1-C3) alkyl groups;

[0404] R 3 is R', halogen (e.g., Cl, F) or CN;

[0405] R 4’ is H or C1-C6 (e.g. C1-C3) alkyl;

[0406] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 (e.g. C1-C3) alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen (e.g., Cl, F), OR', NRR', CN, CONRR', NRCOR', and C1-C6 (e.g., C1-C3) alkyl, which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR'; and

[0407] Each of R and R' is independently hydrogen or C1-C 12 (e.g. C1-C6, C7-C 12 ) unsubstituted or substituted alkyl (eg, CH2F, CHF2 or CF3).

[0408] In certain embodiments, the pharmaceutical compositions of the present invention are suitable for oral administration.

[0409] In certain embodiments, the pharmaceutical compositions of the present invention are administered topically.

[0410] In certain embodiments, the pharmaceutical compositions of the present invention are suitable for GI-localized administration.

[0411] In certain embodiments, the pharmaceutical compositions of the present invention can be used to treat or alleviate one or more inflammatory diseases, immune-mediated diseases and cancers or related diseases or disorders.

[0412] In certain embodiments, the disease or disorder amenable to treatment is an inflammatory disease.

[0413] In certain embodiments, the disease or disorder amenable to treatment is an immune-mediated disease.

[0414] In certain embodiments, the disease or disorder amenable to treatment is cancer.

[0415] In certain embodiments, the disease or disorder suitable for treatment is selected from inflammatory bowel disease, psoriasis, vitiligo, atopic dermatitis, systemic lupus erythematosus, asthma, diabetic nephropathy, chronic myeloid leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), breast cancer and ovarian cancer.

[0416] In another aspect, the present invention generally relates to a unit dosage form comprising a pharmaceutical composition disclosed herein.

[0417] In certain embodiments, the unit dosage form is in the form of a tablet.

[0418] In certain embodiments, the unit dosage form is in the form of a capsule.

[0419] In certain embodiments, the unit dosage form is in the form of a topical dosage form.

[0420] In another aspect, the present invention generally relates to a method for treating or alleviating a disease or disorder, comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable form or isotopic derivative thereof, which is effective for treating, preventing or alleviating one or more inflammatory diseases, immune-mediated diseases, cancer, or related diseases or disorders in mammals, including humans, and a pharmaceutically acceptable excipient, carrier, or diluent:

[0421]

[0422] in

[0423] X is N or CR x , where R x is R', halogen (e.g., Cl, F), CN or OR';

[0424] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0425] R 1 It is Cl;

[0426] R 2 is a C1-C ... 16 (e.g. C1-C6, C7-C 16) aliphatic groups (e.g., linear or cyclic), wherein the aliphatic groups are optionally substituted with one or more of halogen, OR', NRR', CN, CONRR', NRCOR', and C1-C6 (e.g., C1-C3) alkyl, which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR';

[0427] R 3 is R', halogen (e.g., Cl, F) or CN;

[0428] R 4’ is H or C1-C6 (e.g. C1-C3) alkyl;

[0429] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 (e.g. C1-C3) alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen (e.g., Cl, F), OR', NRR', CN, CONRR', NRCOR', and C1-C6 (e.g., C1-C3) alkyl, which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR'; and

[0430] Each of R and R' is independently hydrogen or C1-C 12 (e.g. C1-C6, C7-C 12 ) unsubstituted or substituted alkyl (eg, CH2F, CHF2 or CF3).

[0431] In another aspect, the present invention generally relates to a method for treating or alleviating a disease or disorder, comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable form or isotopic derivative thereof, which is effective for treating, preventing or alleviating one or more inflammatory diseases, immune-mediated diseases, cancer, or related diseases or disorders in mammals, including humans, and a pharmaceutically acceptable excipient, carrier, or diluent:

[0432]

[0433] in

[0434] X is N or CR x , where R x is R', halogen (e.g., Cl, F), CN or OR';

[0435] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0436] R 1 It is CH3;

[0437] R 2 is a C1-C ... 16 (e.g. C1-C6, C7-C 16 ) aliphatic groups (e.g., linear or cyclic), wherein the aliphatic groups are substituted with one or more of CN, CONRR', or NRCOR', which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR';

[0438] R 3 is R', halogen (e.g., Cl, F) or CN;

[0439] R 4’ is H or C1-C6 (e.g. C1-C3) alkyl;

[0440] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 (e.g. C1-C3) alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen (e.g., Cl, F), OR', NRR', CN, CONRR', NRCOR', and C1-C6 (e.g., C1-C3) alkyl, which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR'; and

[0441] Each of R and R' is independently hydrogen or C1-C 12 (e.g. C1-C6, C7-C 12 ) unsubstituted or substituted alkyl (eg, CH2F, CHF2 or CF3).

[0442] In another aspect, the present invention generally relates to a method for treating or alleviating a disease or disorder, comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable form or isotopic derivative thereof, which is effective for treating, preventing or alleviating one or more inflammatory diseases, immune-mediated diseases, cancer, or related diseases or disorders in mammals, including humans, and a pharmaceutically acceptable excipient, carrier, or diluent:

[0443]

[0444] in

[0445] X is N or CR x , where R x is R', halogen (e.g., Cl, F), CN or OR';

[0446] Each of Z1 and Z2 is independently selected from N and CR', provided that one of Z1 and Z2 is N and the other is CR';

[0447] R 1 It is CH3;

[0448] R 2 is a C3-C ... 16 an aliphatic group (e.g., linear or cyclic), wherein the aliphatic group is substituted with 0-4 C1-C6 (e.g., C1-C3) alkyl groups;

[0449] R 3 is R', halogen (e.g., Cl, F) or CN;

[0450] R 4’ is H or C1-C6 (e.g. C1-C3) alkyl;

[0451] R 4 Yes-CHR"-R 5 , wherein R" is H or C1-C6 (e.g. C1-C3) alkyl, and R 5 is CN, CF3, OR' or a C1-C ... 11 an aliphatic group, wherein the aliphatic group is optionally substituted with one or more of halogen (e.g., Cl, F), OR', NRR', CN, CONRR', NRCOR', and C1-C6 (e.g., C1-C3) alkyl, which in turn are optionally substituted with F (e.g., CH2F, CHF2, or CF3), OR', or NRR'; and

[0452] Each R and R' is independently hydrogen or C1-C 12 (e.g. C1-C6, C7-C 12 ) unsubstituted or substituted alkyl (eg, CH2F, CHF2 or CF3).

[0453] In certain embodiments, the present invention generally relates to a method of treating or ameliorating a disease or disorder comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound disclosed herein, wherein the disease or disorder is one or more of an inflammatory disease, an immune-mediated disease, and cancer, or a related disease or disorder.

[0454] In certain embodiments, the disease or disorder is an inflammatory disease.

[0455] In certain embodiments, the disease or disorder is an immune-mediated disease.

[0456] In certain embodiments, the disease or disorder is cancer.

[0457] In certain embodiments, the disease or disorder is selected from inflammatory bowel disease, psoriasis, vitiligo, atopic dermatitis, systemic lupus erythematosus, asthma, diabetic nephropathy, chronic myeloid leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), breast cancer, and ovarian cancer.

[0458] In certain embodiments, administration is oral administration.

[0459] In certain embodiments, administration is by topical administration.

[0460] In certain embodiments, administration is via GI localized administration.

[0461] In another aspect, the present invention generally relates to the use of a compound disclosed herein and a pharmaceutically acceptable excipient, carrier, or diluent for the preparation of a medicament for treating a disease or disorder.

[0462] In certain embodiments, the disease or disorder is one or more of an inflammatory disease, an immune-mediated disease, and cancer.

[0463] In certain embodiments, the disease or disorder is an inflammatory disease.

[0464] In certain embodiments, the disease or disorder is an immune-mediated disease.

[0465] In certain embodiments, the disease or disorder is cancer.

[0466] In certain embodiments, the medicament is for oral administration.

[0467] In certain embodiments, the medicament is for topical administration.

[0468] In certain embodiments, the medicament is for GI-localized administration.

[0469] A list of non-limiting examples of compounds of the present invention is provided in Table 3. Some exemplary data for select compounds are provided in Table 4.

[0470] As discussed herein, isotopic derivative compounds having one or more (e.g., 1, 2, 4, 5, 6, 7, 8, 9, 10, etc.) hydrogen atoms replaced with deuterium atoms are contemplated by the present invention.

[0471] The term "inflammatory disease" refers to a disease or condition characterized by abnormal inflammation, such as elevated levels of inflammation compared to a control, such as a healthy person without the disease. Examples of inflammatory diseases that can be treated using the compounds, pharmaceutical compositions, or methods described herein include autoimmune diseases, traumatic brain injury, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, type 1 diabetes, Guillain-Barré syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjögren's syndrome, vasculitis, In some embodiments, the present invention relates to a group of diseases that are inflammatory, such as inflammatory bowel disease, ... Other diseases and disorders that may be associated with chronic inflammation include Alzheimer's disease, congestive heart failure, stroke, aortic stenosis, atherosclerosis, osteoporosis, Parkinson's disease, infections, inflammatory bowel disease (IBD), allergic contact dermatitis and other eczemas, systemic sclerosis, transplantation, and multiple sclerosis. Some of the above-mentioned diseases, disorders, and conditions for which the compounds of the present disclosure may be particularly effective (due to, for example, limitations of current therapies) are described in more detail below.

[0472] The term "autoimmune disease" refers to a disease or condition in which the immune system of a subject has an abnormal immune response to a substance that does not normally elicit an immune response in a healthy subject. Examples of autoimmune diseases that can be treated using the compounds, pharmaceutical compositions, or methods described herein include acne vulgaris, acute diffuse encephalomyelitis, acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, gammaglobulinemia, Aicardi-Goutières syndrome (AGS), alopecia areata, alopecia totalis, amyloidosis, ankylosing spondylitis, anti-GBM / anti-TBM nephritis, antiphospholipid syndrome, autoimmune angioedema, autoimmune aplastic anemia, autoimmune dysautonomia, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease, autoimmune myocarditis, autoimmune ovarian inflammation, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thrombocytopenic purpura, autoimmune thyroid disease, autoimmune urticaria, axonal or neuronal neuropathy, Ballou disease, Behçet's disease, bullous pemphigoid, cardiomyopathy, Castleman disease, celiac disease, Chagas disease, chronic atypical neutrophilic dermatitis with lipodystrophy and fever (CANDLE), chronic active hepatitis, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy, chronic relapsing multifocal osteomyelitis, Churg-Strauss syndrome, cicatricial pemphigoid / benign mucous membrane pemphigoid, Crohn's disease, Cogans syndrome, cold agglutination encephalopathy, congenital heart block, coxsackievirus myocarditis, CREST disease, Cushing's disease, demyelinating neuropathy, depression, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dressler syndrome, dry eye syndrome (DES), endometriosis, eosinophilic esophagitis, eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, experimental allergic encephalomyelitis, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis, graft-versus-host disease ( GVDH), Graves' disease, Guillain-Barré syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, hemolytic anemia, Henlein-Schönlein purpura, herpes gestationis, hidradenitis suppurativa, hypogammaglobulinemia, idiopathic thrombocytopenic purpura, IgA nephropathy, IgG4-related sclerosis, inflammatory bowel disease (IBD), immunomodulatory lipoproteins, inclusion body myositis, interstitial cystitis, juvenile arthritis, juvenile diabetes mellitus (type 1 diabetes), juvenile dermatomyositis (JDM), juvenile myositis, Kawasaki syndrome, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, woody conjunctivitis, linear IgA disease, lupus, chronic Lyme disease,Meniere's disease, microscopic polyangiitis, mixed connective tissue disease, Mooren's ulcer, Mucha-Habermann disease, multiple sclerosis (MS), myasthenia gravis, myositis, narcolepsy, neuromyelitis optica, neutropenia, ocular cicatricial pemphigoid, optic neuritis, rheumatoid arthritis, streptococcal autoimmune neuropsychiatric disorders in children, paraneoplastic cerebellar degeneration, paroxysmal nocturnal hemoglobinuria, Parry's Romberg syndrome, Parsonnage-Turner syndrome, pars planitis (peripheral uveitis), pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, POEMS syndrome, polyarteritis nodosa, polycystic ovary syndrome (PCOS), autoimmune polyglandular syndromes types I, II, and III, polymyalgia rheumatica, polymyositis, myocardial infarction syndrome, postpericardiotomy syndrome, progesterone-induced dermatitis, primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, plaque psoriasis, idiopathic pulmonary fibrosis, pyoderma gangrenosum, pure red cell aplasia, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, Reiter's syndrome, relapsing polychondritis, Restless legs syndrome, retroperitoneal fibrosis, rheumatism, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjögren's syndrome, sperm and testicular autoimmunity, stiff-man syndrome, stimulator of interferon genes (STING)-associated vasculopathy in infancy (SAVI), subacute bacterial endocarditis, Susac syndrome, sympathetic ophthalmia, systemic lupus erythematosus (SLE), Takayasu arteritis, temporal arteritis / giant cell arteritis, thrombocytopenic purpura, Tolosa-Hunt syndrome, transplant rejection (allogeneic graft rejection), transverse myelitis, type 1 diabetes mellitus, ulcerative colitis, undifferentiated connective tissue disease, uveitis, vasculitis, bullous dermatosis, vitiligo, or Wegener's granulomatosis.

[0473] The term "immune-mediated disease" refers to chronic inflammatory diseases that are perpetuated by antibodies and cellular immunity. Immune-mediated diseases include, for example, but are not limited to, asthma, allergies, arthritis (e.g., rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis), juvenile arthritis, inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), endocrinopathy (e.g., type 1 diabetes and Graves' disease), neurodegenerative diseases (e.g., multiple sclerosis (MS)), autism spectrum disorders, depression, Alzheimer's disease, Guillain-Barré syndrome, obsessive-compulsive disorder, optic neuritis, retinal degeneration, dry eye syndrome (DES), Sjögren's syndrome, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's disease, Graves' disease, and others. Lin-Barré syndrome, myasthenia gravis, chronic idiopathic demyelinating disease (CID), vascular diseases (e.g., autoimmune deafness, systemic vasculitis, and atherosclerosis), skin diseases (e.g., dermatomyositis acne vulgaris, pemphigus, systemic lupus erythematosus (SLE), discoid lupus erythematosus, scleroderma, psoriasis, plaque psoriasis, vasculitis, vitiligo, and alopecia), Hashimoto's thyroiditis, pernicious anemia, Cushing's disease, Addison's disease, chronic active hepatitis, polycystic ovary syndrome (PCOS), celiac disease, pemphigus, transplant rejection (allogeneic transplant rejection), graft-versus-host disease (GVDH).

[0474] As used herein, the term "cancer" refers to all types of cancers, tumors, or malignancies found in mammals, such as humans, including blood cancers leukemias and lymphomas, T-ALL, large B-cell lymphomas, solid tumors such as epithelial cancers and sarcomas. Exemplary cancers include blood cancers, brain cancers, gliomas, glioblastomas, neuroblastomas, prostate cancer, colorectal cancer, pancreatic cancer, cervical cancer, stomach cancer, ovarian cancer, lung cancer, and cancer of the head. Exemplary cancers include thyroid cancer, cancer of the endocrine system, brain cancer, breast cancer, cervical cancer, colon cancer, head and neck cancer, liver cancer, kidney cancer, lung cancer, non-small cell lung cancer, melanoma, mesothelioma, ovarian cancer, sarcoma, stomach cancer, uterine cancer, medulloblastoma, colorectal cancer, and pancreatic cancer. Other examples include penis, skin - non-melanoma, anus, hepatobiliary, esophageal and gastric, uterine sarcoma, gastrointestinal stromal tumor, salivary gland, peripheral nervous system, soft tissue sarcoma, bone, kidney, myeloproliferative tumors, thyroid cancer, bile duct cancer, pancreatic adenocarcinoma, skin melanoma, colon adenocarcinoma, rectal adenocarcinoma, gastric adenocarcinoma, esophageal cancer, head and neck squamous cell carcinoma, invasive breast cancer, lung adenocarcinoma, lung squamous cell carcinoma, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary platelet hypercalcemia, primary macroglobulinemia, primary brain tumor, cancer, malignant pancreatic insulinoma, malignant carcinoid tumor, bladder cancer, precancerous skin lesions, testicular cancer, lymphoma, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenocortical cancer, tumors of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid epithelial carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, metastatic leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, round cell liposarcoma, or prostate cancer.

[0475] In certain embodiments of the use, the disease or disorder is selected from inflammatory bowel disease, psoriasis, vitiligo, atopic dermatitis, systemic lupus erythematosus, asthma, diabetic nephropathy, chronic myeloid leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), breast cancer and ovarian cancer.

[0476] Isotopically labeled compounds are also within the scope of the present disclosure. As used herein, "isotopically labeled compound" refers to a compound of the present disclosure, each as described herein, including pharmaceutically acceptable salts and prodrugs thereof, in which one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, for example, 2 H. 3 H. 13C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl.

[0477] By isotopically labeling the compounds of the present disclosure, the compounds can be used in drug and / or substance tissue distribution assays. 3 H) and carbon-14 ( 14 Compounds labeled with heavier isotopes such as deuterium ( 2 H) substitution may result in certain therapeutic advantages due to greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and therefore may be preferred in certain circumstances. Isotopically labeled compounds of the present disclosure, including pharmaceutically acceptable salts, esters, and prodrugs thereof, may be prepared by any means known in the art.

[0478] In addition, the usually abundant hydrogen ( 1 H) Substitution with heavier isotopes, such as deuterium, may provide certain therapeutic advantages resulting from improved absorption, distribution, metabolism and / or excretion (ADME) properties, resulting in drugs with improved efficacy, safety and / or tolerability. 12 C was 13 Advantages may also be obtained by replacing C (see WO 2007 / 005643, WO 2007 / 005644, WO 2007 / 016361 and WO 2007 / 016431).

[0479] Stereoisomers (eg, cis and trans isomers) and all optical isomers (eg, R and S enantiomers) of the compounds of the present disclosure, as well as racemates, diastereoisomers and other mixtures of these isomers, are within the scope of the present disclosure.

[0480] The compounds of the present invention are preferably isolated and purified after their preparation to obtain compositions containing equal to or greater than 95% by weight ("substantially pure"), which are then used or formulated as described herein. In certain embodiments, the compounds of the present invention are more than 99% pure.

[0481] Solvates and polymorphs of the compounds of the invention are also contemplated herein. Solvates of the compounds of the invention include, for example, hydrates.

[0482] Any suitable route of administration may be used, for example, parenteral, intravenous, subcutaneous, intramuscular, intracerebroventricular, intracorporeal, intraperitoneal, rectal or oral administration. The most suitable means of administration for a particular patient will depend on the nature and severity of the disease or condition being treated or the nature of the therapy being used and the properties of the active compound.

[0483] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the compounds described herein or their derivatives are mixed with at least one inert conventional excipient (or carrier), such as sodium citrate or dicalcium phosphate, or (i) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, (ii) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic, (iii) humectants, such as glycerol, (iv) disintegrants, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate, (v) solution retarders, such as paraffin, (vi) absorption accelerators, such as quaternary ammonium compounds, (vii) wetting agents, such as cetyl alcohol and glyceryl monostearate, (viii) adsorbents, such as kaolin and bentonite, and (ix) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also contain a buffering agent. Similar types of solid compositions may also be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols. Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings known in the art.

[0484] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compound, the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers, and emulsifiers, such as ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, or mixtures thereof. In addition to these inert diluents, the composition may also include other agents such as wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, or flavoring agents.

[0485] The materials, compositions, and components disclosed herein can be used in the disclosed methods and compositions, can be used in conjunction with them, can be used in their preparation, or are products thereof. It should be understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed, although the specific designation of each of the various individual and collective combinations and arrangements of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a method is disclosed and discussed, and a large number of modifications that can be made to a large number of molecules included in the method are discussed, then every combination and arrangement of the method and possible modifications are specifically contemplated unless specifically indicated to the contrary. Similarly, any subset or combination of them is also specifically contemplated and disclosed. This concept applies to all aspects of the present disclosure, including but not limited to steps in methods using the compositions of the present disclosure. Therefore, if there are various different additional steps that can be performed, it should be understood that each of these additional steps can be performed together with any specific method step or combination of steps of the method of the present disclosure, and each of these combinations or subsets of combinations are specifically contemplated and should be considered to have been disclosed.

[0486] Certain compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds falling within the scope of the present invention, including cis and trans isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures, and other mixtures thereof. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are intended to be included in the present invention.

[0487] According to the present invention, isomeric mixtures containing any of a variety of isomeric ratios can be utilized. For example, when only two isomers are combined, the present invention contemplates mixtures containing isomeric ratios of 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0. One of ordinary skill in the art will readily recognize that similar ratios are contemplated for more complex isomeric mixtures.

[0488] If, for example, a specific enantiomer of a compound of the invention is desired, it can be prepared by asymmetric synthesis or by derivatization with a chiral auxiliary, in the latter case separation of the resulting diastereomeric mixture and cleavage of the auxiliary group to provide the pure desired enantiomer. Alternatively, where the molecule contains a basic functional group such as an amino group or an acidic functional group such as a carboxyl group, diastereomeric salts are formed with a suitable optically active acid or base, and the diastereomers thus formed are resolved by fractional crystallization or chromatographic methods well known in the art, followed by recovery of the pure enantiomer. Example

[0489] A series of analogs were designed, synthesized and tested. Examples of these compounds are provided below.

[0490] Abbreviations

[0491] Some abbreviations are listed below:

[0492] Methanol: MeOH

[0493] Dichloromethane: DCM

[0494] Petroleum ether: PE

[0495] Ethyl acetate: EtOAc

[0496] Acetonitrile: ACN

[0497] Tetrahydrofuran: THF

[0498] Triethylamine: TEA

[0499] 4-Dimethylaminopyridine: DMAP

[0500] Tetrakis(triphenylphosphine)palladium: Pd(PPh3)4

[0501] 1,2-Dichloroethane: DCE

[0502] N,N-Diisopropylethylamine: DIPEA

[0503] N,N-dimethylformamide: DMF

[0504] Dicyclohexyl (2', 4', 6'-triisopropyl-[1, 1'-biphenyl]-2-yl) phosphine: X-Phos

[0505] O-(7-Aza-1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate: HATU

[0506] Tris(dibenzylideneacetone)dipalladium: Pd2(dba)3

[0507] [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II): Pd(dppf)Cl2

[0508] Room temperature: RT

[0509] Hours: hrs

[0510] Representative method for preparative HPLC: (flow rate and gradient can be varied)

[0511] An exemplary method for preparative HPLC is provided below.

[0512] Method A: NH4HCO3:

[0513] (Column: XBrige Prep C18 5μm OBD 19*150mm, PN 186002979; mobile phase: CH3CN aqueous solution (0.1% NH4HCO3) from 20% to 60%, flow rate: 15mL / min).

[0514] Method B: Formic acid

[0515] (Column: XBridge Prep C18 5μm OBD 19*150mm, PN 186002979; Mobile phase: CH3CN in water (0.1% formic acid) from 15% to 40%, flow rate: 15mL / min)

[0516] Representative methods for analytical HPLC

[0517] Method 1: Analyses were performed on an Agilent 1260 Series HPLC-6120MS. A long UHPLC gradient was equivalent to 5% to 95% acetonitrile in water (containing 0.02% NH4OAc) with a run time of 6.5 minutes and a flow rate of 1.5 mL / min. An XBridge C18 column (5 μm, 4.6 x 50 mm; PN 186003113) was used at 40°C.

[0518] Method 2: Analysis was performed on an Agilent 1260 Series HPLC-6120MS. A long UHPLC gradient was equivalent to 5% to 95% acetonitrile in water (containing 0.1% trifluoroacetic acid) with a run time of 6.5 minutes and a flow rate of 1.5 mL / min. An XBridge C18 column (5 μm, 4.6 x 50 mm; PN 186003113) was used at 40°C.

[0519] Method 3: Analysis was performed on an Agilent 1260 Series HPLC-6120MS. A long UHPLC gradient was equivalent to 5% to 95% acetonitrile in water (containing 0.02% NH4OAc) with a run time of 6.5 minutes and a flow rate of 2 mL / min. A Diamonsil Plus C18 column (5 μm, 4.6 x 30 mm, Cat# 99436) was used at 40°C.

[0520] Example 1

[0521]

[0522] Step 1. Methyl 4-(2-chloro-5-methylpyrimidin-4-yl)benzoate (1b)

[0523] To a mixture of 2,4-dichloro-5-methylpyrimidine (12.86 g, 78.9 mmol) in 1,4-dioxane (100 mL) and H2O (20 mL) were added (4-(methoxycarbonyl)phenyl)boronic acid (14.2 g, 78.9 mmol), Na2CO3 (6.73 g, 157.8 mmol) and Pd(dppf)Cl2 (4.04 g, 5.52 mmol) in sequence. The mixture was stirred at 60 ° C for 7 hrs under N2 atmosphere. After cooling, the mixture was concentrated to remove volatiles and extracted with EtOAc (100 mL). The organic layer was washed with water (100 mL), separated, and then concentrated to dryness. The residue was purified by chromatography on silica gel (eluent: PE:EtOAc=1:1) to give the title product (4.8 g, 23% yield) as a white solid. 1 H NMR (400MHz, CDCl3) δ8.54 (s, 1H), 8.15 (d, J = 8.0 Hz, 2H), 7.69 (d, J = 8.0 Hz, 2H), 3.95 (s, 3H), 2.38 (s, 3H).

[0524] Step 2. tert-Butyl 4-(4-((4-(4-(methoxycarbonyl)phenyl)-5-methylpyrimidin-2-yl)amino)-1H-pyrazol-1-yl)piperidine-1-carboxylate (1c)

[0525] Compound 1b (2.96 g, 11.28 mmol), tert-butyl 4-(4-amino-1H-pyrazol-1-yl)piperidine-1-carboxylate (3.0 g, 11.28 mmol), Cs2CO3 (7.3 g, 22.56 mmol), X-Phos (1.08 g, 2.26 mmol) and Pd2(dba)3 (1.03 g, 1.13 mmol) were dissolved in 1,4-dioxane (100 mL), and the resulting mixture was stirred at 110 ° C for 7 hrs under N2 atmosphere. After cooling, the mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by chromatography on silica gel (eluent: PE: EtOAc = 1: 1) to give the title product (5.5 g, 99% yield) as a yellow solid. LC-MS (method 1): t R =1.85min, m / z(M+H)+=492.8.

[0526] Step 3. 4-(2-((1-(1-(tert-Butoxycarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (1d)

[0527] To a solution of compound 1c (1.0 g, 2.03 mmol), MeOH (10 mL) and H2O (2 mL) was added NaOH (406 mg, 10.15 mmol) in one portion. The mixture was stirred at 40 ° C for 7 hrs. The mixture was adjusted to pH = 6-7 with 10% HCl aqueous solution. The mixture was extracted with a mixture of DCM and MeOH (55 mL, V / V = 10 / 1). The organic layer was separated and concentrated in vacuo to give the title product as a yellow solid (980 mg, 100% yield). LC-MS (Method 1): t R =1.25min, m / z (M+H) + =478.8.

[0528] Step 4. tert-Butyl 4-(4-((4-(4-((cyanomethyl)carbamoyl)phenyl)-5-methylpyrimidin-2-yl)amino)-1H-pyrazol-1-yl)piperidine-1-carboxylate (1e)

[0529] Compound 1d (272 mg, 0.57 mmol), 2-aminoacetonitrile (33 mg, 0.57 mmol), HATU (258 mg, 0.68 mmol) and DIPEA (220 mg, 1.71 mmol) were dissolved in 5 mL of DMF and the resulting mixture was stirred at RT for 3 hrs. The mixture was concentrated to dryness and the residue was purified by preparative HPLC (Method A) to give the title product as a yellow solid (225 mg, 77% yield). LC-MS (Method 1): t R =3.62min, m / z (M+H) + =517.3; 1 H NMR (400MHz, CDCl3) δ8.31(s,1H),8.09(s,1H),7.92(d,J=8.4Hz,2H),7.77(d,J=8.4Hz,2H),7.45(s,1H),7.23(s,1H),6.87(s,1H),4.41( d,J=5.6Hz,2H),4.32-4.26(m,1H),4.17-4.13(m,2H),2.98-2.91(m,2H),2.29(s,3H),2.14-2.12(m,2H),1.90-1.86(m,2H),1.47(s,9H).

[0530] Step 5. Hydrochloride (1f)

[0531] To a mixture of compound 1e (200 mg, 0.39 mmol) and EtOAc (6 mL) was added dropwise a solution of HCl (g) in EtOAc (2 N, 2 mL) at 0°C. The mixture was stirred at this temperature for 3 hrs. The mixture was filtered and the filter cake was dried to give the title product as a yellow solid (100 mg, 63% yield). LC-MS (Method 1): t R =1.08min, m / z(M+H) + =416.8.

[0532] Step 6. N-(Cyanomethyl)-4-(2-((1-(1-(Cyanomethyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (1)

[0533] Compound 1f (100 mg, 0.24 mmol), 2-bromoacetonitrile (29 mg 0.24 mmol) and K2CO3 (133 mg 0.96 mmol) were dissolved in DMF (3 mL). The resulting mixture was stirred at 30 ° C overnight. The mixture was diluted with EtOAc (30 mL) and washed with water (30 mL). The organic layer was separated and concentrated to dryness. The residue was purified by chromatography on silica gel (eluent: DCM: MeOH = 20: 1) to give the title product (50 mg, 46% yield) as a yellow solid. LC-MS (method 1): t R =3.03min, m / z (M+H) + =456.2; 1 H NMR (400MHz, DMSO-d6) δ9.38(s,1H),9.32(t,J=5.2Hz,1H),8.37(s,1H),8.00(d,J=8.0Hz,2H),7.89(s,1H),7.80(d,J=7.6Hz,2H),7.54(s ,1H),4.35(d,J=5.6Hz,2H),4.09-4.13(m,1H),3.76(s,2H),2.87(d,J=10.8Hz,2H),2.34(t,J=9.6Hz,2H),2.19(s,3H),2.02-1.90(m,4H).

[0534] Example 2

[0535]

[0536] Step 1. Methyl 4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (2a)

[0537] Using a similar preparation procedure to the second step of Example 1, compound 2a (2.8 g) was synthesized in 74% yield using compound 1b (3.1 g, 11.8 mmol) and 1-methyl-1H-pyrazol-4-amine (1.14 g, 11.8 mmol) as starting materials. 1 HNMR(400MHz, CDCl3)δ8.31(s,1H),8.15(d,J=7.6Hz,2H),7.82(s,1H),7.68(d,J=7.6Hz,2H),7.45(s,1H),7.03-7.18(br s,1H),3.96(s,3H),3.87(s,3H),2.23(s,3H).

[0538] Step 2. 4-(5-Methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (2b)

[0539] Using a similar preparation procedure to the third step of Example 1, compound 2b (2.67 g) was synthesized in 100% yield using compound 2a (2.8 g, 8.72 mmol) as a starting material. 1 H NMR (400MHz, DMSO-d6) δ9.39(s,1H),8.35(s,1H),8.03(d,J=8.0Hz,2H),7.85(s,1H),7.69(d,J=8.0Hz,2H),7.47(s,1H),3.78(s,3H),2.19(s,3H).

[0540] Step 3. N-(2-cyanoethyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (2)

[0541] Using a similar preparation procedure to the fourth step of Example 1, compound 2b (70 mg, 0.23 mmol) and 3-aminopropionitrile (16.1 mg, 0.23 mmol) were used as starting materials to synthesize compound 2 (36 mg) in a yield of 43%. LC-MS (Method 1): t R =2.82min, m / z (M+H) + =362.0; 1H NMR (400MHz, DMSO-d6) δ9.39(s,1H),8.95(t,J=5.6Hz,1H),8.36(s,1H),7.98(d,J=8.0Hz,2H),7.83(s,1H) ,7.77(d,J=8.0Hz,2H),7.47(s,1H),3.78(s,3H),3.53(q,J=6.4Hz,2H),2.80(t,J=6.8Hz,2H),2.19(s,3H).

[0542] Example 3

[0543]

[0544] Step 1. Methyl 4-(5-methyl-2-((1-(piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate hydrochloride (3a)

[0545] To a solution of compound 1c (1.0 g, 2.0 mmol) and MeOH (10 mL) was added a solution of HCl (g) in MeOH (2 N, 15 mL) at RT. The mixture was stirred at RT for 3 hrs and then concentrated to dryness to give the crude title product as a yellow solid (1.1 g, 100% yield). LC-MS (Method 3): t R =1.09min, m / z(M+H) + =393.0. Step 2. Methyl 4-(2-((1-(1-(tert-Butylcarbamoyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (3b)

[0546] To the well-stirred mixture of compound 3a (300 mg, 0.77 mmol), DMAP (18.7 mg, 0.15 mmol), TEA (232 mg, 2.28 mmol) and DCM (15 mL) was added dropwise 2-isocyanato-2-methylpropane (91 mg, 0.92 mmol). The mixture was stirred at RT for 2 hrs, then DCM (30 mL) and water (30 mL) were added. The organic layer was separated and concentrated to dryness. The residue was purified by reverse phase column chromatography (gradient eluent: 5% to 95% acetonitrile in water) to obtain the title product (239 mg, 64% yield) as a yellow solid. LC-MS (method 3): t R =1.72min, m / z (M+H) + =491.8.

[0547] Step 3. 4-(2-((1-(1-(tert-Butylcarbamoyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (3c)

[0548] To a solution of compound 3b (170 mg, 0.35 mmol), THF (4 mL) and H2O (0.7 mL) was added solid LiOH.H2O (72.6 mg, 1.73 mmol) in one portion. The mixture was stirred at 40°C for 5 hrs and then adjusted to pH 6-7 with 10% aqueous HCl. The mixture was extracted with a solution of DCM and MeOH (55 mL, V / V=10 / 1). The organic layer was separated and then concentrated to dryness in vacuo to give the title product as a yellow solid (140 mg, 85% yield). LC-MS (Method 1): t R =2.73min, m / z (M+H) + =478.2. Step 4. N-(tert-Butyl)-4-(4-((4-(4-((cyanomethyl)carbamoyl)phenyl)-5-methylpyrimidin-2-yl)amino)-1H-pyrazol-1-yl)piperidine-1-carboxamide (3)

[0549] Using a similar preparation procedure to the fourth step of Example 1, compound 3c (130 mg, 0.27 mmol) and 2-aminoacetonitrile hydrochloride (25 mg, 0.27 mmol) were used as starting materials to synthesize compound 3 (30 mg) in a yield of 21%. LC-MS (Method 1): t R =3.42min, m / z (M+H) + =516.2; 1 H NMR (400MHz, DMSO-d6) δ9.41 (s, 1H), 9.34 (s, 1H), 8.38 (s, 1H), 8.00 (d, J = 7. 6Hz,2H),7.88(s,1H),7.80(d,J=6.8Hz,2H),7.54(s,1H),5.85(s,1H),4.36 (d,J=3.2Hz,2H),4.24-4.22(m,1H),4.02(d,J=13.6Hz,2H),2.75(t,J=12.4 Hz, 2H), 2.19 (s, 3H), 1.91 (d, J = 11.2Hz, 2H), 1.76-1.70 (m, 2H), 1.25 (s, 9H).

[0550] Example 4

[0551]

[0552] Step 1. tert-Butyl 4-nitro-1H-pyrazole-1-carboxylate (4b)

[0553] To a solution of compound 4a (10.0 g, 88.44 mmol), di-tert-butyl dicarbonate (19.3 g, 88.50 mmol) and DCM (100 mL) was added DMAP (23.14 g, 106.1 mmol) at one time. Under N2 atmosphere, the mixture was stirred at 30 ° C for 2 hours. The mixture was diluted with water (300 mL) and then extracted with EtOAc (300 mL x 2). The combined organic layers were washed with brine (300 mL), dried over Na2SO4, filtered and concentrated to obtain the title product (18 g, 96% yield) as a white solid. LC-MS (method 1): t R =1.60min, m / z(M+H) + =214.1; 1 H NMR (400MHz, DMSO-d6) δ9.29(s,1H),8.52(s,1H),150(s,9H).

[0554] Step 2. tert-Butyl 4-amino-1H-pyrazole-1-carboxylate (4c)

[0555] To a well-stirred solution of compound 4b (18.0 g, 84.5 mmol) and EtOH (200 mL) was added Pd / C (2 g, 10% palladium on carbon, wetted with 55% water) in one portion. The mixture was hydrogenated under H2 (50 psi) at 30°C for 18 hrs. The mixture was passed through Filter. The filtrate was concentrated to dryness to give the title product as a brown solid (15 g, 97% yield). LC-MS (Method 1): t R =1.18min, m / z(M+H-56) + =128.0; 1 H NMR (400MHz, DMSO-d6) δ7.34(s,1H),7.32(s,1H),4.40(br.s,2H),1.53(s,9H).

[0556] Step 3. Methyl 4-(2-((1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (4d)

[0557] Compound 4c (3.49 g, 19.08 mmol), 1b (5.0 g, 19.08 mmol), Cs2CO3 (12.36 g, 38.16 mmol), X-Phos (1.82 g, 3.82 mmol) and Pd2(dba)3 (1.75 g, 1.91 mmol) were dissolved in 1,4-dioxane (100 mL). The resulting mixture was stirred at 110 ° C for 3 hrs under N2 atmosphere. After cooling to RT, the mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by chromatography on silica gel (eluent: DCM: MeOH = 10: 1) to give the title product (3.5 g, 59% yield) as a yellow solid. LC-MS (method 1): t R =1.45min, m / z (M+H-100) + =310.0; 1 H NMR (400MHz, DMSO-d6) δ9.85 (s, 1H), 8.49 (s, 1H), 8.44 (s, 1H), 8.10 (d, J = 8.0Hz ,2H),7.86(d,J=8.0Hz,2H),7.82(s,1H),3.90(s,3H),2.23(s,3H),1.55(s,9H).

[0558] Step 4. 4-(2-((1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (4e)

[0559] To a solution of 4d (3.5 g, 11.33 mmol), MeOH (120 mL) and H2O (24 mL) was added solid NaOH (2.27 g, 56.75 mmol) in one portion. The mixture was stirred at 40 ° C for 18 hrs and then adjusted to pH 6-7 with 10% HCl aqueous solution. The reaction was extracted with a mixture of DCM and MeOH (110 mL, V / V=10:1). The organic layer was separated and then concentrated to dryness to give the title product as a yellow solid (3.1 g, 93% yield). LC-MS (method 1): t R =0.92min, m / z(M+H)+=296.0.

[0560] Step 5. 4-(2-((1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)-N-(cyanomethyl)benzamide (4f)

[0561] Compound 4e (3.1 g, 10.51 mmol), 2-aminoacetonitrile (972 mg, 10.51 mmol), HATU (4.2 g, 11.04 mmol) and DIPEA (5.4 g, 42.04 mmol) were dissolved in DMF (50 mL). The resulting mixture was stirred at RT for 18 hrs. The mixture was diluted with water (100 mL) and then extracted with EtOAc (200 mL x 2). The combined organic layers were washed with brine (200 mL), dried over Na2SO4 and filtered. The filtrate was concentrated to dryness. The residue was purified by chromatography on silica gel (eluent: DCM: MeOH = 10: 1) to obtain the title product (2.26 g, 65% yield) as a yellow solid. LC-MS (method 1): t R =1.13min, m / z(M+H) + =334.0; 1 H NMR(400MHz,DMSO-d6)δ12.39(s,1H),9.37(s,1H),9.32(br.s,1H),8.37(s,1H),8.00(d, J=8.0Hz,2H),7.79(d,J=8.0Hz,2H),7.75(br.s,1H),4.35(d,J=5.2Hz,2H),2.19(s,3H).

[0562] Step 6. N-(Cyanomethyl)-4-(2-((1-(Cyanomethyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (4)

[0563] To a solution of compound 4f (100 mg, 0.3 mmol), 2-chloroacetonitrile (46 mg, 0.6 mmol) and DMF (2 mL) was added CsCO (292 mg, 0.9 mmol) at one time. The mixture was stirred at 120 ° C for 4 hrs under microwave irradiation. After cooling to RT, the mixture was diluted with water (10 mL) and then extracted with EtOAc (20 mL x 2). The combined organic layer was washed with brine (20 mL), dried over NaSO, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (eluent: DCM: MeOH=10: 1) to obtain the title product (9.9 mg, 9% yield) as a yellow solid. LC-MS (method 1): t R =3.20min, m / z (M+H) + =373.1; 1H NMR (400MHz, DMSO-d6) δ9.60 (s, 1H), 9.36 (t, J = 5.6Hz, 1H), 8.41 (s, 1H), 8.04-8.00 (m, 3 H), 7.82 (d, J = 8.0Hz, 2H), 7.64 (s, 1H), 5.45 (s, 2H), 4.36 (d, J = 5.2Hz, 2H), 2.21 (s, 3H).

[0564] Example 5

[0565]

[0566] Step 1. 1-(4-(2-((1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoyl)azetidine-3-carbonitrile (5a)

[0567] Using a similar preparation procedure to the fifth step of Example 4, compound 5a (648 mg) was synthesized with a yield of 77% using compound 4f (696 mg, 2.36 mmol) and azetidine-3-carbonitrile (420 mg, 3.54 mmol) as starting materials. LC-MS (Method 1): t R =1.12min, m / z(M+H) + =360.0.

[0568] Step 2. 1-(4-(5-methyl-2-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoyl)azetidine-3-carbonitrile (5)

[0569] Using a similar preparation procedure to the last step of Example 4, compound 5a (150 mg, 0.42 mmol) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (194 mg, 0.84 mmol) were used as starting materials to synthesize compound 5 (17.4 mg) in a yield of 9%. LC-MS (Method 1): t R =3.43min, m / z (M+H) + =442.0; 1 H NMR(400MHz,DMSO-d6)δ9.56(s,1H),8.41(s,1H),8.03(s,1H),7.77(s,4H),7.65(s,1H),5.12- 5.05(m,2H),4.63-4.57(m,2H),4.41-4.35(m,1H),4.22(s,1H),3.91-3.84(m,1H),2.21(s,3H).

[0570] Example 6

[0571]

[0572] N-(2-Methoxyethyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (6)

[0573] Compound 2b (65 mg, 0.21 mmol), 2-methoxyethylamine (19 mg, 0.25 mmol), HATU (160 mg, 0.42 mmol) and DIPEA (109 mg, 0.84 mmol) were dissolved in DMF (1 mL), and the resulting mixture was stirred at 30 ° C overnight. The mixture was diluted with water (10 mL) and then extracted with EtOAc (20 mL). The organic layer was separated, dried over Na2SO4 and filtered. The filtrate was concentrated to dryness. The residue was purified by preparative HPLC (method A) to obtain the title product (22.5 mg, 26% yield) as a yellow solid. LC-MS (method 1): t R =4.04min, m / z (M+H) + =367.0; 1 HNMR(400MHz,DMSO-d6)δ9.38(s,1H),8.64-8.62(m,1H),8.36(s,1H),7.98(d,J=8.0Hz,2H),7.84(s ,1H),7.75(d,J=8.0Hz,2H),7.48(s,1H),3.78(s,3H),3.50-3.44(m,4H),3.28(s,3H),2.19(s,3H).

[0574] Example 7

[0575]

[0576] N-(3-Hydroxypropyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (7)

[0577] Using a similar preparation procedure to the fourth step of Example 1, compound 2b (65 mg, 0.21 mmol) and 3-aminopropan-1-ol (19 mg, 0.25 mmol) were used as starting materials to synthesize compound 7 (19.9 mg) in a 29% yield. LC-MS (Method 1): t R =2.48min, m / z(M+H) + =367.0; 1H NMR (400MHz, DMSO-d6) δ9.37(s,1H),8.56-8.53(m,1H),8.36(s,1H),7.96(d,J=8.4Hz,2H),7.83(s,1H),7.74(d,J=8.0Hz ,2H),7.48(s,1H),4.49-4.47(m,1H),3.78(s,3H),3.51-3.46(m,2H),3.37-3.32(m,2H),2.19(s,3H),1.74-1.67(m,2H).

[0578] Example 8

[0579]

[0580] N-(2-Hydroxyethyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (8)

[0581] Using a similar preparation procedure to the fourth step of Example 1, compound 8 (20 mg) was synthesized with a yield of 25% using compound 2b (70 mg, 0.23 mmol) and 2-aminoethanol (14 mg, 0.23 mmol) as starting materials. The mixture was purified by preparative HPLC (Method A). LC-MS (Method 1): t R =2.89min, m / z (M+H) + =353.0; 1 H NMR (DMSO-d6, 400MHz): δ9.37 (s, 1H), 8.55-8.51 (m, 1H), 8.36 (s, 1H), 7.98 (d, J = 8.4Hz, 2H), 7.8 (s, 1H), 7.75 (d, J=8.4Hz,2H),7.48(s,1H),4.73(t,J=5.6Hz,1H),3.78(s,3H),3.56-3.51(m,2H),3.38-3.34(m,2H),2.19(s,3H).

[0582] Example 9

[0583]

[0584] N-(3-Hydroxycyclobutyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (9)

[0585] Using a similar preparation procedure to the fourth step of Example 1, compound 9 (43 mg) was synthesized with a yield of 49% using compound 2b (70 mg, 0.23 mmol) and 3-aminocyclobutanol (56 mg, 0.28 mmol) as starting materials. LC-MS (Method 1): t R =2.97min, m / z (M+H) + =379.0; 1 H NMR (400MHz, DMSO-d6): 9.40 (s, 1H), 8.68 (t, J = 8.0Hz, 1H), 8.36 (s, 1H), 7 .97(d,J=6.8Hz,2H),7.84(s,1H),6.82(s,1H),7.74(d,J=6.8Hz,2H),7.49 (s,1H),4.48-4.31(m,1H),3.96-3.84(m,1H),3.78(s,3H),2.59-2.54(m, 1H),2.33-2.27(m,1H),2.19(s,3H),2.17-2.14(m,1H),1.97-1.90(m,1H).

[0586] Example 10

[0587]

[0588] N-Methyl-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (10)

[0589] Using a similar preparation procedure to the fourth step of Example 1, compound 10 (51.5 mg) was synthesized with a yield of 69% using compound 2b (70 mg, 0.23 mmol) and methylamine hydrochloride (16 mg, 0.23 mmol) as starting materials. LC-MS (Method 1): t R =3.08min, m / z (M+H) + =323.0; 1 H NMR (400MHz, CDCl3)8.30(s,1H),7.87(d,J=8.4Hz,2H),7.82(s,1H),7.68(d,J=8.4Hz,2H),7.48(s,1H),6.82(s,1H),6.19(br s, 1H), 3.87 (s, 3H), 3.06 (d, J = 6.0Hz, 3H), 2.23 (s, 3H).

[0590] Example 11

[0591]

[0592] N-(Cyanomethyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (11)

[0593] Using a similar preparation procedure to the fourth step of Example 1, compound 11 (40 mg) was synthesized with a yield of 50% using compound 2b (70 mg, 0.23 mmol) and 2-aminoacetonitrile hydrochloride (21 mg, 0.23 mmol) as starting materials. LC-MS (Method 1): t R =3.01min, m / z (M+H) + =348.1; 1 H NMR(400MHz, DMSO-d6)9.39(s,1H),9.32(t,J=5.6Hz,1H),8.38(s,1H),8.00(d,J=8.4Hz,2H),7 .83(s,1H),7.79(d,J=8.0Hz,2H),7.48(s,1H),4.35(d,J=5.6Hz,2H),3.78(s,3H),2.19(s,3H).

[0594] Example 12

[0595]

[0596] N-((1-Cyanocyclopropyl)methyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (12)

[0597] Using a similar preparation procedure to the fourth step of Example 1, compound 2b (90 mg, 0.29 mmol) and 1-(aminomethyl)cyclopropanecarbonitrile (56 mg, 0.58 mmol) were used as starting materials to synthesize compound 12 (45 mg) in a 40% yield. LC-MS (Method 1): t R =2.97min, m / z (M+H) + =388.2; 1 H NMR (400MHz, CDCl3) δ8.31(s,1H),7.92(d,J=8.4Hz,2H),7.84(s,1H),7.71(d,J=8.0Hz,2H),7.47(s,1H),6.86(br s,1H),6.73(t,J=6.4Hz,1H),3.88(s,3H),3.61(d,J=6.0Hz,2H),2.24(s,3H),1.35-1.32(m,2H),1.29-1.22(m,2H).

[0598] Example 13

[0599]

[0600] N-(2-cyano-2-methylpropyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (13)

[0601] Using a similar preparation procedure to the fourth step of Example 1, compound 2b (90 mg, 0.29 mmol) and 3-amino-2,2-dimethylpropionitrile (57 mg, 0.58 mmol) were used as starting materials to synthesize compound 13 (52 mg) in a yield of 46%. LC-MS (Method 1): t R =2.74min, m / z (M+H) + =390.2; 1 H NMR (400MHz, CDCl3) δ8.31(s,1H),7.92(d,J=8.0Hz,2H),7.82(s,1H),7.71(d,J=8.4Hz,2H),7.46(s,1H),6.94(br s, 1H), 6.62 (t, J = 6.0Hz, 1H), 3.88 (s, 3H), 3.66 (d, J = 6.8Hz, 2H), 2.23 (s, 3H), 1.45 (s, 6H).

[0602] Example 14

[0603]

[0604] N-(2,3-Dihydroxypropyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (14)

[0605] Using a similar preparation procedure to the fourth step of Example 1, compound 2b (90 mg, 0.29 mmol) and 3-aminopropane-1,2-diol (535 mg, 5.82 mmol) were used as starting materials to synthesize compound 14 (30 mg) in a 27% yield. The mixture was purified by preparative HPLC (Method B). LC-MS (Method 1): t R =2.49min, m / z(M+H) + =383.0; 1H NMR(DMSO-d6,400MHz): δ9.39(s,1H),8.50(t,J=5.2Hz,1H),8.36(s,1H),7.98(d,J=8.4Hz,2H),7.83(s,1H),7.75 (d,J=8.0Hz,2H),7.48(s,1H),3.78(s,3H),3.46-3.41(m,2H),3.40-3.36(m,2H),3.26-3.20(m,1H),2.19(s,3H).

[0606] Example 15

[0607]

[0608] 1-(4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoyl)azetidine-3-carbonitrile (15)

[0609] Using a similar preparation procedure to the fourth step of Example 1, compound 2b (70 mg, 0.23 mmol) and azetidine-3-carbonitrile hydrochloride (27 mg, 0.23 mmol) were used as starting materials to synthesize compound 15 (30 mg) in a 36% yield. LC-MS (Method 1): t R =2.78min, m / z (M+H) + =374.1; 1 H NMR(DMSO-d6,400MHz): δ9.38(s,1H),8.37(s,1H),7.83(s,1H),7.79-7.74(m,4H),7.48( s,1H),4.65-4.55(m,2H),4.38-4.22(m,2H),3.89-3.86(m,1H),3.78(s,3H),2.20(s,3H).

[0610] Example 16

[0611]

[0612] N-((cis)-3-cyanocyclobutyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (16)

[0613] Using a similar preparation procedure to the fourth step of Example 1, compound 2b (117 mg, 0.38 mmol) and (cis)-3-aminocyclobutanecarbonitrile hydrochloride (50 mg crude, 0.38 mmol) were used as starting materials to synthesize compound 16 (20 mg) in a 14% yield. LC-MS (Method 1): tR =3.19min, m / z (M+H) + =388.2; 1 H NMR (400MHz, DMSO-d6) δ9.38(s,1H),8.88(d,J=7.6Hz,1H),8.36(s,1H),7.97(d,J=8.4Hz,2H),7.83(s,1H),7.76(d,J=8.4 Hz,2H),7.48(s,1H),4.55-4.44(m,1H),3.78(s,3H),3.15-3.06(m,1H),2.72-2.65(m,2H),2.49-2.41(m,2H),2.19(s,3H).

[0614] Example 17

[0615]

[0616] N-(1-cyanoethyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (17)

[0617] Using a similar preparation procedure to the fourth step of Example 1, compound 2b (200 mg, 0.65 mmol) and 2-aminopropionitrile hydrochloride (69 mg, 0.65 mmol; CAS: 59981-03-2) were used as starting materials to synthesize compound 17 (180 mg) in a yield of 77%. LC-MS (Method 1): t R =2.69min, m / z(M+H) + =362.0; 1 H NMR (400MHz, CDCl3) δ8.31(s,1H),7.88(d,J=8.0Hz,2H),7.78(s,1H),7.70(d,J=8.4Hz,2H),7.45(s,1H) ,7.01(s,1H),6.68(d,J=8.4Hz,1H),5.22-5.15(m,1H),3.86(s,3H),2.22(s,3H),1.70(d,J=7.2Hz,3H).

[0618] Example 18

[0619]

[0620] (S)-N-(1-cyanoethyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (18)

[0621] Using a similar preparation procedure to the fourth step of Example 1, compound 2b (70 mg, 0.23 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (55 mg, 0.23 mmol; CAS: 2119588-41-7) were used as starting materials to synthesize compound 18 (40 mg) in a 49% yield. The mixture was purified by preparative HPLC (Method A). LC-MS (Method 1): t R =2.95min, m / z (M+H) + =362.2; 1 H NMR (DMSO-d6, 400MHz): δ9.40 (s, 1H), 9.26 (d, J = 7.2Hz, 1H), 8.38 (s, 1H), 8.01 (d, J = 8.4Hz, 2H), 7 .83-7.78(m,3H),7.48(s,1H),5.04-5.01(m,1H),3.78(s,3H),2.19(s,3H),1.57(d,J=7.2Hz,3H).

[0622] Example 19

[0623]

[0624] N-(Cyanomethyl)-4-(2-((1-(1-(2,2-difluoroethyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (19)

[0625] Compound 1f (50 mg, 0.11 mmol), 2,2-difluoroethyl trifluoromethanesulfonate (117.7 mg, 0.55 mmol) and DIPEA (42 mg, 0.33 mmol) were dissolved in THF (5 mL). The resulting mixture was stirred at 40 ° C for 4 hrs and then concentrated to dryness. The residue was purified by preparative HPLC (method A) to give the title product as a yellow solid (12 mg, 23% yield). LC-MS (method 1): t R =3.29min, m / z (M+H) + =481.2; 1H NMR (400MHz, CDCl3) δ8.31(s,1H),7.92-7.88(m,3H),7.72(d,J=8.0Hz,2H),7.50(s,1H),6.91(s,1H),6.76(t,J=4.0Hz,1H),6.04-5.76(m,1 H), 4.43 (d, J = 8.0Hz, 2H), 4.12-4.07 (m, 1H), 3.06 (d, J = 8.0Hz, 2H), 2.83-2.75 (m, 2H), 2.41 (t, J = 8.0Hz, 2H), 2.24 (s, 3H), 2.14-2.04 (m, 4H).

[0626] Example 20

[0627]

[0628] 4-(2-((1-(1-acetylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)-N-(cyanomethyl)benzamide (20)

[0629] To a well-stirred solution of compound 1f (110 mg, 0.24 mmol), TEA (131 mg, 1.30 mmol) and DCM (5 mL) was added acetic anhydride (29.8 mg, 0.29 mmol) at 0°C. The mixture was stirred at RT for 2 hrs and then concentrated to dryness to give a residue which was further purified by preparative HPLC (Method A) to afford the title product as a yellow solid (30 mg, 21% yield). LC-MS (Method 1): t R =2.79min, m / z (M+H) + =459.0; 1 H NMR (DMSO-d6, 400MHz): δ9.40 (s, 1H), 9.32 (t, J=5.2Hz, 1H), 8.38 (s, 1H), 8.00 (d, J= 8.4Hz,2H),7.90(s,1H),7.80(d,J=8.0Hz,2H),7.55(s,1H),4.45-4.40(m,1H),4.39 -4.33(m,3H),3.89(d,J=13.6Hz,1H),3.18(t,J=12.4Hz,1H),2.70(d,J=12.4Hz,1H) ,2.20(s,3H),2.03(s,3H),1.99-1.96(m,2H),1.86-1.83(m,1H),1.70-1.66(m,1H).

[0630] Example 21

[0631]

[0632] N-(Cyanomethyl)-4-(5-methyl-2-((1-(1-pivaloylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (21)

[0633] To a well-stirred solution of compound 1f (180 mg, 0.43 mmol), TEA (131 mg, 1.30 mmol) and DCM (5 mL) was added pivaloyl chloride (62.6 mg, 0.52 mmol) at 0°C. The mixture was stirred at RT for 2 hrs and then concentrated to dryness to give a residue which was purified by preparative HPLC (Method A) to afford the title product as a yellow solid (10 mg, 5% yield). LC-MS (Method 1): t R =3.67min, m / z (M+H) + =501.0; 1 H NMR (CD3OD, 400MHz): δ8.36 (s, 1H), 8.08 (s, 1H), 8.02 (d, J = 8.0Hz, 2H), 7.83 (d, J = 8.4Hz, 2H), 7.63 (s, 1H), 4.56 (d, J = 13. 6Hz, 2H), 4.46-4.41 (m, 3H), 3.08 (t, J = 12.8Hz, 2H), 2.28 (s, 3H), 2.16 (d, J = 11.2Hz, 2H), 1.97-1.90 (m, 2H), 1.34 (s, 9H).

[0634] Example 22

[0635]

[0636] N-(Cyanomethyl)-4-(5-methyl-2-((1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (22)

[0637] Compound 1f (100 mg, 0.24 mmol), 2,2,2-trifluoroethyl trifluoromethanesulfonate (56 mg, 0.24 mmol) and TEA (97 mg, 0.96 mmol) were dissolved in DMF (3 mL), and the resulting mixture was stirred at 30 ° C overnight. The mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL x 2). The combined organic layers were concentrated to dryness and then purified by preparative TLC (DCM: MeOH = 10: 1) to give the title compound as a yellow solid (10.3 mg, 9% yield). LC-MS (ESI): R T =3.07min, m / z (M+H) + =499.0. 1 H NMR (400MHz, CDCl3) δ8.31(s,1H),7.91-7.89(m,3H),7.72(d,J=8.4Hz,2H),7.51(s,1H),6.86(s,1H),6.65(t,J=5.6H z,1H),4.42(d,J=5.6Hz,2H),4.10-4.09(m,1H),3.11-3.00(m,4H),2.60-2.53(m,2H),2.23(s,3H),2.11-2.05(m,4H).

[0638] Example 23

[0639]

[0640] Step 1. Methyl 4-(2-((1-(1-(cyanomethyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (23a)

[0641] Compound 3a (200 mg, 0.47 mmol), 2-chloroacetonitrile (39 mg, 0.52 mmol) and DIPEA (182 mg, 1.41 mmol) were dissolved in DMF (2 mL). The resulting mixture was stirred at 40° C. overnight and then concentrated to dryness to give the product as a yellow solid (400 mg, crude). LC-MS (Method 1): tR=1.61 min, m / z (M+H)+=432.1. Step 2. 4-(2-((1-(1-(cyanomethyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (23b)

[0642] Compound 23b (387 mg crude product) was synthesized using a similar preparation procedure to the third step of Example 1. LC-MS (Method 1): t R= 1.12 min, m / z (M+H) + = 418.1. Step 3. 1-(4-(2-((1-(1-(cyanomethyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoyl)azetidine-3-carbonitrile (23)

[0643] Using a similar preparation procedure to the fourth step of Example 1, compound 23b and azetidine-3-carbonitrile hydrochloride were used as starting materials to synthesize compound 23 (56 mg) with an overall yield of 25%. LC-MS (Method 1): t R =3.01min, m / z (M+H) + =482.3; 1 HNMR(400MHz,DMSO-d6)δ9.40(s,1H),8.34(s,1H),7.90(s,1H),7.78(s,4H),7.55(s,1H),4.63-4.58(m,2H),4.41-4.36(m,1H),4.23 (s,1H),4.14-4.07(m,1H),3.91-3.84(m,1H),3.77(s,2H),2.88(d,J=8.0Hz,2H),2.37-2.32(m,2H),2.20(s,3H),2.03-1.87(m,4H).

[0644] Example 24

[0645]

[0646] Step 1. Methyl 4-(2-((1-(1-(cyclopropanecarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (24a)

[0647] To the mixture of compound 3a (200mg, 0.684mmol), DIPEA (265mg, 2.050mmol) and DMF (2mL) was added dropwise cyclopropanecarbonyl chloride (86mg, 0.823mmol). The reaction mixture was stirred at RT for 4hrs. The mixture was concentrated to dryness, and the residue was diluted with H o (30mL) and extracted with EtOAc (30mL x 2). The combined organic layer was concentrated to dryness to obtain the title crude compound (220mg, 70% yield) as a brown solid. LC-MS (method 3): t R =1.52min, m / z (M+H) + =461.2.

[0648] Step 2. 4-(2-((1-(1-(cyclopropanecarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (24b)

[0649] To a mixture of compound 24a (220 mg, 0.478 mmol) and MeOH (2 mL) was added dropwise a solution of NaOH (96 mg, 2.40 mmol) in H2O (2 mL). The mixture was stirred at 40 ° C for 2 hrs. The mixture was adjusted to pH 6-7 with 10% aqueous HCl solution and extracted with a mixed solution of DCM and MeOH (110 mL; V / V=10:1). The organic layer was separated and concentrated in vacuo to give the title crude compound (210 mg, 99%) as a brown solid. LC-MS (Method 3): t R =1.37min, m / z (M+H) + =447.0.

[0650] Step 3. N-(Cyanomethyl)-4-(2-((1-(1-(cyclopropanecarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (24)

[0651] Using a similar preparation procedure to the fourth step of Example 1, compound 24b (100 mg, 0.23 mmol) and 2-aminoacetonitrile hydrochloride (31 mg, 0.33 mmol) were used as starting materials to synthesize compound 24 (14.6 mg) in a 14% yield. LC-MS (Method 1): t R =3.22min, m / z (M+H) + =485.2. 1 H NMR (400MHz, DMSO-d6) δ9.41-9.35(m,2H),8.38(s,1H),8.01(d,J=8.0Hz,2H),7.92(s,1H),7.81(d,J=8.0Hz,2H),7.57( s,1H),4.39-4.37(m,5H),3.26-3.24(m,1H),2.76-2.74(m,1H),2.51(s,3H),2.06-1.85(m,3H),1.83-1.71(m,2H),0.75

[0652] -0.71(m,4H).

[0653] Example 25

[0654]

[0655] N-(Cyanomethyl)-4-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (25)

[0656] Compound 4f (100 mg, 0.3 mmol), cyclopropylboronic acid (26 mg, 0.6 mmol), Na2CO3 (64 mg, 0.6 mmol) and copper (II) acetate (55 mg, 0.3 mmol) were dissolved in 1,2-dichloroethane (2 mL), and 2,2'-bipyridine (47 mg, 0.3 mmol) was added. The mixture was stirred at 70 ° C for 1 hr under N2 atmosphere and then diluted with water (10 mL). The mixture was extracted with EtOAc (20 mL x 2). The combined organic layers were washed with brine (20 mL), dried over Na2SO4 and filtered. The filtrate was concentrated to dryness to give a residue, which was purified by chromatography on silica gel (eluent: DCM:MeOH=10:1) to give the title product as a yellow solid (19.9 mg, 18% yield). LC-MS (method 1): t R =2.90min, m / z (M+H) + =374.0; 1 H NMR (400MHz, DMSO-d6) δ9.42 (s, 1H), 9.35 (t, J = 5.6Hz, 1H), 8.38 (s, 1H), 8.01-7.99 (m, 2H), 7.90 (s, 1H), 7. 81(d,J=8.0Hz,2H),7.47(s,1H),4.36(d,J=5.2Hz,2H),3.67-3.63(m,1H),2.19(s,3H),1.00-0.89(m,4H).

[0657] Example 26

[0658]

[0659] N-(Cyanomethyl)-4-(5-methyl-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (26)

[0660] Using a similar preparation procedure to the last step of Example 4, compound 4f (200 mg, 0.6 mmol) and tetrahydro-2H-pyran-4-yl methanesulfonate (217 mg, 1.2 mmol) were used as starting materials to synthesize compound 26 (14.3 mg) in a 6% yield. LC-MS (Method 1): t R =3.07min, m / z (M+H) + =418.0; 1H NMR(400MHz,DMSO-d6)δ9.42(s,1H),9.34(br s,1H),8.38(s,1H),8.00(d,J=8.4Hz,2H),7.91(s,1H),7.80(d,J=6.4Hz,2H),7.54(s,1H),4 .37-4.34(m,3H),3.95(d,J=10.8Hz,2H),3.47-3.42(m,2H),2.20(s,3H),1.92-1.88(m,4H).

[0661] Example 27

[0662]

[0663] N-(Cyanomethyl)-4-(2-((1-(2,2-difluoroethyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (27)

[0664] Using a similar preparation procedure to the last step of Example 4, compound 27 (6 mg) was synthesized with a yield of 14% using compound 4f (48 mg, 0.14 mmol) and 2,2-difluoroethyl trifluoromethanesulfonate (23 mg, 0.11 mmol) as starting materials. LC-MS (Method 1): t R =3.27min, m / z (M+H) + =398.1; 1 H NMR (400MHz, DMSO-d6) δ9.52 (s, 1H), 9.37 (t, J = 5.2Hz, 1H), 8.41 (s, 1H), 8.02-7.99 (m, 3H), 7.82 (d, J=8.0Hz,2H),7.61(s,1H),6.46-6.19(m,1H),4.62-4.54(m,2H),4.37(d,J=5.6Hz,2H),2.22(s,3H).

[0665] Example 28

[0666]

[0667] N-(Cyanomethyl)-4-(5-methyl-2-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (28)

[0668] Using a similar preparation procedure to the last step of Example 4, compound 4f (100 mg, 0.28 mmol) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (131 mg, 0.56 mmol) were used as starting materials to synthesize compound 28 (14 mg) in a 12% yield. LC-MS (Method 1): t R =4.20min, m / z (M+H) + =416.0; 1 H NMR(400MHz,DMSO-d6)δ9.54(s,1H),9.34(t,J=5.6Hz,1H),8.41(s,1H),8.03-7.99(m,3H) ,7.81(d,J=8.0Hz,2H),7.64(s,1H),5.11-5.04(m,2H),4.36(d,J=5.6Hz,2H),2.21(s,3H).

[0669] Example 29

[0670]

[0671] 1-(4-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoyl)azetidine-3-carbonitrile (29)

[0672] To a mixture of compound 5a (150 mg, 0.418 mmol) and DCE (3 mL) was added cyclopropylboronic acid (71.8 mg, 0.836 mmol), 2,2'-bipyridine (65.3 mg, 0.418 mmol), copper acetate (75.9 mg, 0.418 mmol) and sodium carbonate (88.6 mg, 0.836 mmol) in sequence. The mixture was stirred at 70 ° C for 3 hrs and then concentrated to dryness. The residue was purified by chromatography on silica gel (eluent: DCM: MeOH = 60: 1) and further purified by preparative HPLC (method A) to give the title product as a yellow solid (89 mg, 53.6% yield). LC-MS (method 1): t R =2.58min, m / z (M+H) + =400.2; 1H NMR (400MHz, DMSO-d6) δ9.45(s,1H), δ8.42(s,1H), δ7.94(s,1H), δ7.81(s,4H), δ7.52(s,1H),4.65-4.62(m,2H ),4.42-4.41(m,1H),4.28-4.26(m,1H),3.94-3.90(m,1H),3.72-3.66(m,1H),2.24(s,3H),1.01-0.94(m,4H).

[0673] Example 30

[0674]

[0675] 1-(4-(2-((1-(cyanomethyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoyl)azetidine-3-carbonitrile (30)

[0676] Using a similar preparation procedure to the last step of Example 4, compound 5a (200 mg, 0.56 mmol) and 2-chloroacetonitrile (28 mg, 0.37 mmol) were used as starting materials to synthesize compound 30 (56 mg) in a 38% yield. LC-MS (Method 1): t R =3.06min, m / z (M+H) + =399.0; 1 H NMR(400MHz,DMSO-d6)δ9.58(s,1H),8.41(s,1H),8.04(s,1H),7.77(s,4H),7.65(s,1H),5.45( s,2H),4.61-4.58(m,2H),4.40-4.36(m,1H),4.24-4.20(m,1H),3.91-3.86(m,1H),2.21(s,3H).

[0677] Example 31

[0678]

[0679] 1-(4-(5-methyl-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoyl)azetidine-3-carbonitrile (31)

[0680] Using a similar preparation procedure to the last step of Example 4, compound 5a (200 mg, 0.56 mmol) and tetrahydro-2H-pyran-4-yl methanesulfonate (201 mg, 1.12 mmol) were used as starting materials to synthesize compound 31 (40 mg) in a yield of 16%. LC-MS (Method 1): t R =2.90min, m / z (M+H) + =444.0; 1 H NMR(400MHz,DMSO-d6)δ9.40(s,1H),8.37(s,1H),7.90(s,1H),7.77(s,4H),7.55(s,1H),4.63-4.58(m,2H), 4.40-4.30(m,2H),4.24-4.19(m,1H),3.95-3.83(m,3H),3.47-3.41(m,2H),2.20(s,3H),1.95-1.86(m,4H).

[0681] Example 32

[0682]

[0683] Step 1. 1-(Aminomethyl)cyclopropanol (32b)

[0684] To a mixture of compound 32a (300 mg, 1.1 mmol), Pd / C (150 mg, 10% palladium on carbon, wetted with 55% water) and MeOH (5 mL) was added acetic acid (1 mL). The mixture was hydrogenated at 50° C. under H (50 psi) for 12 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the crude title product (97.6 mg, 100% yield) as a colorless oil. 1 H NMR (CDCl3, 400MHz): δ2.84 (s, 2H), 0.77-0.59 (m, 2H), 0.55-0.54 (m, 2H).

[0685] Step 2. N-((1-hydroxycyclopropyl)methyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (32)

[0686] Using a similar preparation procedure to the fourth step of Example 1, compound 2b (58 mg, 0.19 mmol) and compound 32b (65 mg, 0.74 mmol) were used as starting materials to synthesize compound 32 (15 mg) in 18% yield. The mixture was purified by preparative HPLC (Method A). LC-MS (Method 1): t R=2.75min, m / z (M+H) + =379.0; 1 H NMR (DMSO-d6, 400MHz): δ9.38 (s, 1H), 8.52 (s, 1H), 8.37 (s, 1H), 8.00 (d, J = 7.6Hz, 2H), 7.84 (s, 1H), 7.76 (d,J=7.6Hz,2H),7.49(s,1H),5.45(s,1H),3.79(s,3H),3.47(d,J=5.6Hz,2H),2.20(s,3H),0.58(s,4H).

[0687] Example 33

[0688]

[0689] Step 1. Methyl 4-(2-chloro-5-methylpyrimidin-4-yl)-2-methoxybenzoate (33b)

[0690] Using a similar preparation procedure to the first step of Example 1, compound 33b (500 mg) was synthesized in 72% yield using compound 33a (388 mg, 2.38 mmol) and (4-(methoxycarbonyl)phenyl)boronic acid (500 mg, 2.38 mmol) as starting materials. 1 H NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.22 (d, J = 1.2 Hz, 1H), 7.18 (dd, J = 1.6, 7.6 Hz, 1H), 3.97 (s, 3H), 3.92 (s, 3H), 2.37 (s, 3H). Step 2. Methyl 2-methoxy-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (33c)

[0691] Using a similar preparation procedure to the second step of Example 1, compound 33c (450 mg) was synthesized in 75% yield using compound 33b (500 mg, 1.71 mmol) and 1-methyl-1H-pyrazol-4-amine (166 mg, 1.71 mmol) as starting materials. 1H NMR (400MHz, CDCl3) δ8.31(s,1H),7.89(d,J=8.0Hz,1H),7.84(s,1H),7.48(s,1H),7.25(d,J=8.0Hz ,1H),7.19(dd,J=1.2,8.0Hz,1H),6.93(s,1H),3.96(s,3H),3.91(s,3H),3.88(s,3H),2.23(s,3H).

[0692] Step 3. 2-Methoxy-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (33d)

[0693] Using a similar preparation procedure to the third step of Example 1, compound 33c (450 mg, 1.27 mmol) was used as the starting material to synthesize compound 33d (432 mg) in 100% yield. LC-MS (Method 3): t R =0.96min, m / z (M+H) + =340.0.

[0694] Step 4. N-(Cyanomethyl)-2-methoxy-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (33)

[0695] Using a similar preparation procedure to that of the fourth step of Example 1, compound 33d (80 mg, 0.23 mmol) and 2-aminoacetonitrile hydrochloride (21 mg, 0.23 mg) were used as starting materials to synthesize compound 33 (30 mg) in 35% yield. The final compound was purified by preparative HPLC (Method B) to give the title compound. LC-MS (Method 1): t R =3.19min, m / z (M+H) + =378.1; 1 H NMR (400MHz, DMSO-d6) δ9.44(s,1H),8.90(t,J=5.6Hz,1H),8.38(s,1H),7.94(d,J=8.0Hz,1H),7.86(s,1H),7.4 7(s,1H),7.42(s,1H),7.34(d,J=8.0Hz,1H),4.33(d,J=6.0Hz,2H),3.97-3.95(m,3H),3.78(s,3H),2.21(s,3H).

[0696] Example 34

[0697]

[0698] Step 1. Methyl 4-(2,5-dichloropyrimidin-4-yl)benzoate (34b)

[0699] To a mixture of compound 34a (2.80 g, 15.3 mmol), (4-(methoxycarbonyl)phenyl)boronic acid (2.76 g, 15.3 mmol), DME (30 mL) and H o (10 mL) was added Na cO (3.26 g, 30.7 mmol) and Pd(PPh ) (177 mg, 1.53 mmol) in sequence. The mixture was stirred at 40 ° C for 4 hrs under N atmosphere. After cooling to RT, the mixture was concentrated to dryness. EtOAc (100 mL) and water (100 mL) were added. The organic layer was separated, dried over Na sO and filtered. The filtrate was concentrated to dryness to give a residue, which was purified by chromatography on silica gel (eluent: PE: EtOAc = 5: 1) to give the title compound (950 mg, 22% yield) as a white solid. 1H NMR (400MHz, CDCl3) δ8.69 (s, 1H), 8.18 (d, J = 8.0Hz, 2H), 7.96 (d, J = 8.0Hz, 2H), 3.98 (s, 3H).

[0700] Step 2. Methyl 4-(5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (34c)

[0701] Compound 34b (950 mg, 3.36 mmol), 1-methyl-1H-pyrazol-4-amine (391 mg, 4.03 mmol), Cs2CO3 (2.18 g, 6.72 mmol), X-Phos (320 mg, 0.67 mmol) and Pd2(dba)3 (308 mg, 0.33 mmol) were dissolved in 1,4-dioxane (20 mL). The resulting mixture was stirred at 110 ° C for 3 hrs under N2 atmosphere. After cooling to RT, the mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by chromatography on silica gel (eluent: PE: EtOAc = 3: 1) to give the title compound (552 mg, 48% yield) as a yellow solid. LC-MS (method 3): t R =1.58min, m / z(M+H) + =344.1.

[0702] Step 3. 4-(5-Chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (34d)

[0703] Using a similar preparation procedure to the third step of Example 1, compound 34c (150 mg, 0.44 mmol) was used as the starting material to synthesize compound 34d (140 mg) in 97% yield. LC-MS (Method 3): t R =1.09min, m / z(M+H) + =330.1.

[0704] Step 4. 4-(5-Chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(cyanomethyl)benzamide (34)

[0705] Using a similar preparation procedure to the fourth step of Example 1, compound 34d (140 mg, 0.42 mmol) and 2-aminoacetonitrile hydrochloride (59 mg, 0.64 mmol) were used as starting materials to synthesize compound 34 (17.4 mg) in 11% yield. LC-MS (Method 1): t R =3.15min, m / z (M+H) + =367.9; 1 H NMR (400MHz, CD3OD) δ8.46(s,1H),8.00-7.94(s,4H),7.90(s,1H),7.56(s,1H),4.36(s,2H),3.84(s,3H).

[0706] Example 35

[0707]

[0708] Step 1. Methyl 4-(2-chloropyrimidin-4-yl)-3-fluorobenzoate (35b)

[0709] Compound 35a (290 mg, 1.95 mmol), (2-fluoro-4-(methoxycarbonyl)phenyl)boronic acid (386 mg, 1.95 mmol), Na2CO3 (413 mg, 3.90 mmol) and Pd(dppf)Cl2 (100 mg, 0.1365 mmol) were dissolved in a mixture containing 1,4-dioxane (4 mL) and H2O (1 mL). The resulting mixture was stirred at 60 ° C. overnight under an N2 atmosphere. After cooling to RT, the reaction mixture was concentrated to dryness. The residue was purified by column chromatography on silica gel (eluent: PE: EtOAc = 5: 1) to give the title compound (440 mg, 85% yield) as a white solid. LC-MS (Method 3): t R =1.52min, m / z (M+H) + =267.1.

[0710] Step 2. Methyl 3-fluoro-4-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (35c)

[0711] Compound 35b (440 mg, 1.65 mmol), 1-methyl-1H-pyrazole-4-amine (176 mg, 1.81 mmol), Pd2(dba)3 (151 mg, 0.165 mmol), X-Phos (157 mg, 0.33 mmol) and Cs2CO3 (1.08 g, 3.3 mmol) were dissolved in 1,4-dioxane (6 mL). The resulting mixture was stirred at 100 ° C for 8 hrs under N2. After cooling to RT, the reaction mixture was concentrated to dryness. The residue was purified by column chromatography on silica gel (eluent: DCM: MeOH = 50: 1) to give the title compound (290 mg, 54% yield) as a brown solid. LC-MS (method 3): t R =1.49min, m / z(M+H) + =328.2. Step 3. 3-Fluoro-4-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (35d)

[0712] Using a similar preparation procedure to the third step of Example 1, compound 35c (290 mg, 0.89 mmol) was used as the starting material to synthesize compound 35d (277 mg) in 100% yield. LC-MS (Method 3): t R =1.10min, m / z(M+H) + =314.2.

[0713] Step 4. N-(Cyanomethyl)-3-fluoro-4-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (35)

[0714] Using a similar preparation procedure to the fourth step of Example 1, compound 35 (49.6 mg) was synthesized in a 37% yield using compound 35d (120 mg, 0.38 mmol) and 2-aminoacetonitrile hydrochloride (53 mg, 0.56 mmol) as starting materials. 1 HNMR(400MHz,DMSO-d6)δ9.64(s,1H),9.43(t,J=5.6Hz,1H),8.54(d,J=5.2Hz,1H),8.17-8.14(m,1 H),7.90-7.81(m,3H),7.53(s,1H),7.14(dd,J=2.4,5.2Hz,1H),4.35(d,J=5.6Hz,2H),3.81(s,3H).

[0715] Example 36

[0716]

[0717] Step 1. Methyl 4-(2-chloro-5-fluoropyrimidin-4-yl)-2-fluorobenzoate (36b)

[0718] Compound 36a (5.0 g, 29.95 mmol) was dissolved in a mixture of 1,4-dioxane (75 mL) and H2O (15 mL). (3-Fluoro-4-(methoxycarbonyl)phenyl)boronic acid (5.93 g, 29.95 mmol), K3PO4 (12.7 g, 59.9 mmol) and Pd(dppf)Cl2 (2.44 g, 2.99 mmol) were added sequentially to the above solution. The mixture was stirred at 80 ° C for 3 hrs under N2 atmosphere. After cooling to RT, the mixture was concentrated to dryness. EtOAc (100 mL) and water (100 mL) were added. The organic layer was separated, dried over Na2SO4 and filtered. The filtrate was concentrated to dryness to give a residue, which was purified by chromatography on silica gel (eluent: PE: EtOAc = 10: 1) to obtain the title compound (7.2 g, 85% yield) as a white solid. LC-MS (Method 3): t R =1.60min, m / z(M+H) + =285.0; 1 H NMR (400MHz, CDCl3) δ8.61 (d, J = 2.8Hz, 1H), 8.11-8.07 (m, 1H), 8.03-7.96 (m, 2H), 3.98 (s, 3H).

[0719] Step 2. Methyl 2-fluoro-4-(5-fluoro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (36c)

[0720] Compound 36b (700 mg, 2.46 mmol), 1-methyl-1H-pyrazole-4-amine (263 mg, 2.71 mmol), Cs2CO3 (1.6 g, 4.92 mmol), X-Phos (234 mg, 0.49 mmol) and Pd2(dba)3 (225 mg, 0.25 mmol) were dissolved in 1,4-dioxane (10 mL). The mixture was stirred at 110 ° C for 16 hrs under N2 atmosphere. After cooling to RT, the reaction mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by chromatography on silica gel (eluent: PE: EtOAc = 3: 1) to give the title compound (540 mg, 64% yield) as a yellow solid. LC-MS (method 3): t R=1.38min, m / z(M+H) + =346.1; 1 H NMR (400MHz, CDCl3) δ8.43 (d, J = 4.4Hz, 1H), 8.14-8.09 (m, 1H), 8.00-7.92 (m, 2H), 7.85 (s, 1H), 7.58 (s, 1H), 6.95 (br s,1H),4.02(s,3H),3.96(s,3H).

[0721] Step 3. 2-Fluoro-4-(5-fluoro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (36d)

[0722] To a solution of compound 36c (540 mg, 1.57 mmol), MeOH (3 mL), THF (3 mL) and H2O (2 mL) was added LiOH (132 mg, 3.14 mmol) at one time. The reaction mixture was stirred at RT for 2 hrs. The mixture was adjusted to pH 6-7 with 10% HCl aqueous solution and then extracted with a mixture of DCM and MeOH (55 mL, V / V=10:1). The organic layer was separated and concentrated to dryness in vacuo to give the title compound (426 mg, 82% yield) as an orange solid. LC-MS (method 3): t R =1.04min, m / z(M+H) + =332.1.

[0723] Step 4. N-(Cyanomethyl)-2-fluoro-4-(5-fluoro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (36)

[0724] Using a similar preparation procedure to the fourth step of Example 1, compound 36d (90 mg, 0.27 mmol) and 2-aminoacetonitrile hydrochloride (50 mg, 0.54 mmol) were used as starting materials to synthesize compound 36 (62 mg) in a 62% yield. LC-MS (Method 1): t R =2.98min, m / z(M+H) + =370.1; 1 H NMR (400MHz, DMSO-d6) δ9.70(s,1H),9.19(t,J=4.0Hz,1H),8.64(d,J=3.2Hz,1H),7.96(d,J=8.0Hz,1H),7.92-7.87(m,3H),7.53(br s, 1H), 4.37 (d, J = 5.6Hz, 2H), 3.82 (s, 3H).

[0725] Example 37

[0726]

[0727] Step 1. Ethyl 4-(2-((1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (37a)

[0728] To a suspension of compound 4e (1.5 g, crude) in ethanol (20 mL) was added concentrated sulfuric acid (0.2 mL). The mixture was heated at 90 ° C for 24 hrs. After cooling to RT, the reaction mixture was concentrated to give the desired compound (1.7 g, crude) as a yellow solid, which was used directly in the next step. LC-MS (method 3): t R =1.49min, m / z(M+H) + =324.0; 1 H NMR (400MHz, CD3OD) δ 8.38 (s, 1H), 8.20 (d, J = 8.4Hz, 2H), 8.14 (s, 2H), 7.85 (d, J = 8.4Hz, 2H), 4.42 (q, J = 7.2Hz, 2H), 2.32 (s, 3H), 1.42 (t, J = 7.2Hz, 3H).

[0729] Step 2. 4-(5-Methyl-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (37b)

[0730] Compound 37a (1.7 g, 5.08 mmol), tetrahydro-2H-pyran-4-yl methanesulfonate (2.3 g, 12.7 mmol) and cesium carbonate (8.3 g, 25.4 mmol) were dissolved in DMF (15 mL). The resulting mixture was stirred at 100 ° C for 16 hrs. After cooling to RT, the mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by preparative HPLC (method A) to obtain the title product 37b (620 mg, 32% yield) as a yellow solid. LC-MS (method 3): t R =1.11min, m / z (M+H) + =380.2.

[0731] Step 3. N-((1-cyanocyclopropyl)methyl)-4-(5-methyl-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (37)

[0732] Using a similar preparation procedure to the fourth step of Example 1, compound 37b (80 mg, 0.21 mmol) and 1-(aminomethyl)cyclopropanecarbonitrile (61 mg, 0.63 mmol) were used as starting materials to synthesize compound 37 (20 mg) in a 21% yield. LC-MS (Method 1): t R =3.49min, m / z (M+H) + =458.0; 1 H NMR(400MHz,MeOH-d4)δ8.32(s,1H),8.02-7.98(m,3H),7.78(d,J=8.4Hz,2H),7.61(s,1H),4.35-4.31(m,1H) ,4.07-4.03(m,2H),3.59-3.52(m,4H),2.24(s,3H),2.06-2.00(m,4H),1.31-1.28(m,2H),1.21-1.18(m,2H).

[0733] Example 38

[0734]

[0735] Step 1. Methyl 4-(5-methyl-2-((1-(1-(1-methylcyclopropanecarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (38a)

[0736] Compound 3a (380 mg, 0.89 mmol), 1-methylcyclopropanecarboxylic acid (134 mg, 1.34 mmol), HOBT (600 mg, 4.45 mmol), EDCI (877 mg, 4.45 mmol) and DIPEA (574 mg, 4.45 mmol) were dissolved in DMF (1 mL). The mixture was stirred at RT for 3 hrs. The mixture was concentrated. The residue was purified by column chromatography on silica gel (eluent: PE: EtOAc = 5: 1) to give the title product (380 mg, 90% yield) as a yellow solid. LC-MS (method 3): t R =1.55min, m / z (M+H) + =475.2.

[0737] Step 2. 4-(5-Methyl-2-((1-(1-(1-methylcyclopropanecarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (38b)

[0738] Using a similar preparation procedure to the third step of Example 1, compound 38a (380 mg, 0.8 mmol) was used as the starting material to synthesize compound 38b (360 mg) in 98% yield. LC-MS (Method 3): t R =1.20min, m / z (M+H) + =461.2.

[0739] Step 3. N-(Cyanomethyl)-4-(5-methyl-2-((1-(1-(1-methylcyclopropanecarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (38)

[0740] Using a similar preparation procedure to the fourth step of Example 1, compound 38b (80 mg, 0.17 mmol) and 2-aminoacetonitrile hydrochloride (47 mg, 0.51 mmol) were used as starting materials to synthesize compound 38 (55.2 mg) in a 65% yield. LC-MS (Method 1): t R =3.288min, m / z (M+H) + =499.3. 1 H NMR (400MHz, DMSO-d6) δ9.42(s,1H),9.33(t,J=5.6Hz,1H),8.38(s,1H),8.00(d,J=8.4Hz,2H),7.93(s,1H),7.81(d,J=7.6Hz,2H),7.54(s, 1H),4.40-4.31(m,5H),2.98(s,2H),2.20(s,3H),2.07-2.01(m,2H), 1.76-1.74(m,2H),1.23(s,3H),0.81-0.79(m,2H),0.56-0.53(m,2H).

[0741] Example 39

[0742]

[0743] Step 1. Butyl 4-(5-chloro-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (39a)

[0744] Using a procedure similar to the second step of Example 1, compound 34b (2.96 g, 11.1 mmol) and 1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-amine (42.40 g, 13.3 mmol) were used as starting materials to synthesize compound 39a (2.0 g) in 44% yield. LC-MS (Method 3): t R=1.85min, m / z(M+H) + =414.1;

[0745] Step 2. 4-(5-Chloro-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (39b)

[0746] Using a similar preparation procedure to the third step of Example 1, compound 39b (210 mg) was synthesized with a yield of 96% using compound 39a (250 mg, 0.55 mmol) as the starting material. LC-MS (Method 3): t R =1.11min, m / z (M+H) + =400.1;

[0747] Step 3. (S)-4-(5-Chloro-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide (39)

[0748] Using a similar procedure to the fourth step of Example 1, compound 39b (85 mg, 0.21 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (62.9 mg, 0.26 mmol) were used as starting materials to synthesize compound 39 (20.2 mg) in a 22% yield. LC-MS (Method 1): t R =3.22min, m / z (M+H) + =452.2; 1 H NMR(400MHz,MeOH-d4)δ8.49(s,1H),8.03-7.98(m,5H),7.64(s,1H),5.12-5.07(m,1H),4.41 -4.33(m,1H),4.10-4.06(m,2H),3.34-3.32(m,2H),2.08-2.04(m,4H),1.68(d,J=7.2Hz,3H).

[0749] Example 40

[0750]

[0751] Step 1. 2-(4-Nitro-1H-pyrazol-1-yl)acetonitrile (40a)

[0752] A mixture of 4-nitro-1H-pyrazole (10.0 g, 88.5 mmol), 2-bromoacetonitrile (21.0 g, 177 mmol) and K CO (37.0 g, 266 mmol) in DMF (50 mL) was stirred at 50 ° C for 2 hrs. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (150 mL). The separated organic layer was concentrated to give 40a (13.5 g, 100% yield) as a brown oil. 1 H NMR (400MHz, CDCl3) δ8.40(s,1H),8.16(s,1H),5.18(s,2H).

[0753] Step 2. 2-(4-amino-1H-pyrazol-1-yl)acetonitrile (40c)

[0754] To a mixture consisting of 40a (13.5 g, 88.5 mmol), NH4Cl (71 g, 1327 mmol), EtOH (50 mL) and H2O (10 mL) was added Fe powder (17.4 g, 310 mmol) at 80°C. The mixture was stirred at 80°C for 4 hrs. The mixture was filtered and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE:EtOAc=1:1) to afford 40c (4.0 g, 40% yield) as a brown solid. 1 H NMR (400MHz, DMSO-d6) δ7.14(s,1H),7.08(s,1H),5.29(s,2H),4.06(s,2H).

[0755] Step 3. 4-(2-Chloro-5-methylpyrimidin-4-yl)benzoic acid (40b)

[0756] 2,4-Dichloro-5-methylpyrimidine (14.7 g, 90.2 mmol), 4-dihydroxyborylbenzoic acid (15 g, 90.2 mmol), Na2CO3 (19.2 g, 181.1 mmol) and Pd(PPh3)4 (5.3 g, 4.6 mmol) were dissolved in a mixture of ACN and H2O (200 mL, V / V=1:1). The resulting solution was stirred at 90°C overnight under N2. The mixture was diluted with water (200 mL) and extracted with EtOAc (200 mL*3). The aqueous phase was acidified to pH=2 with 1N HCl, and the mixture was filtered to give the title product (19.8 g, 88% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ8.75 (s, 1H), 8.08 (d, J = 8.4Hz, 2H), 7.80 (d, J = 8.4Hz, 2H), 2.35 (s, 3H).

[0757] Step 4. 4-(2-((1-(Cyanomethyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (40d)

[0758] Compound 40b (3 g, 12.1 mmol), 40c (1.5 g, 12.1 mmol) and TsOH (208 mg, 1.21 mmol) were dissolved in n-BuOH (30 mL). The above solution was stirred at 120 ° C overnight. The mixture was diluted with water (100 mL) and an aqueous NaOH solution (0.5 N, 100 mL) and extracted with EtOAc (100 mL * 3). The aqueous phase was acidified to pH = 2 with HCl (1 N). The formed solid was filtered to obtain the title compound (2.8 g, 70% yield) as a dark green solid. 1 H NMR (400MHz, DMSO-d6) δ9.56(s,1H),8.41(s,1H),8.08(d,J=8.4Hz,2H),8.05(s,1H),7.80(d,J=8.4Hz,2H),7.64(s,1H),5.44(s,2H),2.20(s,3H).

[0759] Step 5. (S)-N-(1-cyanoethyl)-4-(2-((1-(cyanomethyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (40)

[0760] Using a similar preparation procedure to the fourth step of Example 1, compound 40 (19 mg) was synthesized with a yield of 20% using 40d (80 mg, 0.24 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (174 mg, 0.72 mmol) as starting materials. LC-MS (Method 1): t R =2.97min, m / z (M+H) + =387.2. 1 H NMR (400MHz, DMSO-d6) δ9.56(s,1H),9.26(d,J=7.2Hz,1H),8.41(s,1H),8.01(s,1H),8.03(d,J=8.4Hz,2H ),7.80(d,J=8.4Hz,2H),7.64(s,1H),5.44(s,2H),5.04-4.99(m,1H),2.20(s,3H),1.56(d,J=7.2Hz,3H).

[0761] Example 41 and Example 42

[0762]

[0763] Step 1. Methyl 4-(5-chloro-2-((1-(cyanomethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (41a)

[0764] Using a similar preparation procedure as in the second step of Example 1, compound 41a (440 mg) was synthesized in 35% yield using 34b (967 mg, 3.42 mmol) and 40c (500 mg, 4.1 mmol) as starting materials. LC-MS (Method 3): t R =1.58min, m / z(M+H) + =369.1.

[0765] Step 2. 4-(5-chloro-2-((1-(cyanomethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (41b) and 4-(2-((1-(2-amino-2-oxoethyl)-1H-pyrazol-4-yl)amino)-5-chloropyrimidin-4-yl)benzoic acid (42a)

[0766] Using a similar preparation procedure to the third step of Example 3, compounds 41b and 42a (282 mg, ratio = 1:1) were synthesized using 41a (440 mg, 1.19 mmol) as the starting material. LC-MS (Method 3): t R1 =0.97min, m / z (M+H) + =373.1. LC-MS (Method 3): t R2 =1.09min, m / z(M+H) + =355.1.

[0767] Step 3. 4-(5-chloro-2-((1-(cyanomethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(cyanomethyl)benzamide (41) and 4-(2-((1-(2-amino-2-oxoethyl)-1H-pyrazol-4-yl)amino)-5-chloropyrimidin-4-yl)-N-(cyanomethyl)benzamide (42)

[0768] Using a similar preparation procedure to the fourth step of Example 1, compounds 41 (13.2 mg) and 42 (6.0 mg) were synthesized using 41b and 42a (70 mg) and 2-aminoacetonitrile hydrochloride (37 mg, 0.395 mmol) as starting materials.

[0769] 41: LC-MS (Method 1): t1 = 3.43 min, m / z (M+H) + =393.1; 1H NMR(400MHz,DMSO-d6)δ9.99(s,1H),9.38-9.34(m,1H),8.62(s,1H),8.03(d ,J=8.4Hz,3H),7.94(s,2H),7.68(s,1H),5.46(s,2H),4.36(d,J=5.2Hz,2H).

[0770] 42: LC-MS (Method 1): t2 = 3.07 min, m / z (M+H) + =411.1; 1 H NMR (400MHz, DMSO-d6) δ9.88 (s, 1H), 9.36-9.34 (m, 1H), 8.59 (s, 1H), 8.02 (d, J = 8.4Hz, 2H), 7 .95-7.88(m,2H),7.55(s,1H),7.40(s,1H),7.20(s,1H),4.71(s,2H),4.36(d,J=5.6Hz,2H).

[0771] Example 43

[0772]

[0773] Step 1. Methyl 4-(5-chloro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (43a)

[0774] Using a similar preparation procedure to the second step of Example 1, compound 43a (50 mg) was synthesized in 11% yield using 34b (300 mg, 1.06 mmol) and 1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-amine (229 mg, 1.27 mmol) as starting materials. LC-MS (Method 3): t R =1.37min, m / z (M+H) + =427.0.

[0775] Step 2. Lithium 4-(5-chloro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (43b)

[0776] Compound 43a (50 mg, 0.12 mmol) and LiOH.H2O (25 mg, 0.60 mmol) were dissolved in a mixture of THF and H2O (1 mL, V / V = 1 / 1). The resulting mixture was stirred at 50°C for 3 hrs. The mixture was concentrated to dryness to give the desired product as a yellow solid (48 mg, 100% yield). LC-MS (Method 3): t R=1.26min, m / z (M+H) + =413.0.

[0777] Step 3. (S)-4-(5-chloro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide (43)

[0778] Using a similar preparation procedure to the fourth step of Example 1, compound 43 (10.1 mg) was synthesized in 19% yield using 43b (48 mg, 0.12 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (31 mg, 0.13 mmol) as starting materials. LC-MS (Method 1): t R =2.96min, m / z (M+H) + =465.2. 1 H NMR (400MHz, DMSO-d6) δ9.88(s,1H),9.34(d,J=9.6Hz,1H),8.61(s,1H),8.06(d,J=10.8Hz,2H),7.95-7.87(m,3H),7.59(s,1H),5.0 8-5.03(m,1H),4.10-4.07(m,1H),2.86(d,J=14.0Hz,2H),2.21(s,3H),2.08-2.01(m,2H),1.96-1.89(m,4H),1.60(d,J=9.6Hz,3H).

[0779] Example 44

[0780]

[0781] Step 1. 4-(5-chloro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(cyanomethyl)benzamide (44)

[0782] Using a similar preparation procedure to the fourth step of Example 1, compound 44 (5.6 mg) was synthesized with a yield of 6% using 43b (85 mg, 0.21 mmol) and 2-aminoacetonitrile hydrochloride (23 mg, 0.25 mmol) as starting materials. LC-MS (Method 1): t R =2.67min, m / z (M+H) + =451.2. 1H NMR(400MHz, DMSO-d6)δ9.85(s,1H),9.37(t,J=4.8Hz,1H),8.58(s,1H),8.02(d,J=8.0Hz,2H),7.98-7.88(m,3H),7.56-7.53( m,1H),4.36(d,J=5.6Hz,2H),4.08-4.04(m,1H),2.83(d,J=10.4Hz,2H),2.18(s,3H),2.05(t,J=4.0Hz,2H),2.02-1.84(m,4H).

[0783] Example 45

[0784]

[0785] Step 1. Methyl 4-(2-chloro-5-fluoropyrimidin-4-yl)benzoate (45a)

[0786] Using a similar preparation procedure to the first step of Example 36, compound 36a (1.34 g, 8.04 mmol) and (4-(methoxycarbonyl)phenyl)boronic acid (1.45 g, 8.04 mmol) were used as starting materials to synthesize compound 45a (1.5 g) in 70% yield. LC-MS (Method 3): t R =1.71min, m / z (M+H) + =267.0.

[0787] Step 2. Methyl 4-(2-((1-(cyanomethyl)-1H-pyrazol-4-yl)amino)-5-fluoropyrimidin-4-yl)benzoate (45b)

[0788] Using a similar preparation procedure as in the second step of Example 1, compound 45b (523 mg) was synthesized in 72% yield using 45a (500 mg, 1.9 mmol) and 40c (274 mg, 2.2 mmol) as starting materials. LC-MS (Method 3): t R =1.52min, m / z (M+H) + =353.1.

[0789] Step 2. 4-(2-((1-(Cyanomethyl)-1H-pyrazol-4-yl)amino)-5-fluoropyrimidin-4-yl)benzoic acid (45c)

[0790] Using a similar preparation procedure to the third step of Example 3, compound 45b (240 mg) was synthesized with a yield of 53% using 45a (471 mg, 1.3 mmol) as the starting material. LC-MS (Method 3): t R=1.14min, m / z (M+H) + =339.1.

[0791] Step 3. N-(Cyanomethyl)-4-(2-((1-(Cyanomethyl)-1H-pyrazol-4-yl)amino)-5-fluoropyrimidin-4-yl)benzamide (45)

[0792] Using a similar preparation procedure to the fourth step of Example 1, compound 45 (27.1 mg) was synthesized in 30% yield using 45b (80 mg, 0.24 mmol) and 2-aminoacetonitrile hydrochloride (44 mg, 0.48 mmol) as starting materials. LC-MS (Method 1): t R =2.98min, m / z(M+H) + =377.1; 1 H NMR (400MHz, DMSO-d6) δ9.81 (s, 1H), 9.37 (t, J = 5.6Hz, 1H), 8.64 (d, J = 3.6Hz, 1H), 8. 15-8.13(m,2H),8.09-8.05(m,3H),7.68(s,1H),5.48(s,2H),4.36(d,J=5.2Hz,2H).

[0793] Example 46 and Example 47

[0794]

[0795] (S)-4-(5-chloro-2-((1-(cyanomethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide (46) and (S)-4-(2-((1-(2-amino-2-oxoethyl)-1H-pyrazol-4-yl)amino)-5-chloropyrimidin-4-yl)-N-(1-cyanoethyl)benzamide (47)

[0796] Compounds 46 (21 mg) and 47 (31 mg) were synthesized using a similar preparation procedure to the fourth step of Example 1 using 41b and 42a (212 mg) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (291 mg, 1.20 mmol) as starting materials.

[0797] 46: LC-MS (Method 1): t1 = 3.49 min, m / z (M+H) + =407.1; 1H NMR (400MHz, DMSO-d6) δ10.01(s,1H),9.31(d,J=7.6Hz,1H),8.63(s,1H),8.04(d,J=8.4 Hz, 3H), 7.93 (s, 2H), 7.68 (s, 1H), 5.47 (s, 2H), 5.05-5.01 (m, 1H), 1.57 (d, J = 7.2Hz, 3H).

[0798] 47: LC-MS (Method 1): t2 = 2.57 min, m / z (M+H) + =425.1; 1 H NMR (400MHz, DMSO-d6) δ9.91 (s, 1H), 9.31 (d, J = 7.6Hz, 1H), 8.60 (s, 1H), 8.03 (d, J = 8.0Hz, 3H), 7.93-7. 89(m,2H),7.56(s,1H),7.42(s,1H),7.22(s,1H),5.04-5.01(m,1H),4.71(s,2H),1.57(d,J=7.6Hz,3H).

[0799] Example 48

[0800]

[0801] Step 1. Methyl 4-(5-methyl-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (48b)

[0802] Using a similar preparation procedure to the second step of Example 1, compound 48b (300 mg) was synthesized in 79% yield using 1b (300 mg, 1.15 mmol) and 1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-amine (248 mg, 1.37 mmol) as starting materials. LC-MS (Method 3): t R =1.54min, m / z (M+H) + =407.2.

[0803] Step 2. 4-(5-Methyl-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (48c)

[0804] Using a similar preparation procedure to the third step of Example 3, compound 48c (96 mg) was synthesized with a yield of 100% using 48b (100 mg, 0.25 mmol) and LiOH.H2O (52 mg, 1.23 mmol) as starting materials. LC-MS (Method 3): tR =0.33min, m / z(M+H)+=393.2.

[0805] Step 3. (S)-N-(1-cyanoethyl)-4-(5-methyl-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (48)

[0806] Using a similar preparation procedure to the fourth step of Example 1, compound 48 (33.7 mg) was synthesized in 31% yield using 48c (96 mg, 0.25 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (66 mg, 0.27 mmol) as starting materials. LC-MS (Method 1): t R =3.34min, m / z (M+H) + =445.2. 1 H NMR (400MHz, DMSO-d6) δ9.38(s,1H),9.26(d,J=7.2Hz,1H),8.36(d,J=7.6Hz,1H),8.01(d,J=8.4Hz,2H),7.87(s,1H),7.80(d,J=8.0Hz,2H),7.5 4(s,1H),5.06-5.00(m,1H),4.07-4.02(m,1H),2.85(d,J=11.2Hz,2H),2 .20(s,6H),2.08-1.98(m,2H),1.93-1.87(m,4H),1.58(t,J=7.6Hz,3H).

[0807] Example 49

[0808]

[0809] N-(Cyanomethyl)-4-(5-methyl-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (49)

[0810] Using a similar preparation procedure to the fourth step of Example 1, compound 49 (29.8 mg) was synthesized in 34% yield using 48c (80 mg, 0.2 mmol) and 2-aminoacetonitrile hydrochloride (37 mg, 0.4 mmol) as starting materials. LC-MS (Method 1): t R =8.84min, m / z (M+H) + =431.2; 1H NMR (400MHz, DMSO-d6) δ9.39(s,1H),9.33(t,J=4.8Hz,1H),8.37(s,1H),8.00(d,J=8.4Hz,2H),7.88(s,1H),7.80(d,J=7.6Hz,2H),7.5 3(s,1H),4.36(d,J=5.6Hz,2H),4.06-3.99(m,1H),2.82(d,J=10.8Hz,2H),2.19(d,J=4.4Hz,6H),2.04-1.98(m,2H),1.92-1.84(m,4H).

[0811] Example 50

[0812]

[0813] Step 1. Methyl 4-(5-fluoro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (50a)

[0814] Using a similar preparation procedure to the second step of Example 1, compound 50a (2.0 g) was synthesized in 44% yield using compound 45a (2.96 g, 11.1 mmol) and 1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-amine (2.40 g, 13.3 mmol) as starting materials. LC-MS (Method 3): t R =1.54min, m / z (M+H) + =411.2;

[0815] Step 2. 4-(5-Fluoro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (50b)

[0816] Using a similar preparation procedure to the third step of Example 3, compound 50b (1.73 g) was synthesized with a yield of 90% using compound 50a (2.0 g, 4.87 mmol) as the starting material. LC-MS (Method 3): t R =1.012min, m / z (M+H) + =397.1;

[0817] Step 3. (S)-N-(1-cyanoethyl)-4-(5-fluoro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (50)

[0818] Using a similar preparation procedure to the fourth step of Example 1, compound 50 (17 mg) was synthesized with a yield of 22% using 50b (70 mg, 0.177 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (47 mg, 0.193 mmol) as starting materials. LC-MS (Method 1): t R =2.86min, m / z (M+H) + =449.2. 1 H NMR (400MHz, DMSO-d6) δ9.66(s,1H),9.33(d,J=7.2Hz,1H),8.60(d,J=3.6Hz,1H),8.13(d,J=8.0Hz,2H),8.06(d,J=8.4Hz,2H),7.93(s,1H),7.5 8(s,1H),5.05-5.01(m,1H),4.10-4.05(m,1H),2.85(d,J=11.6Hz,2H),2 .19(s,3H),2.07-2.00(m,2H),1.95-1.90(m,4H),1.58(d,J=6.8Hz,3H).

[0819] Example 51

[0820]

[0821] Step 1. Methyl 4-(2-((1-(1-(2-hydroxy-2-methylpropionyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (51a)

[0822] Using a similar preparation procedure to the fourth step of Example 1, compound 51a (190 mg) was synthesized with a yield of 66% using 3a (239 mg, 0.6 mmol) and 2-hydroxy-2-methylpropionic acid (56 mg, 0.6 mmol) as starting materials. LC-MS (Method 3): t R =1.51min, m / z (M+H) + =479.3.

[0823] Step 2. 4-(2-((1-(1-(2-hydroxy-2-methylpropionyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (51b)

[0824] Using a similar preparation procedure to the third step of Example 3, compound 51b (186 mg) was synthesized with a 100% yield using 51a (190 mg, 0.4 mmol) as the starting material. LC-MS (Method 3): t R=1.07min, m / z (M+H) + =465.2.

[0825] Step 3. N-(Cyanomethyl)-4-(2-((1-(1-(2-hydroxy-2-methylpropionyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (51)

[0826] Using a similar preparation procedure to the fourth step of Example 1, compound 51 (30 mg) was synthesized with a yield of 32% using 51b (90 mg, 0.19 mmol) and 2-aminoacetonitrile hydrochloride (35 mg, 0.38 mmol) as starting materials. LC-MS (Method 1): t R =3.14min, m / z (M+H) + =503.2. 1 H NMR (400MHz, CDCl3) δ8.31(s,1H),8.10(s,1H),7.91(d,J=8.4Hz,2H),7.75(d,J=8.4Hz,2H),7.43(s,1H),7.02(s,1H),4 .56-4.54(m,2H),4.42-4.37(m,3H),4.20(s,1H),3.15-3.03(m,2H),2.28-2.21(m,5H),1.96-1.89(m,2H),1.52(s,6H).

[0827] Example 52

[0828]

[0829] Step 1. (S)-N-(1-cyanoethyl)-4-(2-((1-(1-(2-hydroxy-2-methylpropionyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (52)

[0830] Using a similar preparation procedure to the fourth step of Example 1, compound 52 (43.5 mg) was synthesized in 44% yield using 51b (90 mg, 0.19 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (92 mg, 0.38 mmol) as starting materials. LC-MS (Method 1): t R =3.34min, m / z (M+H) + =517.3. 1H NMR(400MHz, CDCl3)δ8.32(s,1H),8.09(s,1H),7.91(d,J=8.0Hz,2H),7.74(d,J=8.0Hz,2H),7.46(s,1H),6.85(s,1H),5.22-5.18(m,1H), 4.53-4.37(m,3H),4.21(s,1H),3.16-3.04(m,2H),2.27-2.21(m,5H),2.00-1.94(m,2H),1.72(d,J=7.2Hz,3H),1.55(s,3H),1.53(s,3H).

[0831] Example 53

[0832]

[0833] (S)-N-(1-cyanoethyl)-4-(2-((1-(cyanomethyl)-1H-pyrazol-4-yl)amino)-5-fluoropyrimidin-4-yl)benzamide (53)

[0834] Using a similar preparation procedure to the fourth step of Example 1, compound 53 (24.3 mg) was synthesized in 26% yield using 45c (80 mg, 0.24 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (116 mg, 0.48 mmol) as starting materials. LC-MS (Method 1): t R =3.28min, m / z (M+H) + =391.1; 1 H NMR (400MHz, DMSO-d6) δ9.83(s,1H),9.33(d,J=7.6Hz,1H),8.65(d,J=3.2Hz,1H),8.15-8.13( m,2H),8.10-8.04(m,3H),7.68(s,1H),5.49(s,2H),5.07-4.99(m,1H),1.57(d,J=7.2Hz,3H).

[0835] Example 54

[0836]

[0837] Step 1. (R)-Benzyl (1-cyanoethyl)carbamate (54b)

[0838] Using a similar preparation procedure to the second step of Example 208, compound 54b (8.8 g) was synthesized in 96% yield using (R)-benzyl (1-amino-1-oxopropan-2-yl)carbamate 54a (10 g, 45 mmol) as the starting material. 1 H NMR (400MHz, DMSO-d6) δ8.17(d,J=6.8Hz,1H),7.37-7.31(m,5H),5.08(s,2H),4.63-4.56(m,1H),1.41(d,J=7.2Hz,3H).

[0839] Step 2. (R)-2-Aminopropionitrile 4-methylbenzenesulfonate (54c)

[0840] A mixture of 54b (4.0 g, 20 mmol), Pd / C (600 mg, 10% wt, wetted with about 55% water), Pd(OH) (600 mg, 20% wt, wetted with about 50% water) in EtOAc (30 mL) was stirred at 40° C. for 7 hrs under H (50 psi). The catalyst was filtered off, and TsOH (3.7 g, 20 mmol) was added to the filtrate with stirring. After stirring at RT for 20 minutes, the solid formed was collected by filtration and dried to give the title product as a yellow solid (2.8 g, 59% yield). 1 H NMR (400MHz, DMSO-d6) δ8.69 (s, 3H), 7.48 (d, J = 8.0Hz, 2H), 7.11 (d, J = 8.0Hz, 2H), 4.59-4.54 (m, 1H), 2.29 (s, 3H), 1.51 (t, J = 7.2Hz, 3H).

[0841] Step 3. (R)-N-(1-cyanoethyl)-4-(2-((1-(cyanomethyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (54)

[0842] Using a similar preparation procedure to the fourth step of Example 1, compound 54 (6.9 mg) was synthesized in 12% yield using 40d (50 mg, 0.15 mmol) and (R)-2-aminopropionitrile 4-methylbenzenesulfonate 54c (72.6 mg, 0.3 mmol) as starting materials. LC-MS (Method 1): t R =3.37,m / z(M+H) + =387.1; 1H NMR (400MHz, DMSO-d6) δ9.56 (s, 1H), 9.26 (d, J = 6.0Hz, 1H), 8.41 (s, 1H), 8.03-8.01 (m, 3H), 7.80 ( d,J=6.4Hz,2H),7.65(s,1H),5.44(s,2H),5.06-4.98(m,1H),2.20(s,3H),1.57(d,J=6.8Hz,3H).

[0843] Example 55

[0844]

[0845] Step 1. (S)-Benzyl (1-amino-1-oxobutan-2-yl)carbamate (55b)

[0846] (S)-2-(((benzyloxy)carbonyl)amino)butanoic acid 55a (5.0 g, 21.1 mmol) and NMM (6.4 g, 63.2 mmol) were dissolved in THF (40 mL), and then methyl chloroformate (4.0 g, 42.2 mmol) was added dropwise at 0°C for 1 hour. The solid formed was filtered off. To the above filtrate was added a solution of NH3(g) in THF (30 mL, 4 M in THF). The resulting mixture was stirred at 0°C for 2 hrs. The mixture was concentrated to dryness and the residue was recrystallized from EtOAc (20 mL) to give the title product (4.5 g, 90% yield) as a white solid. LC-MS (Method 3): t R =1.23min, m / z (M+H) + =237.1. Step 2. (S)-Benzyl (1-cyanopropyl)carbamate (55c)

[0847] To a solution of 55b (4.5 g, 19.0 mmol) in DMF (45 mL) was added dropwise POCl (12.0 mL) at 0°C for 1 hour. The mixture was poured into water (100 mL) and extracted with EtOAc (400 mL). The separated organic layer was washed with brine (300 mL*3). The organic layer was concentrated to give the title product (3.3 g, 80% yield) as a yellow oil. 1 HNMR(400MHz,DMSO-d6)δ8.16(d,J=7.2Hz,1H),7.40-7.31(m,5H),5.09(s,2 H), 4.48 (dd, J = 14.8Hz, 7.2Hz, 1H), 1.79-1.71 (m, 2H), 0.95 (t, J = 7.2Hz, 3H).

[0848] Step 3. (S)-2-Aminobutyronitrile (55d)

[0849] A mixture of 55c (3.3 g, 15.1 mmol), Pd / C (330 mg, 10% wt, wet with about 55% water), Pd(OH) (330 mg, 20% wt, wet with about 50% water) in EtOAc (30 mL) was stirred at 40° C. under H (50 psi) for 6 hrs. The mixture was filtered and the filtrate was concentrated to give the crude product (720 mg, 57% yield) as a yellow oil. 1 H NMR (400MHz, DMSO-d6) δ3.62 (t, J = 6.8 Hz, 1H), 2.41-2.10 (m, 2H), 1.64-1.57 (m, 2H), 0.95 (t, J = 7.2 Hz, 3H).

[0850] Step 4. (S)-4-(2-((1-(cyanomethyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)-N-(1-cyanopropyl)benzamide (55)

[0851] Using a similar preparation procedure to the fourth step of Example 1, using 40d (70 mg, 0.21 mmol) and (S)-2-aminobutyronitrile (88 mg, 1.05 mmol) as starting materials, compound 55 (13.3 mg) was synthesized with a yield of 16%. LC-MS (Method 1): t R =8.51min, m / z (M+H) + =401.2; 1 H NMR (400MHz, DMSO-d6) δ9.58(s,1H),9.26(d,J=7.6Hz,1H),8.41(s,1H),8.01(s,1H),8.02(d,J=8.0Hz,2H),7.80(d ,J=8.0Hz,2H),7.65(s,1H),5.45(s,2H),4.93-4.91(m,1H),2.21(s,3H),1.95-1.90(m,2H),1.03(t,J=7.2Hz,3H).

[0852] Example 56

[0853]

[0854] Step 1. Methyl 4-(5-fluoro-2-((1-(1-pivaloylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (56a)

[0855] Using a preparation procedure similar to the second step of Example 1, compound 56a (420 mg) was synthesized in a yield of 92% using 45a (320 mg, 1.2 mmol) and 1-(4-(4-amino-1H-pyrazol-1-yl)piperidin-1-yl)-2,2-dimethylpropan-1-one (300 mg, 1.2 mmol) as starting materials. 1 H NMR (400MHz, CDCl3) δ8.41(d,J=4.4Hz,1H),8.23-8.17(m,4H),7.95(s,1H),7.62(s,1H),6.95(s,1H),4.63-4.58( m,2H),4.42-4.35(m,1H),4.01(s,3H),3.05(t,J=16.0Hz,2H),2.28-2.24(m,2H),2.07-1.99(m,2H),1.36(s,9H).

[0856] Step 2. 4-(5-Fluoro-2-((1-(1-pivaloylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (56b)

[0857] To a solution of 56a (90 mg, 0.237 mmol), THF (2 mL) and H2O (1 mL) was added LiOH.H2O (30 mg, 0.711 mmol) in one portion. The mixture was stirred at RT for 2 hrs. The reaction mixture was diluted with 2N aqueous HCl and concentrated to dryness to give the crude product as a yellow solid (87 mg, 100% yield). LC-MS (Method 3): t R =1.23min, m / z (M+H) + =467.2.

[0858] Step 3. N-(Cyanomethyl)-4-(5-fluoro-2-((1-(1-pivaloylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (56)

[0859] Using a similar preparation procedure to the fourth step of Example 1, compound 56 (68.5 mg) was synthesized in 73% yield using 56b (87 mg, 0.19 mmol) and 2-aminoacetonitrile hydrochloride (19 mg, 0.21 mmol) as starting materials. LC-MS (Method 1): t R =6.41min,m / z(M+H) + =505.2. 1H NMR (400MHz, DMSO-d6) δ9.65(s,1H),9.36(d,J=5.2Hz,1H),8.61(d,J=4.0Hz,1H),8.13(d,J=8.0Hz,2H),8.04(d,J=8.0Hz,2H) ,7.96(s,1H),7.57(s,1H),4.42-4.35(m,5H),2.96(t,J=12.4Hz,2H),2.04(d,J=10.0Hz,2H),1.77-1.74(m,2H),1.22(s,9H).

[0860] Example 57

[0861]

[0862] (S)-N-(1-cyanoethyl)-4-(5-fluoro-2-((1-(1-pivaloylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (57)

[0863] Using a similar preparation procedure to the fourth step of Example 1, compound 57 (49.3 mg) was synthesized in 46% yield using 56b (97 mg, 0.21 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (56 mg, 0.23 mmol) as starting materials. LC-MS (Method 1): t R =8.33min, m / z (M+H) + =519.3. 1 H NMR (400MHz, DMSO-d6) δ9.65(s,1H),9.30(d,J=7.2Hz,1H),8.61(d,J=3.2Hz,1H),8.13(d,J=7.6Hz,2H),8.05(d,J=8.8Hz,2H),7.97(s,1H),7.57(s, 1H),5.03(t,J=6.8Hz,1H),4.35-4.27(m,3H),2.96(t,J=12.8Hz,2H),2.0 5(d,J=16.8Hz,2H),1.77-1.73(m,2H),1.57(d,J=7.6Hz,3H),1.22(s,9H).

[0864] Example 58

[0865]

[0866] (R)-4-(5-chloro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide (58)

[0867] Using a similar preparation procedure to the fourth step of Example 1, compound 58 (5.5 mg) was synthesized with a yield of 6% using 43b (82.8 mg, 0.20 mmol) and (R)-2-aminopropionitrile 4-methylbenzenesulfonate (48.4 mg, 0.20 mmol) as starting materials. LC-MS (Method 1): t R =2.97min, m / z (M+H) + =465.2. 1 H NMR(400MHz, CDCl3)δ8.42(s,1H),7.96-7.90(m,5H),7.50(s,1H),7.26(s,1H),7.07(s,1H),5.22-5.15(m,1H),4. 14-4.07(m,1H),2.99(d,J=10.4Hz,2H),2.34(s,3H),2.18-2.13(m,4H),2.06-1.98(m,2H),1.68(d,J=11.2Hz,3H).

[0868] Example 59

[0869]

[0870] (S)-N-(1-cyanopropyl)-4-(5-fluoro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (59)

[0871] Using a similar preparation procedure to the fourth step of Example 1, (S)-2-aminobutyronitrile (25 mg, 0.30 mmol) and 50b (60 mg, 0.15 mmol) were used as starting materials to synthesize compound 59 (2.5 mg) in a 3% yield. LC-MS (Method 1): t R =10.71min, m / z (M+H) + =463.2; 1H NMR (400MHz, CDCl3) δ8.35(d,J=3.2Hz,1H),8.17(d,J=8.4Hz,2H),7.94(d,J=8.4Hz,3H),7.54(s,1H),7.00(s,1H),6.92( s,1H),5.12-5.06(m,1H),4.16-4.10(m,1H),3.01(d,J=7.6Hz,2H),2.35(s,3H),2.20-1.97(m,8H),1.19(t,J=7.4Hz,3H).

[0872] Example 60

[0873]

[0874] Step 1. Methyl 4-(5-chloro-2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (60a)

[0875] Using a similar preparation procedure to the second step of Example 34, compound 60a (2.0 g) was synthesized in 52% yield using 34b (3.0 g, 10.5 mmol) and 1-cyclopropyl-1H-pyrazol-4-amine (1.55 g, 10.5 mmol) as starting materials. 1 H NMR (400MHz, CDCl3) δ8.44(s,1H),8.16(d,J=8.4Hz,2H),7.91(d,J=8.4Hz,2H),7.88(s,1H),7 .49(s,1H),6.97(s,1H),3.97(s,3H),3.60-3.56(m,1H),1.15-1.11(m,2H),1.03-0.96(m,2H).

[0876] Step 2. 4-(5-chloro-2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (60b)

[0877] Using a similar preparation procedure to the third step of Example 3, compound 60b (1.93 g) was synthesized in 100% yield using 60a (2.0 g, 5.42 mmol) and LiOH.H2O (683 mg, 16.3 mmol) as starting materials. LC-MS (Method 3): t R =1.166min, m / z (M+H) + =356.1.

[0878] Step 3. 4-(5-Chloro-2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-((1-cyanocyclopropyl)methyl)benzamide (60)

[0879] Using a similar preparation procedure to that of the fourth step of Example 1, compound 60 (14.6 mg) was synthesized in 15% yield using 60b (80 mg, 0.22 mmol) and 1-(aminomethyl)cyclopropanecarbonitrile (26 mg, 0.27 mmol) as starting materials. The title compound was purified by preparative HPLC (Method A). LC-MS (Method 1): t R =3.850min, m / z (M+H) + =434.0; 1 H NMR(400MHz, DMSO-d6)δ9.83(s,1H),9.04(t,J=5.6Hz,1H),8.58(t,J=5.6Hz,1H),8.02(d,J=8.0Hz,2H),7.78-7.90(m ,3H),7.50(s,1H),3.70-3.66(m,1H),3.47(d,J=6.0Hz,2H),1.26-1.23(m,2H),1.16-1.13(m,2H),0.98-0.92(m,4H).

[0880] Example 61

[0881]

[0882] (S)-4-(5-chloro-2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanopropyl)benzamide (61)

[0883] Using a similar preparation procedure to the fourth step of Example 1, compound 61 (12.5 mg) was synthesized with a yield of 21% using 60b (50 mg, 0.14 mmol) and (S)-2-aminobutyronitrile (59 mg, 0.70 mmol) as starting materials. LC-MS (Method 1): t R =3.08min, m / z (M+H) + =422.1; 1H NMR (400MHz, DMSO-d6) δ9.84(s,1H),9.27(d,J=7.6Hz,1H),8.59(s,1H),8.03(d,J=8.4Hz,1H),7.92(t,J=10.0Hz,3 H),7.50(s,1H),4.94–4.88(m,1H),3.69-3.64(m.1H),1.97-1.88(m,2H),1.03(t,J=14.8Hz,3H),0.98-0.89(m,4H).

[0884] Example 62

[0885]

[0886] (R)-N-(1-cyanoethyl)-4-(5-methyl-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (62)

[0887] Using a similar preparation procedure to the fourth step of Example 1, compound 62 (13.6 mg) was synthesized in 15% yield using 48c (80 mg, 0.20 mmol) and (R)-2-aminopropionitrile 4-methylbenzenesulfonate (99 mg, 0.40 mmol) as starting materials. LC-MS (Method 1): t R =3.08min, m / z (M+H) + =445.2; 1 H NMR (400MHz, DMSO-d6) δ9.38(s,1H),9.26(d,J=7.2Hz,1H),8.37(s,1H),8.01(d,J=8.4Hz,2H),7.87(s,1H),7.80(d,J=8.0Hz,1H),7.54(s, 1H),5.04-4.99(m,1H),4.06-4.00(m,1H),2.83(d,J=11.2Hz,2H),2.1 9(s,6H),2.05-1.99(m,2H),1.95-1.84(m,4H),1.57(d,J=6.8Hz,2H).

[0888] Example 63

[0889]

[0890] (R)-N-(1-cyanoethyl)-4-(5-fluoro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (63)

[0891] To a mixture consisting of 50b (70 mg, 0.18 mmol), (R)-2-aminopropionitrile 4-methylbenzenesulfonate (51 mg, 0.21 mmol) and DMF (2 mL) was added HATU (101 mg, 0.27 mmol) and TEA (54 mg, 0.54 mmol) in sequence. The mixture was stirred at RT for 18 hrs. The mixture was concentrated to dryness. The residue was diluted with H2O (30 mL) and extracted with EtOAc (30 mL*2). The combined organic layers were concentrated and the residue was purified by preparative HPLC (Method A) to give the title product as a yellow solid (16.4 mg, 21% yield). LC-MS (Method 1): t R =3.49min, m / z (M+H) + =449.2. 1 H NMR (400MHz, DMSO-d6) δ9.63(s,1H),9.31(d,J=6.4Hz,1H),8.60(d,J=3.6Hz,1H),8.13(d,J=8.0Hz,2H),8.06(d,J=8.4Hz,2H),7.93(s,1H),7.5 8(s,1H),5.05-5.01(m,1H),4.10-4.05(m,1H),2.84(d,J=11.6Hz,2H),2 .19(s,3H),2.07-1.99(m,2H),1.96-1.90(m,4H),1.58(d,J=7.2Hz,3H).

[0892] Example 64

[0893]

[0894] Step 1. Tert-butyl (1R,3s,5S)-3-((methylsulfonyl)oxy)-8-azabicyclo[3.2.1]octane-8-carboxylate (64b)

[0895] To a solution of 64a (2.5 g, 11.0 mmol; CAS No. 194222-05-4) and TEA (3.3 g, 33.0 mmol) in DCM (30 mL) was added MsCl (2.5 g, 22.0 mmol) at 0°C. The mixture was stirred at RT for 2 hours. The mixture was diluted with water (100 mL) and extracted with DCM (50 mL*2). The combined organic phases were dried over Na2SO4, filtered, and concentrated in vacuo to afford the desired product 76b (3.4 g, 100% yield) as a yellow solid. 1H NMR(400MHz,DMSO-d6)δ4.99-4.95(m,1H),4.10(s,2H),3.21(s,3H),2.14-2.0 7(m,2H),1.87-1.86(m,2H),1.73-1.72(m,2H),1.62-1.60(m,2H),1.41(s,9H).

[0896] Step 2. Tert-butyl (1R,3r,5S)-3-(4-nitro-1H-pyrazol-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (64c)

[0897] To a well stirred mixture of 64b (3.4 g, 11.1 mmol), 4-nitro-1H-pyrazole (630 mg, 5.57 mmol) and NMP (40 mL) was added CsCO (5.4 g, 16.7 mmol) in one portion. The mixture was stirred at 120° C. overnight. The mixture was concentrated to dryness to give the desired crude product as a brown oil (1.8 g, 100% yield). LC-MS (Method 3): t R =1.66min, m / z (M+H-56) + =267.1.

[0898] Step 3. (1R,3r,5S)-3-(4-nitro-1H-pyrazol-1-yl)-8-azabicyclo[3.2.1]octane hydrochloride (64d)

[0899] Compound 64d (620 mg) was synthesized in 100% yield using a similar preparation procedure to the fifth step of Example 1 using 64c (1.3 g, 4.03 mmol) as the starting material. LC-MS (Method 3): t R =0.50min, m / z (M+H) + =223.1.

[0900] Step 4. Cyclopropyl((1R,3r,5S)-3-(4-nitro-1H-pyrazol-1-yl)-8-azabicyclo[3.2.1]octan-8-yl)methanone (64e)

[0901] Using a similar preparation procedure to the first step of Example 24, compound 64e (260 mg) was synthesized in 100% yield using 64d (200 mg, 0.90 mmol) and cyclopropanecarbonyl chloride (141 mg, 1.35 mmol) as starting materials. LC-MS (Method 3): t R =1.36min, m / z(M+H) + =291.1.

[0902] Step 5. ((1R,3r,5S)-3-(4-amino-1H-pyrazol-1-yl)-8-azabicyclo[3.2.1]octan-8-yl)(cyclopropyl)methanone (64f)

[0903] Using a similar preparation procedure as in the second step of Example 4, compound 64f (230 mg) was synthesized in 100% yield using 64e (260 mg, 0.90 mmol) as the starting material. LC-MS (Method 3): t R =0.98min, m / z (M+H) + =261.1.

[0904] Step 6. 4-(2-((1-((1R,3r,5S)-8-(cyclopropanecarbonyl)-8-azabicyclo[3.2.1]oct-3-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (64 g)

[0905] 64f (250 mg, 0.96 mmol), 40b (238 mg, 0.96 mmol) and 4-methylbenzenesulfonic acid (17 mg, 0.096 mmol) were dissolved in 1,4-dioxane (5 mL). The resulting mixture was stirred at 120 ° C for 3 hrs in a sealed tube. After cooling to RT, the mixture was concentrated to dryness. The residue was purified by reverse phase flash chromatography to give the title product as a yellow solid (320 mg, 71% yield). LC-MS (method 3): t R =1.14min, m / z (M+H) + =473.2.

[0906] Step 7. N-(Cyanomethyl)-4-(2-((1-((1R,3r,5S)-8-(cyclopropanecarbonyl)-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (64)

[0907] Using a similar preparation procedure to the fourth step of Example 1, 64 g (70 mg, 0.15 mmol) and 2-aminoacetonitrile hydrochloride (70 mg, 0.75 mmol) were used as starting materials to synthesize compound 64 (30 mg) in a 39% yield. LC-MS (Method 1): t R =3.38min, m / z (M+H) + =511.2; 1H NMR(400MHz,DMSO-d6)δ9.43(s,1H),9.35-9.32(m,1H),8.40(s,1H),8.09(s ,1H),8.01(d,J=8.0Hz,2H),7.81(d,J=7.6Hz,2H),7.57(s,1H),4.59(s,1H), 4.45(s,1H),4.37-4.34(m,2H),2.67-2.60(m,2H),2.33-2.24(m,2H),2.21( s,3H),1.97-1.80(m,2H),1.66-1.54(m,2H),1.23(s,1H),0.76-0.64(m,4H).

[0908] Example 65

[0909]

[0910] Step 1. Tert-butyl (1R,3r,5S)-3-(4-amino-1H-pyrazol-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (65b)

[0911] Using a similar preparation procedure to the second step of Example 4, compound 65b (450 mg) was synthesized in 100% yield using 64c (500 mg, 1.55 mmol) as the starting material. 1 H NMR (400MHz, CDCl3) δ7.17 (d, J = 4.8Hz, 2H), 4.23-4.19 (m, 2H), 4.15-4.13 (m, 1H), 2.1 7-2.12(m,2H),1.95-1.94(m,2H),1.85-1.81(m,2H),1.72-1.68(m,2H),1.47(s,9H).

[0912] Step 2. Tert-butyl (1R,3r,5S)-3-(4-((4-(4-(methoxycarbonyl)phenyl)-5-methylpyrimidin-2-yl)amino)-1H-pyrazol-1-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (65c)

[0913] Using a similar preparation procedure to the sixth step of Example 64, compound 65c (510 mg) was synthesized in 100% yield using 65b (400 mg, 1.37 mmol) and 1b (240 mg, 0.91 mmol) as starting materials. LC-MS (Method 3): t R =1.83min, m / z(M+H) + =519.2.

[0914] Step 3. Methyl 4-(2-((1-((1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate hydrochloride (65d)

[0915] Using a similar preparation procedure as in the second step of Example 1, compound 65d (420 mg) was synthesized in 97% yield using 65c (510 mg, 0.98 mmol) as the starting material. LC-MS (Method 3): t R =1.46min, m / z(M+H) + =419.2.

[0916] Step 4. Methyl 4-(5-methyl-2-((1-((1R,3r,5S)-8-(1-methylcyclopropanecarbonyl)-8-azabicyclo[3.2.1]oct-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (65e)

[0917] Using a similar preparation procedure to the first step of Example 38, compound 65e (160 mg) was synthesized in 36% yield using 65d (370 mg, 0.89 mmol) and 1-methylcyclopropanecarboxylic acid (89 mg, 0.89 mmol) as starting materials. LC-MS (Method 3): t R =1.65min, m / z (M+H) + =501.2.

[0918] Step 5. 4-(5-Methyl-2-((1-((1R,3r,5S)-8-(1-methylcyclopropanecarbonyl)-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (65f)

[0919] Using a similar preparation procedure to the third step of Example 3, compound 65f (155 mg) was synthesized with a 100% yield using 65e (160 mg, 0.32 mmol) as the starting material. LC-MS (Method 3): t R =1.20min, m / z (M+H) + =487.2.

[0920] Step 6. N-(Cyanomethyl)-4-(5-methyl-2-((1-((1R,3r,5S)-8-(1-methylcyclopropanecarbonyl)-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (65)

[0921] Using a similar preparation procedure to that of step 4 of Example 1, compound 65 (15 mg) was synthesized in 20% yield using 65f (70 mg, 0.14 mmol) and 2-aminoacetonitrile hydrochloride (67 mg, 0.72 mmol) as starting materials. The title compound was purified by preparative HPLC (Method B). LC-MS (Method 1): t R =10.25min, m / z (M+H) + =525.3; 1 H NMR(400MHz, CDCl3)δ8.26(s,1H),8.02(s,1H),7.97(d,J=8.4Hz,2H),7.75(d,J=8.4Hz,2H),7.61(s,1H),7.29-7.26(m,1H),4.66(s,2H),4.4 3(d,J=5.6Hz,2H),4.28-4.25(m,1H),2.46-2.40(m,2H),2.28(s,3H), 2.04(s,2H),1.82-1.71(m,4H),1.36(s,3H),0.94(s,2H),0.59(s,2H).

[0922] Example 66

[0923]

[0924] Step 1. 4-(4-Nitro-1H-pyrazol-1-yl)piperidin-2-one (66b)

[0925] To a suspension consisting of 4a (1.9 g, 17.0 mmol), 4-hydroxypiperidin-2-one (1.3 g, 11.3 mmol), PPh (4.5 g, 17.0 mmol) and THF (20 mL) was added DIAD (3.4 g, 17.0 mmol) at 0°C. The mixture was stirred at RT for 18 hrs and concentrated to dryness. The residue was purified by column chromatography on silica gel (PE: EtOAc = 2: 1) to afford 66b (1.1 g, 48% yield) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ8.20 (s, 1H), 8.13 (s, 1H), 5.84 (s, 1H), 4.72-4.69 (m, 1H), 3.46-3.40 (m, 2H), 2.94 (d, J = 7.2Hz, 2H), 2.37-2.39 (m, 2H).

[0926] Step 2. 1-Methyl-4-(4-nitro-1H-pyrazol-1-yl)piperidin-2-one (66c)

[0927] To a suspension consisting of 66b (200 mg, 0.95 mmol), CHI (176 mg, 1.24 mmol) and DMF (2 mL) was added NaH (57.2 mg, 1.43 mmol, 60% in mineral oil) at 0°C. The mixture was stirred at RT for 40 mins. The mixture was diluted with water (1 mL) and extracted with EtOAc (6 mL). The separated organic layer was washed with brine (2 mL) and concentrated to dryness to afford 66c (180 mg, 85% yield) as a yellow solid. LC-MS (Method 3): t R =1.03min, m / z(M+H) + =225.1.

[0928] Step 3. 4-(4-Amino-1H-pyrazol-1-yl)-1-methylpiperidin-2-one (66d)

[0929] Using a similar preparation procedure to the second step of Example 4, compound 66d (200 mg) was synthesized in 100% yield using 66c (180 mg, 0.80 mmol) as the starting material. 1 H NMR (400MHz, CDCl3) δ8.25(s,1H),8.12(s,1H),4.66(s,1H),3.97(s,3H),3.46-3.36(m,2H),2.97-2.93(m,2H),2.40-2.37(m,2H).

[0930] Step 4. 4-(5-methyl-2-((1-(1-methyl-2-oxopiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (66e)

[0931] Using a similar preparation procedure to the sixth step of Example 64, compound 66e (140 mg) was synthesized in 51% yield using 66d (130 mg) and 40b (166 mg) as starting materials. LC-MS (Method 1): t R =1.07min, m / z (M+H) + =407.1.

[0932] Step 5. N-(Cyanomethyl)-4-(5-methyl-2-((1-(1-methyl-2-oxopiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (66)

[0933] Using a similar preparation procedure to the fourth step of Example 1, compound 66 (2.7 mg) was synthesized with a yield of 4% using 66e (70 mg, 0.17 mmol) and 2-aminoacetonitrile hydrochloride (79 mg, 0.85 mmol) as starting materials. LC-MS (Method 1): t R =2.63min, m / z (M+H) + =445.2; 1 H NMR (400MHz, CDCl3) δ8.24(s,1H),7.99(s,1H),7.89(d,J=8.4Hz,2H),7.67(d,J=8.4Hz,2H),7.41(s,1H),6 .83(s,1H),4.59-4.57(m,1H),4.42-4.27(m,2H),3.26-3.17(m,2H),2.88-2.78(m,5H),2.27-2.19(m,5H).

[0934] Example 67

[0935]

[0936] Step 1. 4-Nitro-1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazole (67b)

[0937] To a solution consisting of 4a (1 g, 8.8 mmol), tetrahydro-2H-pyran-3-ol (1 g, 9.8 mmol), PPh 3 (3.34 g, 12.7 mmol) and THF (20 mL) was added DIAD (2.57 g, 12.7 mmol) at 0° C. The mixture was stirred at 0° C. to RT for 5 hrs. The reaction mixture was concentrated to dryness and purified by flash chromatography (PE:EtOAc=4:1) to give the product as a colorless oil (1.5 g, 78% yield). 1 H NMR(400MHz, CDCl3)δ8.38(s,1H),8.09(s,1H),4.37-4.33(m,1H),4.10-4.08(m, 1H),3.89-3.81(m,2H),3.71-3.66(m,1H),2.23-2.15(m,2H),1.81-1.72(m,2H).

[0938] Step 2. 1-(Tetrahydro-2H-pyran-3-yl)-1H-pyrazol-4-amine (67c)

[0939] Using a similar preparation procedure to the second step of Example 4, compound 67c (1.2 g) was synthesized in 92% yield using 67b (1.5 g, 7.6 mmol) as the starting material. LC-MS (Method 3): t R =0.60min, m / z (M+H) + =168.1.

[0940] Step 3. Methyl 4-(5-methyl-2-((1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (67d)

[0941] Using a similar preparation procedure as in the second step of Example 1, compound 67d (90 mg) was synthesized in 20% yield using 67c (230 mg, 1.37 mmol) and 1b (300 mg, 1.15 mmol) as starting materials. LC-MS (Method 3): t R =1.55min, m / z (M+H) + =394.2. 1 H NMR (400MHz, CDCl3) δ8.32 (s, 1H), 8.16 (d, J = 8.4Hz, 2H), 7.97 (s, 1H), 7.70 ( d,J=8.4Hz,2H),7.55(s,1H),6.88(s,1H),4.28-4.22(m,1H),4.15-4.10(m, 1H),3.97(s,3H),3.92-3.90(m,1H),3.69(t,J=9.6Hz,1H),3.53(t,J=10.8H z,1H),2.24(s,3H),2.22-2.20(m,1H),2.15-2.10(m,1H),1.85-1.74(m,2H).

[0942] Step 4. 4-(5-methyl-2-((1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (67e)

[0943] Using a similar preparation procedure to the third step of Example 3, compound 67e (86 mg) was synthesized with a yield of 99% using 67d (90 mg, 0.23 mmol) as the starting material. LC-MS (Method 3): t R =1.36min, m / z(M+H) + =380.0.

[0944] Step 5. N-(Cyanomethyl)-4-(5-methyl-2-((1-(tetrahydro-2H-pyran-3-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (67)

[0945] Using a similar preparation procedure to the fourth step of Example 1, compound 67 (33.1 mg) was synthesized in 34% yield using 67e (86 mg, 0.23 mmol) and 2-aminoacetonitrile hydrochloride (64 mg, 0.69 mmol) as starting materials. LC-MS (Method 1): t R =4.93min, m / z (M+H) + =418.2. 1 H NMR (400MHz, DMSO-d6) δ9.40 (s, 1H), 9.32 (t, J = 5.2Hz, 1H), 8.38 (s, 1H), 8.00 (d,J=8.0Hz,2H),7.97(s,1H),7.81(d,J=7.6Hz,2H),7.55(s,1H),4.35(d,J= 5.6Hz,2H),4.25-4.20(m,1H),3.96-3.92(m,1H),3.78(m,1H),3.57(t,J=9.2 Hz,1H),3.44-3.38(m,1H),2.20(s,3H),2.11-1.99(m,2H),1.73-1.61(m,2H).

[0946] Example 68

[0947]

[0948] Step 1. cis-2,6-dimethyltetrahydro-2H-pyran-4-ol (68b)

[0949] Compound 68a (4 g, 32.2 mmol) and Pd / C (4 g, 10% palladium on carbon, wetted with 55% water) were dissolved in EtOH (40 mL), and the resulting suspension was stirred under H (50 psi) at RT for 18 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the desired product (4 g, crude) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ 3.90-3.75 (m, 1H), 3.49-3.42 (m, 2H), 1.96-1.90 (m, 3H), 1.23 (d, J = 6.4Hz, 6H), 1.15-1.09 (m, 2H).

[0950] Step 2. cis-2,6-dimethyltetrahydro-2H-pyran-4-yl methanesulfonate (68c)

[0951] To a mixture of 68b (1.0 g, 7.69 mmol), EtN (2.3 g, 23.07 mmol) and DCM (20 mL) was added MsCl (1.76 g, 15.37 mmol) at 0° C. The mixture was stirred at 0° C. for 2 hrs. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by chromatography on silica gel (eluent: DCM:MeOH=100:1) to give the desired product (1.35 g, 84% yield) as a colorless oil. 1 H NMR (400MHz, CDCl3), δ: 4.84-4.76 (m, 1H), 3.54-3.46 (m, 2H), 3.02 (s, 3H), 2.12-2.08 (m, 2H), 1.48-1.37 (m, 2H), 1.25 (d, J = 6.0Hz, 6H).

[0952] Step 3. 1-(cis-2,6-dimethyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazole (68d)

[0953] A solution of 68c (1.35 g, 6.47 mmol), 4-nitro-1H-pyrazole (366 mg, 3.23 mmol) and Cs2CO3 (3.2 g, 9.69 mmol) in 20 mL of NMP was stirred at 140 ° C for 18 hrs under N2 atmosphere. The mixture was cooled to RT, diluted with water (50 mL) and extracted with EtOAc (50 mL*2). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography on silica gel (eluent: PE: EtOAc = 3: 1) to give the title product (655 mg, 89% yield) as a yellow solid. LC-MS (method 3): t R =1.40min, m / z (M+H) + =226.1.

[0954] Step 4. 1-(cis-2,6-Dimethyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-amine (68e)

[0955] A mixture of 68d (655 mg, 2.89 mmol) and Pd / C (100 mg, 10% palladium on carbon, wetted with 55% water) in MeOH (20 mL) was stirred at 50° C. under H 2 (50 psi) for 18 hrs. The mixture was filtered and the filtrate was concentrated to give the desired product as a brown oil (523 mg, 92% yield). LC-MS (Method 3): t R =0.74min, m / z (M+H) +=196.2.

[0956] Step 5. Butyl 4-(2-((1-(cis-2,6-dimethyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (68f)

[0957] Using a similar preparation procedure to the fourth step of Example 40, compound 68f (468 mg) was synthesized in 64% yield using 40b (392 mg, 1.58 mmol) and 68e (463 mg, 2.37 mmol) as starting materials. LC-MS (Method 3): t R =1.89min, m / z(M+H) + =464.3.

[0958] Step 6. 4-(2-((1-(cis-2,6-dimethyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (68 g)

[0959] Using a similar preparation procedure to the third step of Example 3, compound 68g (411 mg) was synthesized with a yield of 100% using 68f (468 mg, 1.01 mmol) as the starting material. LC-MS (Method 3): t R =1.11min, m / z (M+H) + =408.2.

[0960] Step 7. N-(Cyanomethyl)-4-(2-(1-cis-2,6-dimethyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (68)

[0961] Using a similar preparation procedure to the fourth step of Example 1, 68 g (60 mg, 0.15 mmol) and aminoacetonitrile hydrochloride (68 mg, 0.74 mmol) were used as starting materials to synthesize compound 68 (14.9 mg) in a yield of 23%. LC-MS (Method 1): t R =3.25min, m / z (M+H) + =446.2; 1H NMR(400MHz,CD3OD)δ8.34(s,1H),8.14(s,1H),8.02-8.00(m,2H),7.82-7.79(m,2H),7.62(s,1H),4.5 4(s,1H),4.39(s,2H),3.80-3.76(m,2H),2.31-2.26(m,5H),1.76-1.69(m,2H),1.16(d,J=6.0Hz,6H).

[0962] Example 69

[0963]

[0964] Step 1. (1R,5S)-8-Oxabicyclo[3.2.1]octan-3-ol (69b)

[0965] To a solution of 69a (2 g, 15.9 mmol) in THF (20 mL) was added LiAlH solution (13 mL, 32 mmol, 2.5 M in THF) at 0 ° C. After stirring for 1 hour at RT, the mixture was diluted with THF (100 mL) and recooled to 0 ° C. The reaction mixture was quenched with water (1.2 mL) and a 10% NaOH aqueous solution (1.2 mL), and then water (3.6 mL) was added. The resulting mixture was diluted with EtOAc (50 mL), and then stirred for 10 hrs at RT. The solid was filtered off and the filtrate was concentrated to give the desired compound (2.03 g) as a colorless oil. 1 H NMR (400MHz, CDCl3) δ4.48-4.37(m,1H),4.14-3.17(m,1H),3.71-3.68(m,1H),2.30-2.23(m,1H),1.97-1.83(m,3H),1.78-1.45(m,4H).

[0966] Step 2. 1-((1R,5S)-8-oxabicyclo[3.2.1]octan-3-yl)-4-nitro-1H-pyrazole (69c)

[0967] To 69b (1.61 g, 12.5 mmol), TEA (3.8 g, 37.5 mmol) and DCM (20 mL) was added MsCl (2.1 g, 18.7 mmol) at 0 ° C. The mixture was stirred at RT for 2 hrs, then diluted with EtOAc (100 mL) and washed with water (50 mL). The separated organic phase was concentrated to dryness to give the crude intermediate (1R, 5S)-8-oxabicyclo [3.2.1] octane-3-yl methanesulfonate (2.5 g, 96% yield) as a yellow oil. A mixture of (1R, 5S)-8-oxabicyclo [3.2.1] octane-3-yl methanesulfonate (2.5 g, 12.1 mmol), 4-nitro-1H-pyrazole (1.4 g, 12.1 mmol) and K2CO3 (5 g, 36.3 mmol) in 40 mL DMF was stirred at 60 ° C overnight. After cooling to RT, the mixture was diluted with water (200 mL) and extracted with EtOAc (200 mL). The separated organic phase was concentrated and purified by silica gel column (PE: EtOAc = 2: 1) to give 69c (2 g, 76% yield) as a yellow oil. 1 H NMR(400MHz,DMSO-d6)δ8.94(s,1H),8.29(s,1H),4.70-4.40(m,1H),4.26-4.22(m ,1H),4.05-4.00(m,1H),2.20-1.90(m,4H),1.90-1.85(m,2H),1.57-1.52(m,2H).

[0968] Step 3. 1-((1R,5S)-8-oxabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-amine (69d)

[0969] Compound 69c (2 g, 8.96 mmol) and 10% palladium on carbon (400 mg) were suspended in MeOH (40 mL). The resulting mixture was stirred at RT for 2 hrs under H2 (50 psi). The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by reverse phase chromatography (5-95% CH3CN in water) to give the title product as a yellow solid (400 mg, crude product, 23% yield). LC-MS (method 3): t R =0.42min, m / z (M+H) + =194.0. Step 4. 4-(2-((1-((1R,5S)-8-oxabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (69e)

[0970] A mixture of 69d (100 mg, 0.52 mmol), 40b (194 mg, 0.78 mmol) and TsOH (9 mg, 0.052 mmol) in 1,4-dioxane (4 mL) was stirred at 120° C. overnight. The mixture was concentrated to dryness under reduced pressure and purified by reverse phase flash chromatography (5% to 60% ACN in water) to give the desired product as a yellow solid (160 mg, 76% yield). LC-MS (Method 3): t R =1.09min, m / z(M+H) + =406.2. 1 H NMR (400MHz, CDCl3) δ9.42(s,1H),8.38(s,1H),8.06(d,J=8.0Hz,2H),7.84(s,1H),7.78(d,J=8.0Hz,2H),7.54(d,J=8.0Hz,1H), 4.60-4.51(m,0.6H),4.41(br.s,2H),4.41-4.30(m,0.4H),2.19(s,3H),2.01-1.95(m,2H),1.86-1.82(m,5H),1.72-1.52(m,1H).

[0971] Step 6. 4-(2-((1-((1R,5S)-8-oxabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)-N-(cyanomethyl)benzamide (69)

[0972] Using a similar preparation procedure to the fourth step of Example 1, compound 69 (30.1 mg) was synthesized in 56% yield using 69e (50.0 mg, 0.12 mmol) and 2-aminoacetonitrile hydrochloride (34.0 mg, 0.37 mmol) as starting materials. LC-MS (Method 1): t R =3.29min, m / z (M+H) + =444.2. 1H NMR(400MHz,DMSO-d6)δ9.41-9.38(m,1H),9.32(t,J=5.6Hz,1H),8.39-8.37(m,1H) ,8.00(d,J=8.4Hz,2H),7.87(s,1H),7.79(d,J=8.0Hz,2H),7.56-7.54(m,1H),4.58 -4.53(m,0.6H),4.41(br.s,2H),4.35(d,J=5.6Hz,2H),4.33-4.31(m,0.4H),2.38- 2.23(m,1H),2.19(s,3H),2.02-1.95(m,2H),1.86-1.83(m,4H),1.66-1.56(m,1H).

[0973] Example 70

[0974]

[0975] 4-(2-((1-((1R,5S)-8-oxabicyclo[3.2.1]oct-3-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)-N-((S)-1-cyanoethyl)benzamide (70)

[0976] Using a similar preparation procedure to the fourth step of Example 1, compound 70 (27.6 mg) was synthesized in 50% yield using 69e (50.0 mg, 0.12 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (89.0 mg, 0.37 mmol) as starting materials. LC-MS (Method 1): t R =3.43min, m / z (M+H) + =458.2. 1 H NMR (400MHz, DMSO-d6) δ9.39(d,J=8.4Hz,1H),9.25(d,J=7.2Hz,1H),8.38(d,J=6.0Hz,1 H),8.02(d,J=6.4Hz,1H),8.00(s,1H),7.87(s,1H),7.79(d,J=8.0Hz,2H),7.55(d,J=7. 2Hz,1H),5.04-5.00(m,1H),4.61-4.51(m,1H),4.36(s,2H),2.50-2.49(m,1H),2.34(d, J=9.6Hz,3H),2.07-1.96(m,2H),1.91(s,3H),1.82-1.71(m,1H),1.57(d,J=6.8Hz,4H).

[0977] Example 71

[0978]

[0979] Step 1. tert-Butyl 3-(4-nitro-1H-pyrazol-1-yl)azetidine-1-carboxylate (71b)

[0980] By 4a (2.0g, 17.7mmol), 3-hydroxyazetidine -1- tert-butyl formate (3.1g, 17.7mmol) and PPh3 (7.0g, 26.5mmol) in THF (50mL) mixture is stirred at 0 DEG C for 5min.Then DIAD (5.4g, 26.5mmol) is added to the reaction mixture. After stirring for 16 hours at RT, the reaction mixture is diluted with water (200mL) and extracted with EtOAc (300mL).The separated organic layer is concentrated to dryness.The residue is purified by column chromatography on silica gel (PE: EtOAc = 10: 1) to obtain the crude product (4.7g, 100% yield) as a white solid. 1 H NMR (400 MHz, CDCl3) δ 8.32 (s, 1H), 8.16 (s, 1H), 5.09-5.06 (m, 1H), 4.45-4.41 (m, 2H), 4.35-4.31 (m, 2H), 1.47 (s, 9H). Step 2. tert-Butyl 3-(4-amino-1H-pyrazol-1-yl)azetidine-1-carboxylate (71c)

[0981] A mixture of 71b (4.0 g, 14.9 mmol) and 10% palladium on carbon (400 mg) in MeOH (8 mL) was stirred at RT for 12 hours under H2 (50 psi). The mixture was filtered and the filtrate was concentrated. The residue was purified by flash column chromatography (DCM: MeOH = 20: 1) to give the title product (1.3 g, 35% yield) as a red solid. LC-MS (method 3): t R =1.160min, m / z (M+H-56) + =183.1.

[0982] Step 3. tert-Butyl 3-(4-((4-(4-(methoxycarbonyl)phenyl)-5-methylpyrimidin-2-yl)amino)-1H-pyrazol-1-yl)azetidine-1-carboxylate (71d)

[0983] Compound 71c (800 mg, 3.36 mmol), 1b (880 mg, 3.36 mmol), Pd2(dba)3 (308 mg, 0.34 mmol), XantPhos (320 mg, 0.67 mmol) and Cs2CO3 (2.16 g, 6.72 mmol) were dissolved in dioxane (20 mL). The above mixture was stirred at 110 ° C for 2 hrs under N2 atmosphere. The reaction mixture was cooled to RT, concentrated to dryness and purified by flash chromatography (PE: EtOAc = 1: 1) to give the title product as a white solid (1.5 g, 75% yield). LC-MS (method 3): t R =1.67min, m / z(M+H) + =465.2.

[0984] Step 4. Methyl 4-(2-((1-(azetidin-3-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (71e)

[0985] Compound 71d (1.1 g, 0.25 mmol) was dissolved in MeOH (20 mL) and a solution of HCl (g) in methanol (2N, 8 mL) was added. The resulting mixture was stirred at RT for 4 hrs. The mixture was concentrated and purified by a reverse phase column (5 to 50% acetonitrile in water) to give the title product as a yellow solid (600 mg, 70% yield). LC-MS (method 3): t R =1.33min, m / z(M+H) + =365.1. 1 H NMR(400MHz,DMSO-d6)δ9.58(s,1H),9.12(br s,1H),8.40(s,1H),8.10(d,J=8.4Hz,2H),8.03(s,1H),7.82(d,J=7.6Hz,2 H),7.72(s,1H),5.39-5.37(m,1H),4.30(m,4H),3.90(s,3H),3.20(s,3H).

[0986] Step 5. Methyl 4-(2-((1-(1-(cyclopropanecarbonyl)azetidin-3-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (71f)

[0987] A mixture of 71e (200 mg, 0.55 mmol) and DIPEA (213 mg, 1.65 mmol) in DCM (3 mL) was stirred at 0 ° C for 5 min. Cyclopropanecarbonyl chloride (86 mg, 0.82 mmol) was then added to the reaction mixture. After stirring for 2 hours at RT, the reaction mixture was concentrated and purified by column chromatography on silica gel (PE: EtOAc = 3: 7) to give the product as a yellow solid (160 mg, 67% yield). LC-MS (method 3): t R =1.45min, m / z(M+H)+=433.2. 1 H NMR (400MHz, DMSO-d6) δ9.52(s,1H),8.40(s,1H),8.10(d,J=8.4Hz,2H),8.04(s,1H),7.83(d,J=8.0Hz,2H),7.66(s,1H),5.25(m ,1H),4.67(t,J=8.4Hz,1H),4.46(m,1H),4.27(t,J=9.6Hz,1H),4.05(m,1H),3.32(s,3H),2.20(s,3H),1.57(m,1H),0.72(m,4H).

[0988] Step 6. 4-(2-((1-(1-(cyclopropanecarbonyl)azetidin-3-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (71 g)

[0989] Compound 71f (160 mg, 0.37 mmol) and LiOH.H2O (62.0 mg, 1.48 mmol) were dissolved in a mixture of THF and H2O (6 mL, V:V=1:1), and the mixture was stirred at RT for 4 hrs. The reaction mixture was concentrated to dryness to give the crude product as an orange solid (150 mg, 97% yield). LC-MS (Method 3): t R =1.05min, m / z (M+H) + =419.1.

[0990] Step 7. (S)-N-(1-cyanoethyl)-4-(2-((1-(1-(cyclopropanecarbonyl)azetidin-3-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (71)

[0991] Using a similar preparation procedure to the fourth step of Example 1, compound 71 (4 mg) was synthesized with a yield of 6% using 71e (60 mg, 0.14 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (35 mg, 0.14 mmol) as starting materials. LC-MS (Method 1): t R =2.81min, m / z (M+H) + =471.3. 1 H NMR (400MHz, CD3OD) δ8.38(s,1H),8.18(s,1H),8.00(d,J=8.0Hz,2H),7.81(d,J=8.0Hz,2H),7.71(s 1H),5.27-5.21(m,1H),5.12-5.06(m,1H),4.79-4.77(m,1H),4.65-4.62(m,1H),4.4 7-4.43(m,1H),4.32-4.28(m,1H),2.26(s,3H),1.69-1.59(m,4H),0.90-0.83(m,4H).

[0992] Example 72

[0993]

[0994] Step 1. 1-(2-Methyltetrahydro-2H-pyran-4-yl)-4-nitro-1H-pyrazole (72b)

[0995] Using a similar preparation procedure to the first step of Example 71, compound 72b (1.8 g) was synthesized in 97% yield using 4a (1.0 g, 8.8 mmol) and 2-methyltetrahydro-2H-pyran-4-ol (1.0 g, 8.8 mmol) as starting materials. LC-MS (Method 3): t R =1.37min, m / z (M+H) + =212.1.

[0996] Step 2. 1-(2-Methyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-amine (72c)

[0997] Using a similar preparation procedure to the second step of Example 71, compound 72c (3.4 g) was synthesized in 100% yield using 72b (3.7 g, 17.6 mmol). LC-MS (Method 3): t R =0.60min, m / z (M+H) + =182.1.

[0998] Step 3. 4-(5-Methyl-2-((1-(2-methyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (72d)

[0999] Using a similar preparation procedure to the fourth step of Example 69, compound 72d (110 mg) was synthesized in 47% yield using 72c (217 mg, 1.2 mmol) and 1b (150 mg, 0.6 mmol) as starting materials. LC-MS (Method 3): t R =1.07min, m / z (M+H) + =394.2.

[1000] Step 4. N-(Cyanomethyl)-4-(5-methyl-2-((1-(2-methyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (72)

[1001] Using a similar preparation procedure to the fourth step of Example 1, compound 72 (32 mg) was synthesized with a yield of 27% using 72d (110 mg, 0.28 mmol) and 2-aminoacetonitrile hydrochloride (52 mg, 0.56 mmol) as starting materials. LC-MS (Method 1): t R =7.79min, m / z (M+H) + =432.2. 1 H NMR (400MHz, CD3OD) δ8.38(s,1H),8.17(s,1H),8.05(d,J=8.0Hz,2H),7.85(d,J=8.0Hz,2H),7.67(s,1H),4.60-4.56( m,1H),4.42(s,2H),3.91-3.87(m,2H),3.81-3.74(m,1H),2.37-2.10(m,6H),1.92-1.83(m,1H),1.23(d,J=8.4Hz,3H).

[1002] Example 73

[1003]

[1004] N-((S)-1-cyanoethyl)-4-(2-((1-(cis-2,6-dimethyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (73)

[1005] Using a similar preparation procedure to the fourth step of Example 1, 68 g (100 mg, 0.25 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (65 mg, 0.27 mmol) were used as starting materials to synthesize compound 73 (22 mg) in a 20% yield. LC-MS (Method 1): t R =3.34min, m / z (M+H) + =460.3; 1 H NMR (400MHz, CD3OD) δ8.34(s,1H),8.15(s,1H),8.03(d,J=8.4Hz,2H),7.82(d,J=8.0Hz,2H),7.62(s,1H),5. 13-5.07(m,1H),4.54(s,1H),3.80-3.76(m,2H),2.31-2.26(m,5H),1.76-1.67(m,5H),1.16(d,J=6.0Hz,6H).

[1006] Example 74

[1007]

[1008] Step 1. Methyl 4-(2-((1-(1-(1-hydroxycyclopropanecarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (74b)

[1009] Compound 3a (800 mg, 2.04 mmol), 1-hydroxycyclopropanecarboxylic acid (208 mg, 2.04 mmol), DIPEA (789 mg, 6.12 mmol), EDCI (482 mg, 2.45 mmol) and HOBT (330.7 mg, 2.45 mmol) were dissolved in DMF (8 mL). The resulting mixture was stirred overnight at RT. H2O (10 mL) was added to the above solution, followed by extraction with EtOAc (10 mL*3). The combined organic phases were concentrated in vacuo to give a residue, which was purified by preparative HPLC to give the desired product as a yellow solid (500 mg, 51% yield). LC-MS (method 3): t R =1.47min, m / z (M+H) + =477.2. Step 2. 4-(2-((1-(1-(1-hydroxycyclopropanecarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (74c)

[1010] Compound 74b (190 mg, 0.4 mmol) and (CH 3 ) 3 SiOK (154 mg, 1.2 mmol) were dissolved in THF (anhydrous, 2 mL). The resulting solution was stirred at RT for 1 hour. The reaction mixture was adjusted to pH 2-3 using HCl (aqueous solution, 10%) and concentrated in vacuo to give the desired product as a yellow solid (400 mg, crude, 100% yield). LC-MS (Method 3): t R =0.84min, m / z (M+H) + =463.2.

[1011] Step 3. N-(Cyanomethyl)-4-(2-((1-(1-(1-hydroxycyclopropanecarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (74)

[1012] Using a similar preparation procedure to the fourth step of Example 1, compound 74 (50 mg) was synthesized with a yield of 25% using 74c (400 mg, crude product, 0.4 mmol) and 2-aminoacetonitrile hydrochloride (44 mg, 0.48 mmol) as starting materials. LC-MS (Method 1): t R =3.30min, m / z (M+H) + =501.3; 1 H NMR (400MHz, DMSO-d6) δ9.40 (s, 1H), 9.34 (d, J = 5.6Hz, 1H), 8.38 (s, 1H), 8.00 ( d,J=8.4Hz,2H),7.90(s,1H),7.79(d,J=8.0Hz,2H),7.55(s,1H),6.33(d,J=4.8 Hz,1H),4.45-4.34(m,5H),3.14-2.83(m,2H),2.19(s,3H),2.01(d,J=10.8Hz,2 H), 1.80 (d, J = 2.4Hz, 2H), 0.92 (dd, J1 = 8.4, 4.0Hz, 2H,), 0.76 (d, J = 2.4Hz, 2H).

[1013] Example 75

[1014]

[1015] Step 1. 4-(5-Methyl-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (75b)

[1016] Compound 75a (1.7 g, 5.08 mmol), tetrahydro-2H-pyran-4-yl methanesulfonate (2.3 g, 12.7 mmol) and cesium carbonate (8.3 g, 25.4 mmol) were dissolved in N,N-dimethylformamide (15 mL). The resulting mixture was stirred at 100 ° C for 16 hrs. After cooling to RT, the mixture was filtered and the filtrate was concentrated. The residue was purified by reverse phase chromatography (eluent: 5% to 95% acetonitrile in water) to obtain the desired product 89b (620 mg, 32% yield) as a yellow solid. LC-MS (method 3): t R =1.11min, m / z (M+H) + =380.2. Step 2. (S)-4-(5-methyl-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1,1,1-trifluoropropan-2-yl)benzamide (75)

[1017] Using a similar preparation procedure to the fourth step of Example 1, compound 75 (65 mg) was synthesized in 65% yield using 75b (80 mg, 0.21 mmol) and (S)-1,1,1-trifluoropropane-2-amine hydrochloride (63 mg, 0.42 mmol) as starting materials. LC-MS (Method 1): t R =3.27min, m / z (M+H) + =475.2; 1 H NMR (400MHz, DMSO-d6) δ9.39(s,1H),8.97(d,J=8.4Hz,1H),8.37(s,1H),8.02(d,J=8.4Hz,2H),7.89(s,1H),7.79(d,J=8.0Hz,2H),7.56(s, 1H),4.92-4.86(m,1H),4.35-4.29(m,1H),3.94(d,J=11.2Hz,2H),3.4 7-3.41(m,2H),2.19(s,3H),1.93-1.84(m,4H),1.39(d,J=7.2Hz,3H).

[1018] Example 76

[1019]

[1020] 4-(5-methyl-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(2,2,2-trifluoroethyl)benzamide (76)

[1021] Using a similar preparation procedure to the fourth step of Example 1, compound 76 (74.2 mg) was synthesized in 77% yield using 75b (80 mg, 0.21 mmol) and 2,2,2-trifluoroethylamine (42 mg, 0.42 mmol) as starting materials. LC-MS (Method 1): t R =3.30min, m / z (M+H) + =461.2; 1 H NMR (400MHz, DMSO-d6) δ9.38(s,1H),9.21(t,J=6.4Hz,1H),8.37(s,1H),8.02(d,J=8.4Hz,2H),7.90(s,1H),7.79(d,J=8.0Hz,2H ),7.55(s,1H),4.37-4.29(m,1H),4.17-4.08(m,2H),3.94(d,J=11.2Hz,2H),3.48-3.41(m,2H),2.19(s,3H),1.92-1.84(m,4H).

[1022] Example 77

[1023]

[1024] 4-(5-Methyl-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(3,3,3-trifluoropropyl)benzamide (77)

[1025] Using a similar preparation procedure to the fourth step of Example 1, compound 77 (69 mg) was synthesized in 69% yield using 75b (80 mg, 0.21 mmol) and 3,3,3-trifluoropropane-1-amine (63 mg, 0.42 mmol) as starting materials. LC-MS (Method 1): t R =3.42min, m / z (M+H) + =475.2; 1 H NMR (400MHz, DMSO-d6) δ9.39(s,1H),8.81(t,J=5.6Hz,1H),8.37(s,1H),7.96(d,J=8.4Hz,2H),7.90(s,1H),7.78(d,J=8.0Hz,2H),7.55(s ,1H),4.35-4.30(m,1H),3.94(d,J=11.6Hz,2H),3.55-3.50(m,2H),3.47-3.41(m,2H),2.62-2.53(m,2H),2.19(s,3H),1.92-1.83(m,4H).

[1026] Example 78

[1027]

[1028] 4-(5-Chloro-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-((1-cyanocyclopropyl)methyl)benzamide (78)

[1029] Using a similar preparation procedure to that of step 4 of Example 1, compound 78 (73.6 mg) was synthesized in 77% yield using 39b (80 mg, 0.2 mmol) and 1-(aminomethyl)cyclopropanecarbonitrile (38 mg, 0.4 mmol) as starting materials. The title compound was purified by preparative HPLC (Method B). LC-MS (Method 1): t R =3.22min, m / z (M+H) + =478.2; 1 H NMR (400MHz, DMSO-d6) δ9.83(s,1H),9.04(t,J=6.0Hz,1H),8.58(s,1H),8.02(d,J=8.4Hz,2H),7.91(br s,3H),7.57(s,1H),4.36-4.32(m,1H),3.95-3.92(m,2H),3.47-3.42(m,4H),1.93-1.87(m,4H),1.25-1.22(m,2H),1.19-1.13(m,2H).

[1030] Example 79

[1031]

[1032] (S)-N-(1-cyanoethyl)-4-(2-((1-(1-(1-hydroxycyclopropanecarbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (79)

[1033] Using a similar preparation procedure to that of step 4 of Example 1, compound 79 (56 mg) was synthesized in 29% yield using 74c (250 mg, crude, 0.378 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (109.7 mg, 0.454 mmol) as starting materials. The title compound was purified by preparative HPLC (Method B). LC-MS (Method 1): t R =3.03min, m / z (M+H) + =515.3; 1H NMR (400MHz, CD3OD) δ8.34(s,1H),8.06(s,1H),8.03(d,J=8.4Hz,2H),7.83( d,J=8.4Hz,2H),7.65(s,1H),5.10(dd,J1=14.4,6.8Hz,1H),4.89-4.55(m,2H ),4.49-4.41(m,1H),3.21-2.86(m,2H),2.29(s,3H),2.16(d,J=10.0Hz,2H), 2.07-1.92(m,2H),1.68(d,J=7.2Hz,3H),1.07(s,2H),0.92(d,J=2.4Hz,2H).

[1034] Example 80

[1035]

[1036] 4-(5-Chloro-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(2-cyano-2-methylpropyl)benzamide (80)

[1037] Using a similar preparation procedure to that of step 4 of Example 1, compound 80 (47.4 mg) was synthesized in 79% yield using 39b (50 mg, 0.12 mmol) and 3-amino-2,2-dimethylpropionitrile 4-methylbenzenesulfonate (68 mg, 0.25 mmol) as starting materials. The title compound was purified by preparative HPLC (Method B). LC-MS (Method 1): t R =3.30min, m / z (M+H) + =480.2; 1 H NMR (400MHz, DMSO-d6) δ9.82(s,1H),8.93(t,J=8.0Hz,1H),8.57(s,1H),8.01(d,J=8.0Hz,2H),7.90(s,3H),7.58(s,1H ),4.37-4.31(m,1H),3.93(d,J=11.2Hz,2H),3.50(d,J=6.4Hz,2H),3.48-3.41(m,2H),1.93-1.92(m,4H),1.36(s,6H).

[1038] Example 81

[1039]

[1040] Step 1. Methyl 4-(2-((1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (81a)

[1041] Compound 1b (5.0 g, 19.10 mmol), tert-butyl 4-amino-1H-pyrazole-1-carboxylate (5.20 g, 28.6 mmol) and TsOH (328 mg, 1.91 mmol) were dissolved in 1,4-dioxane (5 mL). The resulting solution was stirred at 120 ° C overnight. The reaction mixture was cooled, diluted with water (500 mL) and extracted with EtOAc (300 mL * 2). The combined organic layers were washed with brine (200 mL * 2), dried over Na2SO4 and filtered. The filtrate was concentrated to give a residue, which was purified by column chromatography on silica gel (eluent: DCM: MeOH = 20: 1) to give the desired product as a green solid (1.6 g, 27% yield). LC-MS (Method 3): t R =1.40min, m / z (M+H) + =310.1.

[1042] Step 2. Methyl 4-(2-((1-(2-cyano-2-methylpropyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (81b)

[1043] Compound 81a (300 mg, 0.97 mmol), 2-cyano-2-methylpropyl methanesulfonate (344 mg, 1.94 mmol) and CsCO (629 mg, 1.94 mmol) were dissolved in DMF (1.5 mL). The mixture was stirred at 120 ° C overnight and cooled to RT. Water (30 mL) and EtOAc (60 mL) were added to the above solution. The organic layer was separated and concentrated under vacuum to give a residue, which was purified by column chromatography on silica gel (eluent: DCM: MeOH = 10: 1) to give the title product (255 mg, 67% yield) as a yellow oil. LC-MS (method 3): t R =1.55min, m / z (M+H) + =391.2.

[1044] Step 3. 4-(2-((1-(2-Cyano-2-methylpropyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (81c)

[1045] Using a similar preparation procedure to the third step of Example 3, compound 81c (200 mg) was synthesized with a yield of 83% using 81b (250 mg, 0.64 mmol) as the starting material. LC-MS (Method 3): tR =1.10min, m / z(M+H) + =377.1.

[1046] Step 4. 4-(2-((1-(2-cyano-2-methylpropyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)-N-(2,2,2-trifluoroethyl)benzamide (81)

[1047] Using a similar preparation procedure to the fourth step of Example 1, compound 81 (80 mg) was synthesized with a yield of 33% using 81c (200 mg, 0.53 mmol) and 2,2,2-trifluoroethylamine (63 mg, 0.64 mmol) as starting materials. LC-MS (Method 1): t R =3.09min, m / z (M+H) + =458.2. 1 H NMR (400MHz, DMSO-d6) δ9.51 (s, 1H), 9.22 (t, J = 6.0Hz, 1H), 8.40 (s, 1H), 8.02-8.00 (m, 3H), 7 .81(d,J=7.2Hz,2H),7.59(s,1H),4.28(s,2H),4.17-4.09(m,2H),2.21(s,3H),1.31(s,6H).

[1048] Example 82

[1049]

[1050] Step 1. tert-Butyl 4-(4-((4-(4-((cyanomethyl)carbamoyl)phenyl)-5-methylpyrimidin-2-yl)amino)-1H-pyrazol-1-yl)piperidine-1-carboxylate (82a)

[1051] Using a similar preparation procedure to the fourth step of Example 1, compound 82a (22.5 mg) was synthesized with a yield of 77% using 1d (272 mg, 0.57 mmol) and 2-aminoacetonitrile hydrochloride (32.8 mg, 0.57 mmol) as starting materials. LC-MS (Method 1): t R =3.63min, m / z (M+H) + =517.3; 1H NMR (400MHz, CDCl3) δ8.31(s,1H),8.09(s,1H),7.92(d,J=8.4Hz,2H),7.77(d,J=8.4Hz,2H),7.45(s,1H),6.87(s,1H),4.41(d,J=5 .6Hz,2H),4.32-4.26(m,1H),4.17-4.13(m,2H),2.98-2.91(m,2H),2.29(s,3H),2.14-2.12(m,2H),1.90-1.86(m,2H),1.47(s,9H).

[1052] Step 2. N-(2-amino-2-oxoethyl)-4-(5-methyl-2-((1-(piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide hydrochloride (82)

[1053] Compound 82a (50 mg, 0.1 mmol) was dissolved in HCl / EtOAc (2 N, 2 mL) and the resulting solution was stirred at RT for 3 hrs. The reaction mixture was concentrated to dryness. The residue was purified by preparative HPLC (Method A) to give the title compound 82 (10 mg, 24% yield) as a yellow solid. LC-MS (Method 1): t R =2.38min, m / z(M+H) + =435.0; 1 H NMR(400MHz,DMSO-d6)δ9.37(s,1H),8.79(s,1H),8.37(s,1H),8.02(d,J= 7.2Hz,2H),7.88(s,1H),7.77(d,J=7.2Hz,2H),7.53(s,1H),7.41(s,1H), 7.05(s,1H),4.10-4.14(m,1H),3.85(d,J=5.2Hz,2H),3.02(d,J=11.6Hz, 2H),2.61-2.54(m,2H),2.20(s,3H),1.92-1.90(m,2H),1.74-1.71(m,2H).

[1054] Example 83

[1055]

[1056] Step 1. Methyl 5-(2-chloro-5-methylpyrimidin-4-yl)picolinate (83a)

[1057] Compound 1a (632 mg, 3.88 mmol) was dissolved in a mixture of 1,4-dioxane and H2O (4.5 mL, V / V=8:1), followed by the sequential addition of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinic acid methyl ester (510 mg, 1.94 mmol), Na2CO3 (411 mg, 3.88 mmol) and Pd(dppf)Cl2 (142 mg, 0.19 mmol). The mixture was stirred at 85 ° C for 16 hrs under N2 atmosphere. After cooling to room temperature, the mixture was concentrated to dryness. The residue was purified by chromatography on silica gel (eluent: PE: EtOAc=1:1) to give the title product (290 mg, 57% yield) as a white solid. LC-MS (method 3): t R =1.297min, m / z (M+H) + =264.0; 1 H NMR (400MHz, CDCl3) δ8.99(dd,J=0.8,2.0Hz,1H),8.59(s,1H),8.29(dd,J=0.8,8.4Hz,1H),8.16(d,J=2.0,8.0Hz,1H),4.06(s,3H),2.43(s,3H).

[1058] Step 2. Methyl 5-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)picolinate (83b)

[1059] Using a similar preparation procedure to the second step of Example 1, compound 83b (210 mg) was synthesized in 78% yield using 83a (200 mg, 0.76 mmol) and 1-cyclopropyl-1H-pyrazol-4-amine (112 mg, 0.91 mmol) as starting materials. LC-MS (Method 3): t R =1.373min, m / z(M+H) + =351.1.

[1060] Step 3. 5-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)picolinic acid (83c)

[1061] Using a similar preparation procedure to the third step of Example 1, compound 83c (80 mg) was synthesized with a yield of 40% using 83b (210 mg, 0.6 mmol) as the starting material. LC-MS (Method 3): t R =0.994min, m / z (M+H) + =337.1.

[1062] Step 3. N-(Cyanomethyl)-5-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)picolinamide (83)

[1063] Using a similar preparation procedure to that of step 4 of Example 1, compound 83 (7 mg) was synthesized in 16% yield using 83c (40 mg, 0.12 mmol) and 2-aminoacetonitrile hydrochloride (13.3 mg) as starting materials. The title compound was purified by preparative HPLC (Method B). LC-MS (Method 1): t R =3.070min, m / z (M+H) + =375.2; 1 HNMR(400MHz, CDCl3)δ8.88(s,1H),8.40(d,J=8.0,1H),8.36(d,J=8.0,1H),8.25(s,1H),8.18(dd,J=2.0,8.0Hz,1H), 7.80(s,1H),7.66(s,1H),4.46(d,J=6.4Hz,2H),3.60-3.55(m,1H),2.32(s,3H),1.14-1.10(m,2H),1.03-0.98(m,2H).

[1064] Example 84

[1065]

[1066] Step 1. 8,8-Difluoro-1,4-dioxaspiro[4.5]decane (84b)

[1067] To a solution of 1,4-dioxaspiro[4.5]decane-8-one (1 g, 6.4 mmol) in DCM (5 mL) was added DAST (1.3 g, 8.2 mmol) at 0 ° C. The mixture was stirred at 35 ° C for 4 hrs. The mixture was diluted with saturated NaHCO aqueous solution (20 mL) and extracted with DCM (20 mL*2). KMnO solution (1.3 g, 8.2 mmol in 20 mL H O) was added to the combined organic layers. The resulting mixture was stirred at RT overnight. The organic layer was separated, dried over Na SO and concentrated under vacuum to give the desired product (1 g, 91% yield) as a colorless oil. 1 HNMR (400MHz, CDCl3) δ3.96 (s, 4H), 2.11-2.00 (m, 4H), 1.82-1.78 (m, 4H). 19 F NMR (376MHz, CDCl3) δ-105.03.

[1068] Step 2. 4,4-Difluorocyclohexanone (84c)

[1069] Compound 84b (1 g, 5.6 mmol) was dissolved in an aqueous HCl solution (aq.HCl, 2 mL, 2 N). The resulting mixture was stirred at 100 ° C for 12 hrs. After cooling to RT, the mixture was diluted with DCM (10 mL) and adjusted to pH = 7-8 with a saturated NaHCO aqueous solution. The separated organic layer was washed with a saturated NaHCO aqueous solution, dried over Na SO and filtered. The filtrate was concentrated to dryness to obtain the desired product (700 mg, 93% yield) as a colorless oil. 1 H NMR (400MHz, CDCl3) δ2.56-2.53(m,4H),2.36-2.27(m,4H). 19 FNMR (376MHz, CDCl3) δ-100.27.

[1070] Step 3. 4,4-Difluorocyclohexanol (84d)

[1071] To a solution of 84c (700 mg, 5.2 mmol) in MeOH (15 mL) was added NaBH (395 mg, 10.4 mmol) at 0°C. The mixture was stirred at 25°C for 2 hrs. The mixture was diluted with H2O (20 mL) and extracted with DCM (20 mL*2). The combined organic layers were concentrated to dryness to give the desired product (700 mg, 99% yield) as a colorless oil. 1 HNMR (400MHz, CDCl3) δ3.94-3.90(m,1H),2.17-2.01(m,2H),1.90-1.73(m,6H). 19 F NMR (376MHz, CDCl3) δ-99.68,-102.94.

[1072] Step 4. 1-(4,4-Difluorocyclohexyl)-4-nitro-1H-pyrazole (84e)

[1073] 4-Nitro-1H-pyrazole (576 mg, 5.1 mmol), 84d (700 mg, 5.1 mmol), PPh (2 g, 7.7 mmol) and DIAD (1.56 g, 7.7 mmol) were dissolved in THF (10 mL), and the resulting mixture was stirred overnight at RT. The mixture was concentrated to dryness. The crude product was purified by chromatography on silica gel (eluent: PE: EtOAc = 2: 1) to give the desired product (220 mg, 19% yield) as a white solid. 1H NMR (400MHz, CDCl3) δ8.18(s,1H),8.08(s,1H),4.32-4.26(m,1H),2.33-2.24(m,4H),2.19-2.11(m,2H),2.04-1.90(m,2H). 19 F NMR (376MHz, CDCl3) δ-95.32,-95.96,-100.89,-101.53.

[1074] Step 5. 1-(4,4-Difluorocyclohexyl)-1H-pyrazol-4-amine (84f)

[1075] Compound 84e (220 mg, 0.95 mmol), Fe powder (160 mg, 2.86 mmol) and NHCl (252 mg, 4.75 mmol) were suspended in a mixture of EtOH and H0 (4.5 mL, V:V=8:1), which was stirred for 3 hrs at 85° C. After cooling to RT, the mixture was filtered and the filtrate was concentrated to give the desired product (190 mg, 99% yield) as a black solid. 1 H NMR (400MHz, CDCl3) δ7.20(s,1H),7.11(s,1H),4.17-4.10(m,1H),2.23-2.05(m,6H),1.97-1.82(m,2H). 19 F NMR (376MHz, CDCl3) δ-94.80, -95.43, -100.63, -101.26.

[1076] Step 6. 4-(2-((1-(4,4-difluorocyclohexyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (84 g)

[1077] To a mixture of 40b (233 mg, 0.94 mmol) and 84f (190 mg, 0.94 mmol) in n-BuOH (4 mL) was added catalytic H2SO4 (cat. H2SO4, 0.25 mL, 1 drop in 1 mL n-BuOH). The mixture was stirred at 120 ° C overnight. After cooling to RT, the mixture was concentrated to dryness and purified by preparative HPLC (method A) to give the desired product as a black solid (100 mg, 26% yield). LC-MS (method 3): t R =1.13min, m / z(M+H) + =414.1.

[1078] Step 7. N-(Cyanomethyl)-4-(2-((1-(4,4-difluorocyclohexyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (84)

[1079] Using a similar preparation procedure to the fourth step of Example 1, compound 84 (14 mg) was synthesized with a yield of 21% using 84 g (50 mg, 0.12 mmol) and 2-aminoacetonitrile hydrochloride (55 mg, 0.6 mmol) as starting materials. LC-MS (Method 1): t R =3.42min, m / z (M+H) + =452.2. 1 H NMR (400MHz, CD3OD) δ8.34 (s, 1H), 8.03-8.01 (m, 3H), 7.83 (d, J = 8.4Hz, 2H), 7.65(s,1H),4.39(s,2H),4.34-4.30(m,1H),2.28(s,3H),2.21-1.99(m,8H). 19 F NMR (376MHz, CD3OD) δ-95.69,-96.32,-102.62,-103.25.

[1080] Example 85

[1081]

[1082] (S)-N-(1-cyanoethyl)-4-(2-((1-(4,4-difluorocyclohexyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (85)

[1083] Using a similar preparation procedure to the fourth step of Example 1, 84 g (80 mg, 0.19 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (94 mg, 0.38 mmol) were used as starting materials to synthesize compound 85 (32 mg) in a 36% yield. LC-MS (Method 1): t R =3.61min, m / z (M+H) + =466.2. 1 H NMR (400MHz, CD3OD) δ8.32-8.31(m,1H),8.00-7.99(m,3H),7.78-7.76(m,2H),7.61-7.59(m, 1H),5.09-5.05(m,1H),4.28-4.27(m,1H),2.23(s,3H),2.23-1.96(m,8H),1.67-1.63(m,3H). 19F NMR (376MHz, CD3OD) δ -91.65, -92.28, -98.76, -99.34 (m, CF2).

[1084] Example 86 and Example 87

[1085]

[1086] Step 1. Methyl 4-(2-((1-(4-cyanocyclohexyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (86b)

[1087] Using a similar preparation procedure to the second step of Example 81, compound 86b (55 mg) was synthesized in 16% yield using 86a (250 mg, 0.81 mmol) and 4-cyanocyclohexyl methanesulfonate (328 mg, 1.6 mmol) as starting materials. LC-MS (Method 3): t R =1.57min, m / z(M+H) + =417.1.

[1088] Step 2. 4-(2-((1-(4-Cyanocyclohexyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (86c)

[1089] Using a similar preparation procedure to the third step of Example 3, compound 86c (53 mg) was synthesized in 100% yield using 86b (55 mg, 0.13 mmol) as the starting material. LC-MS (Method 3): t R =1.11min, m / z (M+H) + =403.2.

[1090] Step 3. 4-(2-((1-(cis-4-cyanocyclohexyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)-N-(2,2,2-trifluoroethyl)benzamide (86) and 4-(2-((1-(trans-4-cyanocyclohexyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)-N-(2,2,2-trifluoroethyl)benzamide (87)

[1091] Using a similar preparation procedure to that of the fourth step of Example 1, compounds 86 (3.5 mg) and 87 (3.6 mg) were synthesized in 12% yield using 86c (50 mg, 0.12 mmol) and 2,2,2-trifluoroethylamine (15 mg, 0.15 mmol). The residue was purified by preparative TLC (DCM / MeOH=10 / 1) to afford the title compound.

[1092] 86: LC-MS (method 1): t R =3.77min, m / z (M+H) + =484.2. 1 H NMR(400MHz,CD3OD)δ8.24(s,1H),7.97(s,1H),7.91-7.89(m,2H),7.72(s,2H),7.49(s, 1H),4.04-4.02(m,3H),3.04(s,1H),2.24(s,3H),2.17-2.01(m,6H),1.82-1.75(m,2H).

[1093] 87: LC-MS (method 1): t R =3.78min, m / z (M+H) + =484.2. 1 H NMR(400MHz,CD3OD)δ8.22(s,1H),7.90-7.77(m,3H),7.69-7.67(m,2H),7.50(s,1H),4.07 -4.03(m,3H),2.60(s,1H),2.14(s,3H),2.07-1.94(m,2H),1.78-1.63(m,4H),1.20(m,2H).

[1094] Example 88

[1095]

[1096] (S)-4-(5-chloro-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanopropyl)benzamide (88)

[1097] Using a similar preparation procedure to the fourth step of Example 1, compound 88 (200.2 mg) was synthesized in 43% yield using 43b (400 mg, 0.96 mmol) and (S)-2-aminobutyronitrile (122 mg, 1.45 mmol) as starting materials. LC-MS (Method 1): t R =3.09min, m / z (M+H) + =479.2. 1H NMR (400MHz, DMSO-d6) δ9.82(s,1H),9.27(d,J=7.6Hz,1H),8.58(s,1H),8.03(d,J=8.4Hz,2H),7.92-7.88(m,3H),7.56(s,1H),4.91( q,J=7.6Hz,1H),4.10-4.01(m,1H),2.83(d,J=11.2Hz,2H),2.19(s,3H),2.07-2.02(m,2H),2.00-1.85(m,6H),1.03(t,J=7.2Hz,3H).

[1098] Example 89

[1099]

[1100] Step 1. 1-Cyclohexyl-4-nitro-1H-pyrazole (89b)

[1101] 4-Nitro-1H-pyrazole (3.39 g, 30 mmol), compound 89a (3 g, 30 mmol), PPh (11.8 g, 45 mmol) and DIAD (9.1 g, 45 mmol) were dissolved in THF (40 mL). The resulting mixture was stirred overnight at RT. The mixture was concentrated to dryness. The crude product was purified by chromatography on silica gel (eluent: PE: EtOAc = 5: 1) to give the desired product (2 g, 34% yield) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ8.89(s,1H),8.24(s,1H),4.27-4.19(m,1H),2.04-1.98(m,2H),1.83-1.63(m,5H),1.44-1.32(m,2H),1.25-1.20(m,1H).

[1102] Step 2. 1-Cyclohexyl-1H-pyrazol-4-amine (89c)

[1103] Compound 89b (2 g, 10 mmol), Fe (1.68 g, 30 mmol) and NH4Cl (2.65 g, 50 mmol) were suspended in a mixture of EtOH and HO (45 mL, V:V=8:1). The resulting mixture was stirred at 85°C for 3 hrs. After cooling to RT, the mixture was filtered and the filtrate was concentrated to dryness to give the crude product (1.7 g, 100% yield) as a black solid. 1HNMR(400MHz,DMSO-d6)δ7.18(s,1H),6.98(s,1H),3.96-3.90(m,1H),1.94-1.90( m,2H),1.79-1.74(m,2H),1.65-1.58(m,3H),1.39-1.29(m,2H),1.21-1.15(m,1H).

[1104] Step 3. Methyl 4-(2-((1-cyclohexyl-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (89d)

[1105] Compound 1b (300 mg, 1.14 mmol), 89c (376 mg, 2.28 mmol) and concentrated HSO (one drop) were dissolved in n-BuOH (10 mL). The mixture was stirred at 120 ° C overnight. After cooling to RT, the reaction mixture was concentrated to dryness. The residue was purified by silica gel column (PE: EtOAc = 2: 1) to give the product as a yellow solid (250 mg, 56% yield). 1 H NMR (400MHz, DMSO-d6) δ9.39(s,1H),8.38(s,1H),8.09(d,J=8.0Hz,2H),7.86(s,1H),7.82(d,J=8.0Hz,2H),7.52(s,1H),4.08-4.02(m,1H ),3.90(s,3H),2.19(s,3H),1.97(d,J=10.8Hz,2H),1.78(d,J=12.8Hz,2H),1.64(d,J=12.0Hz,2H),1.46-1.31(m,3H),0.98-0.94(m,1H).

[1106] Step 4. 4-(2-((1-cyclohexyl-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (89e)

[1107] To a solution of 89d (250 mg, 0.64 mmol) in MeOH and H2O (6 mL, V:V=1:1) was added NaOH (128 mg, 3.20 mmol) in one portion. The mixture was stirred at 50 ° C for 0.5 hours. The reaction mixture was diluted with H2O (5 mL) and extracted with EtOAc (10 mL*2). The aqueous phase was adjusted to pH=3 with HCl aqueous solution (1 N). The formed solid was filtered and dried to give the crude product (200 mg, 83% yield) as a yellow solid. LC-MS (method 3): t R =1.18min, m / z(M+H) + =378.1.

[1108] Step 5. (S)-N-(1-cyanoethyl)-4-(2-((1-cyclohexyl-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (89)

[1109] Using a similar preparation procedure to the fourth step of Example 1, compound 89 (51 mg) was synthesized in 56% yield using 89e (80 mg, 0.21 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (57 mg, 0.24 mmol) as starting materials. LC-MS (Method 1): t R =3.73min, m / z (M+H) + =430.2. 1 H NMR (400MHz, DMSO-d6) δ9.36 (s, 1H), 9.25 (d, J = 6.8Hz, 1H), 8.37 (s, 1H), 8.01 (d, J=8.4Hz,2H),7.85(s,1H),7.79(d,J=8.4Hz,2H),7.52(s,1H),5.02(t,J=7.6Hz, 1H),4.01-4.07(m,1H),2.19(s,3H),1.98(d,J=10.8Hz,2H),1.79(d,J=13.2Hz,2 H),1.60-1.70(m,3H),1.57(d,J=7.2Hz,3),1.33-1.43(m,2H),1.17-1.24(m,1H).

[1110] Example 90 and Example 91

[1111]

[1112] Step 1. 1-(4-Methoxycyclohexyl)-4-nitro-1H-pyrazole (90a)

[1113] To a mixture of 4-methoxycyclohexanol (500mg, 3.85mmol) and EtN (1.2g, 11.5mmol) in DCM (5mL) was added MsCl (664mg, 5.77mmol) at 0°C. The mixture was stirred at RT for 2hrs. The reaction mixture was then diluted with water (5mL) and extracted with DCM (5mL*3). The separated organic layer was washed with brine (5mL), dried over NaSO and filtered. The filtrate was concentrated to give 4-methoxycyclohexyl methanesulfonate (600mg crude product, 75% yield).

[1114] 4-Methoxycyclohexyl methanesulfonate (167 mg, 1.48 mmol), 4-nitro-1H-pyrazole (400 mg, 1.92 mmol) and K2CO3 (612 mg, 4.44 mmol) were dissolved in DMF (1 mL). The above mixture was stirred at 100 ° C for 1 hour. After cooling to RT, the mixture was diluted with water (1 mL) and extracted with EtOAc (5 mL * 3). The separated organic layer was washed with brine (5 mL), dried over Na2SO4 and filtered. The filtrate was concentrated to dryness. The residue was purified by FCC (petroleum ether: EtOAc = 5: 1) to obtain the desired compound (220 mg, 62% yield) as a yellow solid. LC-MS (method 3): t R =1.44min, m / z(M+H) + =226.1.

[1115] Step 2. 1-(4-Methoxycyclohexyl)-1H-pyrazol-4-amine (90b)

[1116] Compound 90a (220 mg, 0.97 mmol) and Pd / C (50 mg, 10% palladium on carbon, moistened with 55% water) were suspended in MeOH (20 mL). The resulting mixture was stirred at 40 ° C for 12 hours under an H2 atmosphere (50 psi). The reaction mixture was filtered and the filtrate was concentrated to dryness to give the crude product as a red solid (220 mg, 100% yield). LC-MS (method 3): t R =1.00min, m / z(M+H) + =196.1.

[1117] Step 3. Methyl 4-(2-((1-(4-methoxycyclohexyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (90c)

[1118] Compound 90b (120 mg, 0.61 mmol), 1b (108 mg, 0.41 mmol) and TsOH (7 mg, 0.04 mmol) were dissolved in n-butanol (3 mL). The reaction was stirred at 120 ° C overnight. The reaction mixture was concentrated to dryness and purified by silica gel column (PE: EtOAc = 4: 1) to give the crude product as a yellow solid (90 mg, 52% yield). LC-MS (Method 3): t R =1.67min, m / z(M+H) + =422.2.

[1119] Step 4. 4-(2-((1-(4-methoxycyclohexyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (90d)

[1120] Compound 90c (90 mg, 0.21 mmol) and LiOH.H2O (45 mg, 1.06 mmol) were dissolved in a mixture of THF and H2O (6 mL, V:V=1:1). The resulting mixture was stirred at RT overnight. The reaction mixture was extracted with EtOAc (10 mL). The separated aqueous layer was acidified to pH=4.0 with HCl aqueous solution (1 N). The mixture was then extracted with EtOAc (10 mL*3). The organic layer was washed with water (10 mL). The separated organic phase was concentrated to dryness to give the crude product (65 mg, 76% yield) as a yellow solid. LC-MS (method 3): t R =1.24min, m / z (M+H) + =408.2.

[1121] Step 5. N-((S)-1-Cyanoethyl)-4-(2-((1-(cis-4-methoxycyclohexyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (90) and N-((S)-1-Cyanoethyl)-4-(2-((1-(trans-4-methoxycyclohexyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (91)

[1122] Compounds 90 (4 mg) and 91 (5.2 mg) were synthesized in 5% and 7% yields using a similar preparation procedure to that of the fourth step of Example 1, using 90d (65 mg, 0.16 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (78 mg, 0.32 mmol) as starting materials. They were purified by preparative HPLC (Method A).

[1123] 90: LC-MS (method 1): t R =3.61min, m / z (M+H) + =460.3. 1 H NMR (400MHz, CD3OD) δ8.21(s,1H),7.90-7.88(m,3H),7.68(d,J=6.8Hz,2H),7.46(s,1H),4.97(q,J=7.2Hz,1H),4.04-3.98(m,1H),3.39(br s,1H),3.23(s,3H),2.13(s,3H),1.96-1.90(m,4H),1.76-1.74(m,2H),1.56(d,J=7.2Hz,3H),1.50-1.47(m,2H).

[1124] 91: LC-MS (method 1): tR =3.52min, m / z (M+H) + =460.2. 1 H NMR (400MHz, CD3OD) δ8.33(s,1H),8.02-7.97(m,3H),7.79(d,J=8.0Hz,2H),7.61(s,1H),5.09(q,J=7.2Hz,1H),4.15-4.09(m,1 H),3.39(s,3H),3.27-3.24(m,1H),2.25(s,3H),2.23-2.13(m,4H),1.89-1.80(m,2H),1.68(d,J=7.2Hz,3H),1.44-1.35(m,2H).

[1125] Example 92

[1126]

[1127] Step 1. Methyl 4-(5-methyl-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (92a)

[1128] To a mixture of 3a (500 mg, 0.934 mmol) in DMF (5 mL) was added iodomethane (165.2 mg, 1.214 mmol) and KCO (646 mg, 4.68 mmol) in sequence. The mixture was stirred at 60 ° C for 16 hrs. After cooling, the mixture was cooled and diluted with EtOAc. The mixture was washed with water and separated. The organic layer was concentrated. The residue was purified by preparative TLC (eluent: DCM: MeOH = 10: 1) to obtain the desired product (82 mg, 22% yield) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ8.31(s,1H),8.16(d,J=8.4Hz,2H),7.92(s,1H),7.68(d,J=8.4Hz,2H),7.52(s,1H),6.78(s, 1H),4.13(s,1H),3.97(s,3H),3.52-3.49(m,2H),3.04-3.01(m,2H),2.34(s,3H),2.27(s,3H),2.24-2.06(m,4H).

[1129] Step 2. 4-(5-Methyl-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (92b)

[1130] To a solution of 92a (60 mg, 0.148 mmol) in MeOH and H2O (4 mL, V:V=3:1) was added NaOH (8.9 mg, 0.221 mmol). The mixture was stirred at RT for 3 hrs. The mixture was adjusted to pH=6-7 with 10% aqueous HCl and filtered to give the title product as a yellow solid (116 mg, 100% yield). LC-MS (Method 3): t R =1.049min, m / z(M+H) + =393.2.

[1131] Step 3. 1-(4-(5-methyl-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoyl)azetidine-3-carbonitrile (92)

[1132] Compound 92b (116 mg, 0.296 mmol), azetidine-3-carbonitrile hydrochloride (35 mg, 0.296 mmol), HATU (169 mg, 0.444 mmol) and DIEA (153 mg, 1.184 mmol) were dissolved in DMF (4 mL). The above mixture was stirred at 30 ° C for 2 hrs. The mixture was concentrated and the residue was purified by preparative HPLC (Method A) to give the title product as a yellow solid (8.5 mg, 6% yield). LC-MS (Method 3): t R =2.782min, m / z (M+H) + =457.0; 1 H NMR(400MHz,CD3OD)δ8.31(s,1H),8.00(s,1H),7.78(s,4H),7.59(s,1H),4.77(s,2H),4.65(s,1H),4.52(s, 1H), 4.11 (s, 1H), 3.81 (t, J = 7.6Hz, 1H), 2.98 (d, J = 11.2Hz, 2H), 2.32 (s, 3H), 2.23 (s, 5H), 2.08-2.01 (m, 4H).

[1133] Example 93

[1134]

[1135] Step 1. 4-[2-(1-Cyclopropyl-1H-pyrazol-4-ylamino)-5-methyl-pyrimidin-4-yl]-benzoic acid methyl ester (93a)

[1136] Using a similar preparation procedure to the second step of Example 1, compound 93a (784 mg) was synthesized in 30% yield using 1b (2.0 g, 7.6 mmol) and 1-cyclopropyl-1H-pyrazol-4-amine (935 mg, 7.6 mmol) as starting materials. LC-MS (Method 3): t R =1.562min, m / z(M+H) + =350.1.

[1137] Step 2. 4-[2-(1-Cyclopropyl-1H-pyrazol-4-ylamino)-5-methyl-pyrimidin-4-yl]-benzoic acid (93b)

[1138] Using a similar preparation procedure to the third step of Example 1, compound 93b (747 mg) was synthesized in 100% yield using 93a (780 mg, 2.23 mmol) as the starting material. 1 H NMR (400MHz, DMSO-d6) δ9.67 (s, 1H), 8.44 (s, 1H), 8.11 (d, J = 10.8Hz, 2H), 7.96 (s, 1H), 7.84(d,J=10.4Hz,2H),7.53(s,1H),3.73-3.68(m,1H),2.23(s,3H),1.05-0.91(m,4H).

[1139] Step 3. N-((1-Cyanocyclopropyl)methyl)-4-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (93)

[1140] Using a similar preparation procedure to the fourth step of Example 1, compound 93 (38.9 mg) was synthesized in 45% yield using 93b (70 mg, 0.21 mmol) and 1-aminomethyl-cyclopropanecarbonitrile (68 mg, 0.83 mmol) as starting materials. LC-MS (Method 1): t R =3.327min, m / z (M+H) + =414.0; 1H NMR (400MHz, CDCl3) δ8.31(s,1H),7.92(d,J=8.4Hz,2H),7.88(s,1H),7.71(d,J=8.4Hz,2H),7.46(s,1H),7.04(s,1H),6.87(s,1H) ,3.62(d,J=6.4Hz,2H),3.57-3.55(m,1H),2.24(s,3H),1.35-1.32(m,2H),1.24-1.23(m,2H),1.12-1.11(m,2H),1.00-0.98(m,2H).

[1141] Example 94

[1142]

[1143] (S)-N-(1-cyanoethyl)-4-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (94)

[1144] Using a similar preparation procedure to that of the fourth step of Example 1, compound 94 (24.3 mg) was synthesized in 26% yield using 93b (60 mg, 0.18 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (87 mg, 0.36 mmol) as starting materials. The title compound was purified by preparative HPLC (Method A). LC-MS (Method 1): t R =3.28min, m / z (M+H) + =388.2; 1 H NMR (400MHz, DMSO-d6) δ9.42(s,1H),9.27(d,J=7.2Hz,1H),8.38(s,1H),8.01(d,J=8.0Hz,2H),7.90(s,1H),7.80(d,J =7.2Hz,2H),7.47(s,1H),5.04-4.99(m,1H),3.67-3.63(m,1H),2.19(s,3H),1.57(d,J=7.2Hz,3H),0.97-0.90(m,4H).

[1145] Example 95

[1146]

[1147] 4-(5-Chloro-2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(cyanomethyl)benzamide (95)

[1148] Using a similar preparation procedure to the fourth step of Example 1, compound 95 (23.3 mg) was synthesized in 42% yield using 60b (50 mg, 0.14 mmol) and 2-aminoacetonitrile hydrochloride (26 mg, 0.28 mmol) as starting materials. LC-MS (Method 1): t R =8.86min, m / z (M+H) + =394.1; 1 H NMR(400MHz,DMSO-d6)δ9.84(s,1H),9.35(t,J=5.2Hz,1H),8.59(s,1H),8.02(d,J=8.0Hz,2H) ,7.98-7.90(m,3H),7.49(s,1H),4.36(d,J=5.2Hz,2H),3.67-3.66(m,1H),0.98-0.91(m,4H).

[1149] Example 96

[1150]

[1151] Step 1. (R)-N-(1-cyanoethyl)-4-(5-methyl-2-((1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (96)

[1152] Using a similar preparation procedure to the fourth step of Example 1, compound 96 (12.5 mg) was synthesized in 15% yield using 75b (75 mg, 0.20 mmol) and (R)-2-aminopropionitrile 4-methylbenzenesulfonate (53 mg, 0.218 mmol) as starting materials. LC-MS (Method 1): t R =3.38min, m / z (M+H) + =432.2. 1 H NMR (400MHz, DMSO-d6) δ9.41(s,1H),9.27(d,J=7.2Hz,1H),8.38(s,1H),8.01(d,J=8.0Hz,2H),7.90(s,1H),7.80(d,J=8.0Hz,2H),7.55(s,1H ),5.02(t,J=7.6Hz,1H),4.37-4.29(m,1H),3.93(d,J=11.2Hz,2H),3.47-3.41(m,2H),2.19(s,3H),1.92-1.87(m,4H),1.57(d,J=7.2Hz,3H).

[1153] Example 97

[1154]

[1155] (R)-4-(5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide (97)

[1156] Using a similar preparation procedure to the fourth step of Example 1, compound 97 (45 mg) was synthesized in 56% yield using 2b (70 mg, 0.21 mmol) and (R)-2-aminopropionitrile 4-methylbenzenesulfonate (103 mg, 0.42 mmol) as starting materials. LC-MS (Method 1): t R =3.26min, m / z (M+H) + =382.1. 1 H NMR(400MHz,DMSO-d6)δ9.84(s,1H),9.29(d,J=6.8Hz,1H),8.58(s,1H),8.03(d,J=8.0Hz, 2H),7.99-7.83(m,3H),7.51(s,1H),5.04-5.01(m,1H),3.80(s,3H),1.57(d,J=6.8Hz,3H).

[1157] Example 98

[1158]

[1159] Step 1. 2,2-Dimethyl-1-(4-(4-nitro-1H-pyrazol-1-yl)piperidin-1-yl)propan-1-one (98b)

[1160] To a solution of 98a (3.0 g, 12.9 mmol) and TEA (3.9 g, 38.7 mmol) in DCM (30 mL) was added pivaloyl chloride (2.33 g, 19.35 mmol) at 0°C. The mixture was stirred overnight at RT. The mixture was diluted with DCM (100 mL) and H2O (30 mL). The separated organic phase was dried over Na2SO4 and filtered. The filtrate was concentrated in vacuo to give the title compound (4.0 g, 100% yield) as a white solid. LC-MS (method 1): t R =1.48min, m / z(M+H) + =281.2.

[1161] Step 2. 1-(4-(4-Amino-1H-pyrazol-1-yl)piperidin-1-yl)-2,2-dimethylpropan-1-one (98c)

[1162] Compound 98b (4.0 g, 12.9 mmol) and Pd / C (600 mg, 10% palladium on carbon, moistened with 55% water) were suspended in MeOH (40 mL). The resulting mixture was stirred overnight at RT under H2 (50 psi). The mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by reverse phase chromatography (5 to 95% ACN in water) to give the title compound (1.4 g, 44% yield) as a red oil. LC-MS (method 1): t R =1.15min, m / z (M+H) + =251.2.

[1163] Step 3. Methyl 4-(5-chloro-2-((1-(1-pivaloylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (98d)

[1164] Using a similar preparation procedure as in the second step of Example 1, compound 98d (200 mg) was synthesized in 11% yield using 98c (300 mg, 1.06 mmol) and 34b (338 mg, 1.06 mmol) as starting materials. LC-MS (Method 1): t R =1.72min, m / z (M+H) + =497.0.

[1165] Step 4. 4-(5-Chloro-2-((1-(1-pivaloylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (98e)

[1166] Using a similar preparation procedure as in the third step of Example 3, compound 98e (171 mg) was synthesized in 100% yield using 98d (180 mg, 0.36 mmol) as the starting material. LC-MS (Method 1): t R =1.15min, m / z (M+H) + =483.0.

[1167] Step 5. 4-(5-Chloro-2-((1-(1-pivaloylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(cyanomethyl)benzamide (98)

[1168] Using a similar preparation procedure to the fourth step of Example 1, compound 98 (16.1 mg) was synthesized in 16% yield using 98e (95 mg, 0.20 mmol) and 2-aminoacetonitrile hydrochloride (22 mg, 0.24 mmol) as starting materials. LC-MS (Method 1): t R =4.93min, m / z (M+H)+ =521.2. 1 H NMR (400MHz, DMSO-d6) δ9.85 (s, 1H), 9.36 (s, 1H), 8.58 (s, 1H), 8.02 (d, J = 8.0Hz, 2H), 7.93 (s, 3H), 7.56 ( s, 1H), 4.37 (s, 5H), 2.95 (t, J = 12.4Hz, 2H), 2.02 (d, J = 11.2Hz, 2H), 1.73 (d, J = 10.4Hz, 2H), 1.21 (s, 9H).

[1169] Example 99

[1170]

[1171] (S)-4-(5-chloro-2-((1-(1-pivaloylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide (99)

[1172] Using a similar preparation procedure to the fourth step of Example 1, compound 99 (21.3 mg) was synthesized in 19% yield using 98e (95 mg, 0.20 mmol) and (S)-2-aminopropionitrile 4-methylbenzenesulfonate (57 mg, 0.24 mmol) as starting materials. LC-MS (Method 1): t R =4.42min, m / z (M+H) + =535.2. 1 H NMR (400MHz, DMSO-d6) δ9.85(s,1H),9.29(d,J=7.2Hz,1H),8.58(s,1H),8.02(d,J=8.4Hz,2H),7.92(s,3H),7.56(s,1H),5.02(t,J=7.2Hz 1H), 4.43-4.34 (m, 3H), 2.95 (t, J = 12.0Hz, 2H), 2.02 (d, J = 11.2Hz, 2H), 1.73 (d, J = 11.2Hz, 2H), 1.57 (d, J = 7.2Hz, 3H), 1.21 (s, 9H).

[1173] Example 100

[1174]

[1175] Step 1. Methyl 4-(2-chloro-5-methylpyrimidin-4-yl)-2-fluorobenzoate (100b)

[1176] Using a similar preparation procedure to the first step of Example 1, compound 100b was synthesized in 85% yield using 1a and (3-fluoro-4-(methoxycarbonyl)phenyl)boronic acid as starting materials. LC-MS (Method 1): t R =1.55min, m / z (M+H) + =281.1.

[1177] Step 2. Methyl 2-fluoro-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (100c)

[1178] Using a similar preparation procedure as in the second step of Example 1, compound 100c was synthesized in 60% yield using 100b and 1-methyl-1H-pyrazol-4-amine as starting materials. LC-MS (Method 3): t R =1.46min, m / z(M+H) + =342.2.

[1179] Step 3. 2-F-Fluoro-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (100d)

[1180] Using a similar preparation procedure as in the third step of Example 1, compound 100d was synthesized in 100% yield using 100c and NaOH as starting materials. LC-MS (Method 1): t R =1.03min, m / z(M+H) + =328.1.

[1181] Step 4. N-(Cyanomethyl)-2-fluoro-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (100)

[1182] Using a similar preparation procedure to the fourth step of Example 1, compound 100 was synthesized in 38% yield using 100d and 2-aminoacetonitrile hydrochloride as starting materials. LC-MS (Method 1): t R =2.97min, m / z (M+H) + =365.9. 1 HNMR(400MHz,DMSO-d6)δ9.42(s,1H),9.12-9.10(m,1H),8.39(s,1H),7.84-7.81(m, 2H),7.64-7.60(m,2H),7.48(s,1H),4.35(d,J=5.2Hz,2H),3.78(s,3H),2.20(s,3H); 19F NMR(376MHz,DMSO-d6)δ-113.31.

[1183] Example 101

[1184]

[1185] Step 1. tert-Butyl (R)-(1-cyanoethyl)carbamate (101b)

[1186] To a mixture of 101a (5.0 g, 26.56 mmol) in DMF (50 mL) was added POCl (50 mL) at 0°C. The reaction mixture was stirred at 0°C for 2 hours and then quenched with H2O (1500 mL). The solution was extracted with DCM (1000 mL*2). The combined organic layers were concentrated in vacuo, and the residue was purified by column chromatography on silica gel (eluent: PE: EtOAc = 5: 1) to give the desired product (1.97 g, 44% yield) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ7.72 (d, J = 5.6 Hz, 1H), 4.48-4.51 (m, 1H), 1.41 (s, 9H), 1.37 (d, J = 7.2 Hz, 3H).

[1187] Step 2. (R)-2-Aminopropionitrile (101c)

[1188] To a mixture of 101c (66 mg, 0.388 mmol) in DCM (2 mL) was added TFA (0.5 mL, 6.732 mmol). The mixture was stirred at RT for 2 hrs and then concentrated to dryness to give the crude product as a brown oil (65 mg, 100%) which was used in the next step without purification.

[1189] Step 3. (R)-N-(1-cyanoethyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (101)

[1190] Using a similar preparation procedure to the fourth step of Example 1, compound 101 (27.1 mg) was synthesized in 29% yield using 2b (80 mg, 0.26 mmol) and 101c (44 mg, 0.26 mmol) as starting materials. LC-MS (Method 1): t R =3.038min, m / z (M+H) + =362.1; 1H NMR (400MHz, DMSO-d6) δ9.42(s,1H),9.29(d,J=7.2Hz,1H),8.38(s,1H),8.01(d,J=7.6Hz,2H),7. 79-7384(m,3H),7.49(s,1H),5.01-5.05(m,1H),3.79(s,3H),2.20(s,3H),1.57(d,J=7.2Hz,3H).

[1191] Example 102

[1192]

[1193] Step 1. tert-Butyl 4-(4-((4-(4-(3-cyanoazetidine-1-carbonyl)phenyl)-5-methylpyrimidin-2-yl)amino)-1H-pyrazol-1-yl)piperidine-1-carboxylate (102a)

[1194] Using a similar preparation procedure to the fourth step of Example 1, compound 102a was synthesized in 57% yield using 1d and azetidine-3-carbonitrile hydrochloride as starting materials. LC-MS (Method 1): t R =3.706min, m / z (M+H) + =543.1; 1 H NMR(400MHz,DMSO-d6)δ9.41(s,1H),8.37(s,1H),7.89(s,1H),7.77(s,4H),7.54(s,1H),4.63-4.58(m,2H),4.38-4.22(m,3H) ,4.02-3.96(m,2H),3.91-3.83(m,1H),2.96-2.82(m,2H),2.20(s,3H),1.96(d,J=10.8Hz,2H),1.76-1.67(m,2H),1.41(s,9H).

[1195] Step 2. 1-(4-(5-methyl-2-((1-(piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoyl)azetidine-3-carbonitrile hydrochloride (102b)

[1196] A mixture of 102a (100 mg, 0.18 mmol) in EtOAc (5 mL) was added to a solution of HCl (g) in EtOAc (4 N, 3 mL) at 0°C. The mixture was stirred at this temperature for 2 hrs. The mixture was concentrated in vacuo at 0-5°C to give the desired product (150 mg, crude) as a yellow solid. LC-MS (Method 1): t R=1.299min, m / z(M+H) + =443.1.

[1197] Step 3. 1-(4-(2-((1-(1-acetylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoyl)azetidine-3-carbonitrile (102)

[1198] Compound 102b (150 mg, crude product, 0.18 mmol), acetic anhydride (18 mg, 0.18 mmol) and TEA (91 mg, 0.9 mmol) were dissolved in DMF (1 mL). The mixture was stirred at RT for 3 hrs. The mixture was concentrated in vacuo. The residue was purified by preparative HPLC (method A) to give the title product as a yellow solid (17 mg, 20% yield). LC-MS (method 1): t R =3.450min, m / z (M+H) + =485.0; 1 H NMR(400MHz, CDCl3)δ8.32(s,1H),7.89(s,1H),7.74-7.68(m,4H),7.53(s,1H) ),6.80(s,1H),4.71(d,J=12.8Hz,1H),4.60-4.47(m,4H),4.34-4.26(m,1H), 3.94(d,J=14.0Hz,1H),3.64-3.59(m,1H),3.23(t,J=12.0Hz,1H),2.77(t,J= 11.2Hz,1H),2.24(s,3H),2.20-2.13(m,2H),2.10(s,3H),2.01-1.91(m,2H).

[1199] Example 103

[1200]

[1201] 1-(2-Fluoro-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoyl)azetidine-3-carbonitrile (103)

[1202] Using a similar preparation procedure to the fourth step of Example 1, compound 103 was synthesized in 35% yield using 100d and azetidine-3-carbonitrile hydrochloride as starting materials. LC-MS (Method 1): t R =8.81min, m / z (M+H) + =392.0. 1H NMR(400MHz,DMSO-d6)δ9.40(s,1H),8.38(s,1H),7.82(s,1H),7.68(t,J=8.0Hz,1H),7.62 -7.58(m,2H),7.48(s,1H),4.37-4.24(m,4H),3.90-3.86(m,1H),3.78(s,3H),2.21(s,3H); 19 F NMR (376MHz, DMSO-d6) δ-114.27.

[1203] Example 104

[1204]

[1205] Step 1. 2-(Benzyloxy)-5,8-dioxaspiro[3.4]octane (104b)

[1206] The mixture of 104a (3.9g, 22.1mmol), ethylene glycol (1.65g, 26.52mol), p-methyl benzenesulfonic acid (42mg, 0.22mmol) and toluene (50mL, anhydrous) is placed in the 250mL round-bottomed flask that is equipped with Dean-Stark device.Reaction mixture was heated to 140 ℃ 40 hours and azeotropic removal of water.After the collection of water stopped, the mixture was cooled to RT, concentrated, and residue was carried out to purification (5% ethyl acetate in the sherwood oil) by silica gel chromatography, obtained the product (1.29g, 26%) as light brown oily matter. 1 H NMR (400MHz, CDCl3) δ7.39-7.27(m,5H),4.43(s,2H),4.02-2.94(m,1H),3.87(s,4H),2.60-2.52(m,2H),2.42-2.34(m,2H).

[1207] Step 2. 5,8-Dioxaspiro[3.4]octan-2-ol (104c)

[1208] A mixture of 104b (1.29 g, 5.86 mmol), palladium on carbon (250 mg, 10% wt.) and palladium hydroxide on carbon (250 mg, 20% wt.) in methanol (20 mL) was stirred under 50 psi hydrogen atmosphere at 50° C. for 48 h. The mixture was filtered and the filtrate was concentrated to give the desired product (760 mg, 100% yield) as a colorless oil. 1 H NMR (400MHz, CDCl3) δ4.30-2.20(m,1H),3.88(s,4H),2.70-2.61(m,2H),234-2.27(m,2H).

[1209] Step 3. 4-Nitro-1-(5,8-dioxaspiro[3.4]octan-2-yl)-1H-pyrazole (104d)

[1210] Under nitrogen atmosphere, DIAD (1.33 g, 6.57 mmol) was slowly added to a solution of 104c (570 mg, 4.38 mmol), 4-nitro-1H-pyrazole (496 mg, 4.38 mmol) and PPh (1.73 g, 6.57 mmol) in dichloromethane (15 mL) at 0 ° C. The mixture was slowly warmed to room temperature and stirred for 16 hours. The mixture was concentrated to dryness and purified by silica gel column chromatography (10% ethyl acetate in petroleum ether) to obtain the desired product (600 mg, 61% yield) as a white solid. LC-MS (method 3): t R =1.380min, m / z(M+H) + =226.1.

[1211] Step 4. 1-(5,8-Dioxaspiro[3.4]octan-2-yl)-1H-pyrazol-4-amine (104e)

[1212] A mixture of 104d (600 mg, 2.67 mmol) and palladium on carbon (250 mg, 10% wt.) in ethanol (16 mL) was stirred at room temperature under a hydrogen atmosphere (50 psi) for 1 hour. The mixture was filtered and the filtrate was concentrated to dryness to give the desired product as a black solid (520 mg, 100% yield). LC-MS (Method 3): t R =0.561min, m / z (M+H) + =196.1.

[1213] Step 5. Methyl 4-(2-((1-(5,8-dioxaspiro[3.4]octan-2-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (104f)

[1214] Compound 104e (490 mg, 2.51 mmol), 1b (550 mg, 2.10 mmol), tris(dibenzylideneacetone)dipalladium (192 mg, 0.21 mmol), xphos (200 mg, 0.42 mmol) and cesium carbonate (1.37 g, 4.2 mmol) were dissolved in dioxane (20 mL). The mixture was stirred at 110 ° C for 4 hours under a nitrogen atmosphere. The mixture was concentrated and purified by silica gel column chromatography (2% methanol in dichloromethane) to obtain the desired product (590 mg, 66% yield) as a yellow-brown solid. LC-MS (method 3): t R=1.444min, m / z(M+H) + =422.2. 1H NMR (400MHz, CDCl3) δ8.31 (s, 1H), 8.15 (d, J = 8.4Hz, 2H), 7.97 (s, 1H), 7.69 (d, J = 8.0Hz, 2H), 7.54 (s, 1H), 6.88 (br s,1H),4.67-4.58(m,1H),4.00-3.91(m,7H),2.99-2.80(m,4H),2.23(s,3H).

[1215] Step 6. Methyl 4-(5-methyl-2-((1-(3-oxocyclobutyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (104 g)

[1216] At room temperature, hydrochloric acid (2N, 6 mL) was added dropwise to a solution of 104e (545 mg, 1.29 mmol) in acetonitrile (6 mL). The mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with a saturated Na2CO3 aqueous solution (30 mL) solution. The mixture was extracted with dichloromethane (30 mL*3), washed with brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated. The residue was purified by silica gel column chromatography (2% methanol in dichloromethane) to give the desired product (321 mg, 66% yield) as a yellow solid. LC-MS (method 3): t R =1.392min, m / z (M+H) + =378.1.

[1217] Step 7. Methyl 4-(2-((1-(3,3-difluorocyclobutyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (104h)

[1218] DAST (197 mg, 1.22 mmol) was slowly added to a solution of 104 g (230 mg, 0.61 mmol) in dichloromethane (5 mL) at 0 ° C. The mixture was stirred at room temperature for 6 hours. The reaction mixture was quenched with a saturated Na2CO3 aqueous solution (30 mL) solution. The mixture was extracted with dichloromethane (30 mL * 3), washed with brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and the residue was purified by silica gel column chromatography (1% methanol in dichloromethane) to give the desired product (120 mg, 49% yield) as a yellow solid. LC-MS (method 3): t R =1.682min, m / z (M+H+H2O) +=418.1. Step 8. 4-(2-((1-(3,3-difluorocyclobutyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (104j)

[1219] LiOH.H2O (25 mg, 0.30 mmol) was added to a solution of 104h (120 mg, 0.30 mmol) in methanol (2 mL) and H2O (0.5 mL). The mixture was stirred at room temperature for 6 hours. The mixture was concentrated at room temperature and then H2O (3 mL) was added. The mixture was adjusted to pH = 4 with aqueous HCl (0.5 N). The solid was filtered and dried to give the desired product of the title as a yellow-brown solid (92 mg, 80% yield). LC-MS (method 3): t R =1.230min, m / z (M+H+H2O) + =404.1.

[1220] Step 9. N-(Cyanomethyl)-4-(2-((1-(3,3-difluorocyclobutyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzamide (104)

[1221] Compound 104j (30 mg, 0.078 mmol), 2-aminoacetonitrile hydrochloride (14 mg, 0.156 mmol), HATU (59 mg, 0.156 mmol) and N, N-diisopropylethylamine (40 mg, 0.312 mmol) were dissolved in DCM (2 mL). The resulting mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness and the residue was purified by preparative HPLC (Method A) to give the title product as a light yellow solid (4.6 mg, 14% yield). LC-MS (Method 1): t R =7.035min, m / z (M+H+H2O) + =442.1. 1 HNMR (400MHz, DMSO-d6) δ9.30(t,J=5.6Hz,1H),8.86(s,1H),8.33(s,1H),7.97(d,J=8.4Hz,2H),7.74(d,J= 8.4Hz,2H),7.65(d,J=2.8Hz,1H),4.91-4.81(m,1H),4.34(d,J=5.2Hz,2H),3.23-3.06(m,4H),2.17(s,3H). 19 F NMR (376MHz, DMSO-d6) δ -82.48 (d, J = 198Hz, 1F), -97.10 (d, J = 195Hz, 1F).

[1222] Example 105

[1223]

[1224] N-(2-(Dimethylamino)ethyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (105)

[1225] Using a similar preparation procedure to the last step of Example 2, compound 105 was synthesized in 46% yield using 2b and N,N-dimethylethane-1,2-diamine as starting materials. LC-MS (Method 1): t R =2.94min, m / z (M+H) + =380.2; 1 H NMR (400MHz, CDCl3) δ8.29(s,1H),7.91(d,J=8.4Hz,2H),7.83(s,1H),7.67(d,J=8.0Hz,2H),7.47(s,1H), 6.96(s,1H),6.86(s,1H),3.87(s,3H),3.58-3.54(m,2H),3.55(t,J=5.6Hz,2H),2.29(s,6H),2.23(s,3H).

[1226] Example 106

[1227]

[1228] Step 1. 3-Cyanocyclobutyl methanesulfonate (106b)

[1229] At 0 ° C, NaBH4 (600 mg, 15.78 mmol) was added to a solution of 106a (1 g, 10.52 mmol) in tetrahydrofuran (50 mL). The mixture was stirred at room temperature for 1 hour. The mixture was filtered. Triethylamine (2.12 g, 21.04 mmol) and MsCl (1.45 g, 12.62 mmol) were added to the filtrate. The mixture was stirred at room temperature for 4 hours. The reaction mixture was then quenched with 50 mL of saturated aqueous ammonium chloride solution. The resulting mixture was extracted with dichloromethane (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to dryness. The residue was purified by silica gel column chromatography (PE: EtOAc = 20: 1 to 10: 1) to obtain the desired product (440 mg, 24% yield) as a light yellow oil. 1H NMR (400MHz, CDCl3) δ5.00-4.91(m,0.9H),4.80-4.72(m,0.1H),3.04(s,3H),2.95-2.88(m,2H),2.84-2.76(m,3H).

[1230] Step 2. 4-(2-((1-(3-Cyanocyclobutyl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)-N-(cyanomethyl)benzamide (106)

[1231] Compound 4f (68 mg, 0.20 mmol), 106b (105 mg, 0.60 mmol) and cesium carbonate (192 mg, 0.60 mmol) were dissolved in DMF (1 mL). The resulting mixture was irradiated at 120 ° C for 2 hours under microwave. The mixture was filtered. The filtrate was purified by preparative HPLC (method A) to obtain the product as a yellow solid (5.2 mg, 6% yield). LC-MS (method 1): t R =3.488min&3.688min,m / z(M+H) + =413.2; 1 H NMR (400MHz, CDCl3) δ8.44-8.30(m,1.4H),8.00-7.80(m,3.4H),7.74-7.67(m,1.2H) ,7.58-7.49(m,0.8H),7.47-7.33(m,0.8H),7.12(s,0.4H),7.08(s,0.5H),6.96(t,J= 5.6Hz,0.5H),5.05-4.95(m,0.6H),4.89-4.79(m,0.4H),4.43(d,J=5.6Hz,1H),4.34( d,J=0.6Hz,1H),3.32-3.22(m,0.6H),3.10-2.78(m,4.6H),2.33(s,1H),2.24(s,2H).

[1232] Example 107

[1233]

[1234] Step 1. Methyl 4-(5-methyl-2-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)benzoate (107a)

[1235] Using a similar preparation procedure to the second step of Example 1, compound 107a was synthesized in 64% yield using 1b and 1-methyl-1H-pyrazol-3-amine as starting materials. LC-MS (Method 1): tR =3.41min, m / z (M+H) + =324.0. 1 HNMR (400MHz, CDCl3) δ8.34(s,1H),8.15(d,J=8.4Hz,2H),7.71(d,J=8.4Hz,2H),7.61(s, 1H), 7.25 (d, J = 6.4Hz, 1H), 6.74 (d, J = 2.0Hz, 1H), 3.96 (s, 3H), 3.81 (s, 3H), 2.25 (s, 3H).

[1236] Step 2. 4-(5-Methyl-2-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)benzoic acid (107b)

[1237] Using a similar preparation procedure as in the third step of Example 1, compound 107b was synthesized in 100% yield using 107a and NaOH as starting materials. LC-MS (Method 1): t R =2.28min, m / z (MH) - =308.0.

[1238] Step 3. N-(Cyanomethyl)-4-(5-methyl-2-((1-methyl-1H-pyrazol-3-yl)amino)pyrimidin-4-yl)benzamide (107)

[1239] Using a similar preparation procedure to the fourth step of Example 1, compound 107 was synthesized in 27% yield using 107b and 2-aminoacetonitrile hydrochloride as starting materials. LC-MS (Method 1): t R =2.90min, m / z (M+H) + =348.1. 1 HNMR(400MHz,DMSO-d6)δ9.61(s,1H),9.31(t,J=5.6Hz,1H),8.38(s,1H),7.99(d,J=8.4Hz,2H), 7.78(d,J=8.4Hz,2H),7.50(s,1H),6.57(s,1H),4.35(d,J=5.2Hz,2H),3.72(s,3H),2.19(s,3H).

[1240] Example 108

[1241]

[1242] N-(Cyanomethyl)-4-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)-N-methylbenzamide (108)

[1243] Using a similar preparation procedure to the fourth step of Example 1, compound 108 (5 mg) was synthesized in 6% yield using 93b (70 mg, 0.2 mmol) and 2-(methylamino)acetonitrile (82 mg, 1.1 mmol) as starting materials. LC-MS (Method 1): t R =6.34m / z(M+H) + =388.0. 1 H NMR (400MHz, CD3OD) δ8.35 (s, 1H), 7.99 (s, 1H), 7.83 (d, J = 8Hz, 2H), 7.67 (d, J = 8.4Hz, 2H), 7.59(s,1H),4.58(s,2H),3.62-3.58(m,1H),3.21(s,3H),2.28(s,3H),1.07-1.02(m,4H).

[1244] Example 109

[1245]

[1246] Step 1. (4-Chloro-2-(methylthio)pyrimidin-5-yl)methanol (109b)

[1247] To a solution of 109a (20 g, 85.95 mmol) in THF (300 mL) was added DIBAL-H (172 mL, 257.8 mmol, 1.5 M in toluene) at -78 ° C. The mixture was gradually warmed to RT under N2 atmosphere and stirred for 18 hrs. The reaction mixture was diluted with water (500 mL) and extracted with EtOAc (500 mL x 2). The combined organic layers were washed with brine (500 mL), dried over Na2SO4 and filtered. The filtrate was concentrated under vacuum. The residue was purified by chromatography on silica gel (eluent: PE: EtOAc = 5: 1) to obtain the desired product (11.6 g, 71% yield) as a yellow solid. LC-MS (method 3): t R =1.177min, m / z (M+H) + =191.0.

[1248] Step 2. 4-Chloro-2-(methylthio)pyrimidine-5-carbaldehyde (109c)

[1249] To a mixture of 109b (11.6 g, 60.84 mmol) in chloroform (200 mL) was gradually added MnO (53 g, 608.4 mmol) at 0°C. After stirring at RT for 18 hrs under an N atmosphere, the mixture was filtered and concentrated under vacuum. The residue was purified by chromatography on silica gel (eluent: PE: EtOAc = 5: 1) to give the desired title product (8.5 g, 74% yield) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ10.13(s,1H),8.93(s,1H),2.61(s,3H).

[1250] Step 3. Methyl 2-fluoro-4-(5-formyl-2-(methylthio)pyrimidin-4-yl)benzoate (109d)

[1251] Compound 109c (4.0 g, 21.2 mmol) was dissolved in a mixture of DME and H2O (120 mL, V:V=5:1), followed by the sequential addition of (3-fluoro-4-(methoxycarbonyl)phenyl)boronic acid (4.2 g, 21.2 mmol), Na2CO3 (4.5 g, 42.4 mmol) and Pd(Pph3)4 (244 mg, 0.21 mmol). The mixture was stirred at 90°C under an N2 atmosphere for 18 hrs. After cooling to RT, the mixture was concentrated to dryness. The residue was purified by chromatography on silica gel (eluent: PE:EtOAc=5:1) to give the desired product (2.3 g, 35% yield) as a yellow solid. LC-MS (method 3): t R =1.638min, m / z(M+H) + =307.0. Step 4. Methyl 4-(5-(difluoromethyl)-2-(methylthio)pyrimidin-4-yl)-2-fluorobenzoate (109e)

[1252] To a solution of 109d (2.3 g, 7.5 mmol) in DCM (50 mL) was added DAST (2.4 g, 15.02 mmol) at 0 ° C. The mixture was stirred at 30 ° C for 18 hrs. The mixture was diluted with water (50 mL) and extracted with EtOAc (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over Na2SO4 and filtered. The filtrate was concentrated to dryness to obtain the desired product (2.3 g, crude product) as a yellow solid. LC-MS (method 3): t R =1.751min, m / z(M+H) + =329.0.

[1253] Step 5. Methyl 4-(5-(difluoromethyl)-2-(methylsulfonyl)pyrimidin-4-yl)-2-fluorobenzoate (109f)

[1254] To a solution of 109e (2.3 g, 7.0 mmol) in DCM (30 mL) was added m-CPBA (4.87 g, 28.0 mmol) at 0°C. After stirring at 0°C for 2 hrs, the mixture was concentrated under vacuum. The residue was purified by chromatography on silica gel (eluent: PE: EtOAc = 5: 1) to give the desired product as a yellow solid (1.86 g, 74% yield). LC-MS (Method 3): t R =1.486min, m / z(M+H) + =361.0.

[1255] Step 6. Methyl 4-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-(difluoromethyl)pyrimidin-4-yl)-2-fluorobenzoate (109 g)

[1256] To a solution of 109f (1.86 g, 5.1 mmol) and 1-cyclopropyl-1H-pyrazole-4-amine (1.27 g, 10.3 mmol) in 30 mL of THF was added TsOH (89 mg, 0.51 mmol). The mixture was stirred at 85 ° C for 18 hrs. The mixture was concentrated under vacuum. The residue was purified by chromatography on silica gel (eluent: PE: EtOAc = 3: 1) to obtain the desired product (1.5 g, 72% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ10.15(s,1H),8.76(s,1H),8.05-7.85(m,2H),7.64-7. 44(m,3H),6.99(d,J=14.0Hz,1H),3.90(s,3H),3.69(s,1H),1.00-0.85(m,4H).

[1257] Step 7. 4-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-(difluoromethyl)pyrimidin-4-yl)-2-fluorobenzoic acid (109h)

[1258] To a solution of 109 g (200 mg, 0.5 mmol) in THF (20 mL) was added potassium trimethylsilanol (191 mg, 1.5 mmol). The mixture was stirred at 30° C. for 1 hr. The mixture was adjusted to pH 5-6 with 10% aqueous HCl. The organic layer was concentrated under vacuum to give the desired product (193 mg, crude) as a yellow solid. LC-MS (Method 3): t R=1.19min, m / z(M+H) + =390.3.

[1259] Step 8. N-(Cyanomethyl)-4-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-(difluoromethyl)pyrimidin-4-yl)-2-fluorobenzamide (109)

[1260] Compound 109h (40 mg, 0.10 mmol), 2-aminoacetonitrile hydrochloride (46 mg, 0.5 mmol), HATU (380 mg, 1.0 mmol) and DIEA (129 mg, 1 mmol) were dissolved in DMF (3 mL). The mixture was stirred at RT for 18 hrs. The mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL x 2). The combined organic layers were washed with brine (10 mL), dried over Na2SO4 and filtered. The filtrate was concentrated in a vacuum. The residue was purified by preparative HPLC (method A) to obtain the title product (7.5 mg, 17% yield) as a yellow solid. LC-MS (method 1): t R =2.471min, m / z (M+H) + =428.0; 1 H NMR (400MHz, CD3OD.) δ8.76 (s, 1H), 7.99 (s, 2H), 7.63-7.60 (m, 3H), 6.79 (t, J = 14.4Hz, 1H), 4.41 (s, 2H), 3.63 (s, 1H), 1.06 (s, 4H).

[1261] Example 110

[1262]

[1263] Step 1. Methyl 4-(5-formyl-2-(methylthio)pyrimidin-4-yl)benzoate (110b)

[1264] Using a similar preparation procedure to the third step of Example 109, compound 110b (1.6 g) was synthesized in 30% yield using 109c (3.5 g, 18.6 mmol) and 110a (3.33 g, 18.6 mmol) as starting materials. 1 H NMR (400MHz, DMSO-d6) δ9.95 (s, 1H), 9.06 (s, 1H), 8.13 (d, J = 8.4Hz, 2H), 7.89 (d, J = 8.4Hz, 2H), 3.91 (s, 3H), 2.65 (s, 3H).

[1265] Step 2. Methyl 4-(5-(difluoromethyl)-2-(methylthio)pyrimidin-4-yl)benzoate (110c)

[1266] Using a similar preparation procedure to the fourth step of Example 109, compound 110c (1.5 g) was synthesized with a yield of 93% using 110b (1.5 g, 5.2 mmol) as the starting material. LC-MS (Method 3): t R =1.75min, m / z (M+H) + =311.1.

[1267] Step 3. Methyl 4-(5-(difluoromethyl)-2-(methylsulfonyl)pyrimidin-4-yl)benzoate (110d)

[1268] Using a similar preparation procedure to the fifth step of Example 109, compound 110d (1.5 g) was synthesized with a yield of 94% using 110c (1.5 g, 4.8 mmol) as the starting material. LC-MS (Method 3): t R =1.44min, m / z(M+H) + =343.0.

[1269] Step 4. Methyl 4-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-(difluoromethyl)pyrimidin-4-yl)benzoate (110e)

[1270] Using a preparation procedure similar to that of the sixth step of Example 109, compound 110e (1.4 g) was synthesized in 83% yield using 110d (1.5 g, 4.4 mmol) as a starting material. 1 H NMR(400MHz,DMSO-d6)δ10.12(s,1H),8.76(s,1H),8.12(s,2H),7.99-7.88(m,1H),7.80-7.7 4(m,2H),7.54(s,1H),7.07-6.80(m,1H),3.90(s,3H),3.69-3.67(m,1H),1.00-0.93(m,4H).

[1271] Step 5. 4-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-(difluoromethyl)pyrimidin-4-yl)benzoic acid (110f)

[1272] Using a similar preparation procedure to that of the seventh step of Example 109, compound 110f (96 mg) was synthesized with a 100% yield using 110e (100 mg, 0.26 mmol) as the starting material. LC-MS (Method 3): t R=1.18min, m / z(M+H) + =372.1.

[1273] Step 6. N-(Cyanomethyl)-4-(2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)-5-(difluoromethyl)pyrimidin-4-yl)benzamide (110)

[1274] Using a similar preparation procedure to the fourth step of Example 109, compound 110 (9.4 mg) was synthesized with a yield of 8.9% using 110f (96 mg, 0.26 mmol) and 2-aminoacetonitrile hydrochloride (48 mg, 0.52 mmol) as starting materials. LC-MS (Method 1): t R =3.10min, m / z (M+H) + =410.2. 1 H NMR (400MHz, DMSO-d6) δ10.12(s,1H),9.40(s,1H),8.76(d,J=8.8Hz,1H),8.03-7.91(m,3H),7.79-7.72( m,2H),7.55-7.52(m,1H),6.95(t,J=14.4Hz,1H),4.36(d,J=5.2Hz,2H),3.68(s,1H),1.00-0.94(m,4H).

[1275] Example 111

[1276]

[1277] Step 1. Methyl 4-(2,5-dichloropyrimidin-4-yl)benzoate (34b)

[1278] To a mixture of compound 34a (50.0 g, 0.27 mol), (4-(methoxycarbonyl)phenyl)boronic acid (44.3 g, 0.25 mol), DME (500 mL) and H2O (50 mL) was added Na2CO3 (57.8 g, 0.55 mol) followed by Pd(PPh3)4 (3.16 g, 2.73 mmol). The mixture was stirred at 90 ° C for 9 hrs under N2 atmosphere. After cooling to RT, the mixture was filtered and the filtrate was concentrated. The residue was diluted with water (1500 mL) and extracted with EtOAc (1500 mL / min). The combined organic layers were concentrated to dryness. The residue was purified by chromatography on silica gel (eluent: PE:EtOAc=10:1) to give the title compound (37 g, 52% yield) as a white solid. 1H NMR (400MHz, CDCl3) δ8.69 (s, 1H), 8.18 (d, J = 8.0 Hz, 2H), 7.96 (d, J = 8.0 Hz, 2H), 3.98 (s, 3H).

[1279] Step 2. Methyl 4-(5-chloro-2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (60a)

[1280] Compound 34b (3.0 g, 10.5 mmol), 1-cyclopropyl-1H-pyrazole-4-amine (1.55 g, 11.6 mmol), Cs2CO3 (6.9 g, 21.1 mmol), X-Phos (1.0 g, 21.1 mmol) and Pd2(dba)3 (961 mg, 1.05 mmol) were dissolved in 1,4-dioxane (50 mL). The resulting mixture was stirred at 70 ° C for 2 hrs under N2 atmosphere. After cooling, the mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by chromatography on silica gel (eluent: PE: EtOAc = 1: 1) to obtain the title product (2.0 g, 52% yield) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ8.44(s,1H),8.16(d,J=8.4Hz,2H),7.91(d,J=8.4Hz,2H),7.88(s,1H),7 .49(s,1H),6.97(s,1H),3.97(s,3H),3.60-3.56(m,1H),1.15-1.11(m,2H),1.03-0.96(m,2H).

[1281] Step 3. 4-(5-Chloro-2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (60b)

[1282] To a solution of 60a (2.0 g, 5.42 mmol) in a mixture of THF (10 mL) and H2O (3 mL) was added LiOH.H2O (683 mg, 16.26 mmol) in one portion. The mixture was stirred at 40 ° C for 2 hrs. After cooling to RT, the mixture was adjusted to pH = 6-7 with 10% HCl aqueous solution. The mixture was extracted with DCM (30 mL*2). The separated organic layer was concentrated in vacuo to give the title product (1.93 g, 100% yield) as a yellow solid. LC-MS (method 3): t R =1.166min, m / z (M+H) +=356.1. Step 4. (S)-4-(5-chloro-2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide (111)

[1283] Compound 60b (80 mg, 0.23 mmol), (S)-2-aminopropionitrile 4-methylbenzenesulfonate (75 mg, 0.31 mmol), HATU (131 mg, 0.34 mmol) and DIEA (148 mg, 1.15 mmol) were mixed in DMF (2 mL). The reaction was stirred at RT for 2 hrs. The mixture was diluted with DCM (50 mL) and washed with water (20 mL*3). The separated organic layer was concentrated to dryness, and the residue was purified by preparative HPLC (method A) to give the title product as a yellow solid (14 mg, 15% yield). LC-MS (method 1): t R =3.678min, m / z (M+H) + =408.2; 1 H NMR(400MHz,MeOH-d4)δ8.48(s,1H),8.03-7.97(m,5H),7.59(s,1H),5.10(q ,J=7.2Hz,1H),3.63-3.59(m,1H),1.68(d,J=7.2Hz,3H),1.07-1.02(m,4H).

[1284] Example 112

[1285]

[1286] Step 1. Methyl 4-(5-methyl-2-((1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoate (112b)

[1287] Using a similar preparation procedure to the second step of Example 1, compound 112b (145 mg) was synthesized with a yield of 47% using 1b (200 mg, 0.761 mmol) and 112a (150 mg, 0.837 mmol) as starting materials. LC-MS (Method 3): t R =1.70min, m / z (M+H) + =406.1.

[1288] Step 2. 4-(5-Methyl-2-((1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (112c)

[1289] Using a similar preparation procedure to the third step of Example 3, compound 112c (100 mg) was synthesized with a yield of 71% using 112b (145 mg, 0.358 mmol) and LiOH.H2O (75 mg, 1.790 mmol) as starting materials. LC-MS (Method 3): t R =1.22min, m / z (M+H) + =392.1.

[1290] Step 3. N-(Cyanomethyl)-4-(5-methyl-2-((1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (112)

[1291] Using a similar preparation procedure to the fourth step of Example 1, compound 112 (29.7 mg) was synthesized with a yield of 45% using 112c (60 mg, 0.153 mmol) and 2-aminoacetonitrile hydrochloride (21 mg, 0.230 mmol) as starting materials. LC-MS (Method 1): t R =3.35min, m / z (M+H) + =430.2. 1 H NMR(400MHz, DMSO-d6)δ9.52(s,1H),9.32(t,J=5.2Hz,1H),8.41(s,1H),8.04-7.99(m,3H),7.81(d,J= 8.0Hz,2H),7.65(s,1H),5.38-5.35(m,1H),4.35(d,J=5.2Hz,2H),2.21(s,3H),1.63(d,J=6.8Hz,3H). 19 F NMR (376MHz, DMSO-d6) δ-74.81.

[1292] Example 113

[1293]

[1294] Step 1. 2,2,6,6-Tetramethyltetrahydro-2H-pyran-4-ol (113a)

[1295] To a solution of 2,2,6,6-tetramethyldihydro-2H-pyran-4(3H)-one (25 g, 160 mmol) in THF and EtOH (400 mL, V:V=3:1) was added NaBH4 (7.3 g, 192 mmol) at 0°C. After stirring for 2 hrs at RT, the reaction was quenched with 2N HCl (200 mL). Water (500 mL) was added to the above solution. The mixture was extracted with EtOAc (500 mL*3). The combined organic layers were washed with brine (700 mL), dried over Na2SO4, filtered and concentrated to give the title compound (25.3 g, 100% yield) as a white solid. 1 HNMR (400MHz, CDCl3) δ4.21-4.10(m,1H),1.99-1.93(m,2H),1.30-1.28(m,14H).

[1296] Step 2. 2,2,6,6-Tetramethyltetrahydro-2H-pyran-4-yl methanesulfonate (113b)

[1297] To a mixture of 113a (18 g, 114.0 mmol) and TEA (34.5 g, 342.0 mmol) in THF (200 mL) was slowly added MsCl (26 g, 227 mmol) at 0°C. The mixture was stirred at 25°C for 2 hrs. The mixture was diluted with water (500 mL) and extracted with EtOAc (300 mL*3). The separated organic layer was washed with brine (400 mL*3), dried over Na2SO4 and concentrated to give the title compound (27 g, 100% yield) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ 5.15-5.07 (m, 1H), 3.14 (s, 3H), 2.10-2.04 (m, 2H), 1.38 (t, J = 7.6Hz, 2H), 1.30-1.19 (m, 12H).

[1298] Step 3. 4-Nitro-1-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-pyrazole (113c)

[1299] A solution of 113b (27 g, 114 mmol), 4-nitro-1H-pyrazole (8.6 g, 76 mmol) and Cs2CO3 (75 g, 219 mmol) in DMF (90 mL) was stirred at 80 ° C overnight. After cooling to RT, the mixture was diluted with water (300 mL) and extracted with EtOAc (200 mL*3). The separated organic layer was washed with brine (300 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (eluent: PE: EtOAc = 10: 1) to give the title compound (6.6 g, yield 34%) as a yellow solid. LC-MS (method 3): t R =1.521min, m / z(M+H) + =254.1.

[1300] Step 4. 1-(2,2,6,6-Tetramethyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-amine (113d)

[1301] Compound 113c (6.6 g crude product, 26 mmol) and NH4Cl (7 g, 130 mmol) were dissolved in a mixture of EtOH and H2O (77 mL, V:V=10:1), and then Fe powder (4.4 g, 78 mmol) was gradually added at 60°C. The reaction was stirred at 80°C for 3 hrs and cooled to RT. The suspension was filtered and the filtrate was concentrated. The residue was diluted with water (200 mL) and extracted with EtOAc (200 mL*3). The separated organic layer was washed with brine (300 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography on silica gel (eluent: PE:EtOAc=5:1) to give the title compound (4 g, 69% yield) as a purple solid. 1 H NMR(400MHz,DMSO-d6)δ7.08(s,1H),6.96(s,1H),4.55-4.47(m,1H),3.76(s,2H) ,1.85(dd,J=4.0,12.8Hz,2H),1.59(t,J=12.8Hz,2H),1.27(s,6H),1.14(s,6H).

[1302] Step 5. 4-(5-methyl-2-((1-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzoic acid (113e)

[1303] Compound 113d (1.5 g, 6.7 mmol) and 40b (1.1 g, 4.5 mmol) were dissolved in a mixture of NMP and dioxane (20 mL, V: V = 1: 1), and a catalytic amount of H2SO4 (44 mg, 0.4 mmol) was then added dropwise. The resulting mixture was stirred overnight at 130 ° C. After cooling to RT, EtOAc (100 mL) and MeOH (10 mL) were added. The mixture was washed with water (50 mL * 3). The separated organic layer was concentrated to dryness. The residue was suspended in a mixture of PE and EtOAc (30 mL, V: V = 2: 1) and stirred for 30 minutes. The formed solid was filtered. The filter cake was dried to give the title compound (1.08 g, 56% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ13.05(s,1H),9.42(s,1H),8.38(s,1H),8.06(d,J=8.4Hz,2H),7.96(s,1H),7.80(d,J=8.0Hz,2H),7 .54(s,1H),4.72-4.66(m,1H),2.20(s,3H),1.94(dd,J=4.0,12.8Hz,2H),1.65(t,J=12.8Hz,2H),1.30(s,6H),1.14(s,6H).

[1304] Step 6. N-(Cyanomethyl)-4-(5-methyl-2-((1-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)benzamide (113)

[1305] Compound 113e (100 mg, 0.23 mmol), 2-aminoacetonitrile hydrochloride (25 mg, 0.27 mmol), HATU (342 mg, 0.90 mmol) and DIEA (116 mg, 0.90 mmol) were dissolved in DMF (2 mL). The reaction was stirred at RT for 2 hrs. The mixture was concentrated to dryness and the residue was purified by preparative HPLC (Method A) to give the title product as a yellow solid (22 mg, 20% yield). LC-MS (Method 1): t R =3.183min, m / z (M+H) + =474.0; 1H NMR (400MHz, CDCl3) δ8.33(s,1H),7.91-7.88(m,3H),7.73(d,J=8.0Hz,2H),7.55(s,1H),6.85(s,1H),6.66(t,J=4.8Hz,1H),4 .61(t,J=12.8Hz,1H),4.42(d,J=5.6Hz,2H),2.24(s,3H),2.09-2.06(m,2H),1.78(t,J=12.4Hz,2H),1.37(s,6H),1.29(s,6H).

[1306] Example 114

[1307]

[1308] Step 1. Methyl 4-(2-((1-(1-(bicyclo[1.1.1]pentane-1-carbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoate (114a)

[1309] Using a similar preparation procedure to the first step of Example 38, compound 114a (190 mg) was synthesized in 106% yield using 3a (157 mg, 0.36 mmol) and bicyclo[1.1.1]pentane-1-carboxylic acid (45 mg, 0.4 mmol) as starting materials. LC-MS (Method 1): t R =3.687min, m / z (M+H) + =487.2. 1 H NMR (400MHz, DMSO-d6) δ9.42(s,1H),8.39(s,1H),8.09(d,J=8.4Hz,2H),7.92(s,1H),7.83(d,J=8.0Hz,2H),7.52(s,1H),4.41-4.34(m,2 H),4.23-4.19(m,1H),3.90(s,3H),3.18-3.15(m,1H),2.75-2.68(m,1H),2.46(s,1H),2.20(s,3H),2.12-1.96(m,8H),1.76-1.65(m,2H).

[1310] Step 2. 4-(2-((1-(1-(bicyclo[1.1.1]pentane-1-carbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)-5-methylpyrimidin-4-yl)benzoic acid (114b)

[1311] A mixture of 114a (190 mg, 0.39 mmol) and LiOH.H2O (25 mg, 0.59 mmol) in THF / H2O (4 mL / 2 mL) was stirred overnight at RT. The mixture was concentrated. The residue was purified by preparative HPLC (Method A) to give the product as a yellow solid (150 mg, 81% yield). LC-MS (Method 1): t R =3.330min, m / z (M+H) + =473.2. 1 H NMR (400MHz, DMSO-d6) δ9.39(s,1H),8.37(s,1H),8.05(d,J=8.0Hz,2H),7.92(s,1H),7.75(d,J=8.0Hz,2H),7.53(s,1H),4.42-4.3 4(m,2H),4.23-4.19(m,1H),3.18-3.15(m,1H),2.78-2.65(m,1H),2.46(s,1H),2.20(s,3H),2.12-1.96(m,8H),1.78-1.62(m,2H).

[1312] Step 3. 4-(2-((1-(1-(bicyclo[1.1...

Claims

1. A compound, or a pharmaceutically acceptable form or isotopic derivative thereof, for use in the preparation of a medicament for treating a disease or disorder selected from immune-mediated diseases and cancer, wherein the compound has the following structure: in X is N or CR x , where R x is R', halogen, CN or OR'; Z 1 and Z 2 Each of Z is independently selected from N and CR', provided that Z 1 and Z 2 One of them is N and the other is CR'; R 1 Yes CH 3 ; R 2 is C optionally containing one or more heteroatoms selected from N, O and S 3 -C 16 aliphatic group, wherein the aliphatic group is optionally substituted with 0 to 4 C 1 -C 6 Substitution in the alkyl group; R 3 is R', halogen or CN; R 4’ Is H or C 1 -C 6 alkyl; R 4 Yes-CHR"-R 5 , where R' is H or C 1 -C 6 Alkyl, and R 5 It is CN, CF 3 , OR' or C in which 0 to 4 carbon atoms are replaced by one or more heteroatoms selected from N, O and S 1 -C 11 The aliphatic group, wherein the aliphatic group is optionally substituted by halogen, OR', NRR', CN, CONRR', NRCOR' and C 1 -C 6 alkyl, which in turn is optionally substituted with F, OR' or NRR'; and Each of R and R' is independently hydrogen or C 1 -C 12 Unsubstituted or substituted alkyl.

2. The use according to claim 1, wherein X is CR x .

3. The use according to claim 1, wherein X is N.

4. The use according to claim 1, wherein Z 1 is CH, and Z 2 It is N.

5. The use according to any one of claims 1 to 4, wherein R 4’ It's H.

6. The use according to any one of claims 1 to 4, wherein R 3 It's H.

7. The use according to any one of claims 1 to 4, wherein R 3 Yes F, CH 3 or Cl.

8. The method of any one of claims 1 to 4, wherein R" is H, and R 5 It is CN.

9. The use according to any one of claims 1 to 4, wherein X is CR x , in, R x It is H; Z 1 It is CH and Z 1 is N; R 1 Yes CH 3 ; R 2 is a six-membered cyclic aliphatic group containing N or O, wherein the aliphatic group is optionally replaced by one or more C 1 -C 3 Alkyl substitution; R 3 It is H; R 4’ is H; and R 4 Yes-CHR"-R 5 , where R' is H or C 1 -C 3 Alkyl, and R 5 It is CN.

10. The use according to claim 9, wherein R 2 is a six-membered cyclic aliphatic group containing O, wherein the aliphatic group is optionally substituted by two or more C 1 -C 3 Alkyl substitution.

11. The method of claim 9 or 10, wherein R" is H.

12. The use according to claim 9 or 10, wherein R" is C 1 -C 3 alkyl.

13. The use according to claim 9 or 10, wherein the compound is selected from the group consisting of:

14. The use of claim 1, wherein the compound has the following structure:

15. The use of any one of claims 1, 9, 13 and 14, wherein the disease or disorder is an immune-mediated disease.

16. The use of claim 15, wherein the immune-mediated disease is selected from the group consisting of asthma, inflammatory bowel disease, systemic lupus erythematosus and diabetic nephropathy.

17. The use of claim 16, wherein the immune-mediated disease is asthma.

18. The use of claim 16, wherein the immune-mediated disease is inflammatory bowel disease.

19. The use according to claim 16, wherein the drug is a granule.

Citation Information

Patent Citations

  • Ophthalmological composition of the type which undergoes liquid-gel phase transition

    US4861760A

  • Sustained release, comfort formulation for glaucoma therapy

    US4911920A

  • Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions

    US5212162A

  • Use of carrageenans in topical ophthalmic compositions

    US5403841A

  • Novel aryloxyphenylpropanamines

    WO2007005643A2